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Summary 
In the absence of a routine ovarian screening programme, ovarian cancer symptom 
awareness is a potential route to earlier symptomatic presentation and disease 
diagnosis. However, materials to support this strategy may need to be tailored 
according to risk. The work presented in this thesis identified the contributors to 
anticipated symptomatic presentation for women at increased genetic risk of ovarian 
cancer.  
A mixed-method approach was used to identify determinants of anticipated 
symptomatic presentation, and included a systematic search of existing ovarian cancer 
symptom awareness tools, cross-sectional surveys with two risk populations and 
qualitative interviews with women at increased genetic risk. Additionally, a systematic 
search and a virtual reference group were used to identify symptom content. Cognitive 
interviews were undertaken to pilot the draft tool for acceptability and usability with a 
sample of potential users and providers.  
Endorsing more benefits than barriers to presentation was associated with earlier 
anticipated presentation in both risk populations; however, differential effects of 
underlying health beliefs on anticipated presentation were also identified. In those at 
increased genetic risk, emotional (worry) rather than cognitive aspects of risk 
perception predominate in influencing earlier anticipated presentation. Interviews 
with women at increased genetic risk revealed that personal experience with ovarian 
cancer shaped beliefs about the disease. The identified health beliefs were 
incorporated into OvSTAT (ovarian cancer symptom awareness tool), with core content 
applicable for women from the general population and tailored content to address the 
specific needs of women at increased genetic risk. OvSTAT was well received in user 
testing.   
Overall, the findings suggest that the emotional representation of risk distinguishes 
earlier anticipated presentation in women at increased genetic risk from that in the 
general population. OvSTAT could be a mechanism through which appropriate 
symptomatic presentation is improved, by helping women to manage worry associated 
with their increased genetic risk status. 
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1 Introduction and thesis overview 
1.1 Chapter overview 
This chapter will provide an overview of the clinical background for women at 
increased genetic risk of ovarian cancer and present some of the issues these women 
face in relation to ovarian cancer risk management. The psychological background to 
being at increased genetic risk will be explored, and symptom awareness will be 
introduced as a potential strategy to bring about earlier ovarian cancer symptomatic 
presentation. This will lead to the aims, objectives and rationale of the PhD. 
 
1.2 Ovarian cancer clinical background 
1.2.1 Ovarian cancer statistics  
The fifth most common cancer and fourth most common cause of cancer death in 
women in the UK is ovarian cancer (Cancer Research UK 2011). Ovarian cancer is the 
second most common gynaecological cancer after uterus cancer, yet it accounts for 
the most deaths from gynaecological cancer. The approximate lifetime risk of a woman 
living in the UK developing ovarian cancer is 1 in 50 (Cancer Research UK 2011). 
Ovarian cancer is mainly seen in post-menopausal women, with 80% of cases 
presenting in women over the age of 50. Incidence rates vary worldwide, but it is 
estimated that 225,000 cases are diagnosed each year, and account for 4% of all 
cancers diagnosed in women (Cancer Research UK 2011). Developments in platinum 
based chemotherapy have led to increased survival rates, however such treatments 
are only possible in early stage disease. This is problematic as most (around 60%) of 
the 6,500 women who are diagnosed yearly in the UK are diagnosed at late stages 
(Cancer Research UK 2011). 
 
1.2.2 Ovarian cancer risk factors 
There are certain factors that increase a woman’s susceptibility to developing ovarian 
cancer. Gene mutations that increase the risk of ovarian cancer mean that there is a 
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family history link. Gene mutations in BRCA1 and BRCA2 increase the risk of developing 
ovarian cancer, with 5-15% of ovarian cancer cases associated with an identified family 
history or inherited gene (Gayther and Pharoah 2010, Risch et al. 2001, Watson et al. 
2008). The BRCA1/2 genes are also associated with hereditary breast cancer, and 
therefore women at increased genetic risk for ovarian cancer may also be at increased 
risk of breast cancer (Antoniou et al. 2003, Chen and Parmigiani 2007). BRCA1 is 
associated with a higher lifetime risk of ovarian cancer, at around 40-60%, whereas the 
lifetime risk is 10-30% for BRCA2 carriers (Andersen et al. 2003b, Howard et al. 2009, 
Tiller et al. 2005, Watson et al. 2008).  
 
Lifetime risk of ovarian cancer is influenced by many factors, including age of relative 
at diagnosis, relationship to diagnosed family member and number of diagnosed 
relatives. A meta-analysis conducted by Stratton et al. (1998) reported an approximate 
lifetime risk of 4% for women with one first degree relative with an ovarian cancer 
diagnosis. The lifetime risk for women with mothers diagnosed with ovarian cancer 
was estimated at 7.5%, around 5% in those with a sister diagnosed and up to 14% 
when multiple relatives had been diagnosed (Stratton et al. 1998). Up to 2 in 5 women 
who are at increased genetic risk will develop ovarian cancer in their lifetime 
(Antoniou et al. 2003, Chen and Parmigiani 2007). These risk estimates are particularly 
high when compared to the general population lifetime risk of 2% (Cancer Research UK 
2011). Lifetime risk of ovarian cancer is also increased (at 7%) in families with 
hereditary nonpolyposis colorectal cancer, also referred to as Lynch Syndrome 
(Watson et al. 2008). Being of Ashkenazi Jewish decent also increases lifetime risk due 
to high frequencies of the BRCA1/2 genes in this population, with these gene 
mutations found to be present in between 8%-36% of Ashkenazi Jewish women 
(Gayther and Pharoah 2010). 
 
In addition to a positive family history and gene mutations that increase susceptibility 
to ovarian cancer, other risk factors include older age, high body mass index, 
nulliparity, infertility, not breastfeeding and not having taken contraceptives 
(Andersen et al. 2002). Taking oral contraceptives is reported to potentially reduce 
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ovarian cancer risk by 20% with every five years of use (Lockwood-Rayermann et al. 
2009b, Tiller et al. 2005). Most of these non-genetic risk factors relate to childbearing 
or the disruption of the menstrual cycle, with ovarian cancer risk being reduced by 
factors that interrupt ovulation (Cancer Research UK 2011). 
 
1.2.3 Ovarian cancer staging 
Stage of disease at diagnosis is one of the largest determinants of survival rates for 
ovarian cancer. Staging is conducted during laparotomy and follows the International 
Federation of Gynecology and Obstetrics (FIGO) guidelines. There is an inverse 
relationship between stage and survival (Prat 2014). Five year survival rates for early 
stage ovarian cancer (FIGO stages 1 and 2) have been reported to be as high as 90%, 
whereas for late stage disease (FIGO stages 3-5) this falls dramatically to around 10% 
(Cancer Research UK 2011, Hensley et al. 2003, Menon et al. 2009). These statistics are 
concerning when the numbers of women diagnosed at each stage are considered. 
Around 30% of women are diagnosed with early stage disease, whereas around 60% 
are diagnosed with late stage (Cancer Research UK 2011, Gilbert et al. 2012). This 
suggests that much is to be gained by detecting ovarian cancer earlier. 
 
1.3 Ovarian cancer risk management options for women at increased risk 
Women at increased genetic risk of ovarian cancer may use risk management 
strategies including risk reducing surgery, screening and symptom awareness to help 
reduce their susceptibility to the disease, or increase the chances that it will be 
detected at an early stage. 
1.3.1 Ovarian cancer screening  
Screening allows people to undergo tests or medical examinations which aim to detect 
disease presence. The clinical effectiveness of ovarian cancer screening is currently 
being investigated in a large scale UK population screening trial (Jacobs et al. 1999, 
Menon et al. 2009, Quaye et al. 2008), and the partner, UK Familial Ovarian Cancer 
Screening Study (Rosenthal and Jacobs 2006). Until policy recommendations are made 
based on the findings of these studies, ovarian screening should not be offered outside 
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of clinical trials (Brain et al. 2012, Rosenthal and Jacobs 2006). Screening involves a 
combination of blood tests to detect the tumour biomarker CA 125, and transvaginal 
ultrasounds. The results of the UK ovarian cancer screening studies are due out in 2015 
and until then, women at increased genetic risk who had previously been involved in 
the familial screening study may have to pay for private tests and scans if they wish to 
pursue screening, or consider other risk management options. 
 
1.3.2 Risk-reducing salpingo-oophorectomy  
Risk-reducing salpingo-oophorectomy (RRSO) is currently the most reliable method for 
reducing ovarian cancer risk (Hensley et al. 2003). For women who have mutations in 
BRCA1 or BRCA2, this surgery reduces the risk of developing ovarian cancer by up to 
80% (Rebbeck et al. 2009). The procedure involves the pre-emptive removal of healthy 
ovaries and fallopian tubes; however, this may not be a favourable option to all 
women due to the loss of fertility, the earlier onset of menopause and associated 
quality of life issues (Howard et al. 2009, Miller et al. 5094). Consequently, women 
who decide not to have RRSO may have to rely on symptom awareness and presenting 
to primary care until a policy decision has been made regarding the routine 
implementation of ovarian cancer screening. 
 
1.3.3 Symptom awareness and presentation 
There is evidence that cancer survival can be improved by encouraging individuals to 
present earlier for medical advice regarding potential symptoms (Evans et al. 2014, 
Neal 2009). However, in order for symptom awareness to be utilised, an understanding 
of symptom awareness and presentation behaviour in women at increased genetic risk 
is needed. Symptom awareness is defined as knowledge about symptoms for a 
particular disease, and can be assessed through recognition (‘is X a symptom of Y?’), or 
recall (‘can you name any symptoms of Y?) (Simon et al. 2012a). Presentation 
behaviour is often harder to study, due to the associated resources, cost and time 
associated with collecting prospective data on behaviour, or with issues surrounding 
accurate recall of symptoms in retrospective research (Robb et al. 2009). Due to these 
5 
 
difficulties, anticipated presentation is commonly studied, which refers to how long 
people think it will take them to seek medical advice if they experience symptoms.  
Anticipated presentation is often measured by asking individuals ‘if you had a 
symptom you thought might be a sign of X, how long would it take you to go to the 
doctors from the time you first noticed the symptom?’ (Simon et al. 2012b). In ovarian 
cancer, there is currently no agreed presentation interval that is considered 
appropriate. However, it is known that earlier stage diagnosis is associated with better 
treatment outcomes and ultimately survival (Cancer Research UK 2011, Prat 2014). 
Therefore, earlier symptomatic presentation is deemed advantageous (Richards 
2009b).  
 
Tools to promote cancer symptom awareness and encourage earlier anticipated 
presentation include educational materials  which can take the form of  leaflets, 
factsheets, pamphlets, videos and posters (Chung et al. 2007). For a symptom 
awareness approach to be used, an understanding of the symptoms is also needed. 
Ovarian cancer was once referred to as the silent killer, with this phrase frequently 
used to describe what was believed to be an asymptomatic disease (Gajjar et al. 2012, 
Goff et al. 2007, Twombly 2007). However, this has been discounted over recent years, 
with numerous studies highlighting that ovarian cancer does indeed have symptoms 
which are present in various stages of the disease, and are not just limited to advanced 
disease (Bankhead et al. 2005, Goff et al. 2007, Hamilton et al. 2009, Lockwood-
Rayermann et al. 2009b, Rufford et al. 2007). This transition from a silent killer to a 
symptomatic disease has been reflected in policy and medical guidelines. These 
guidelines provide information to health professionals about what they should know 
about ovarian cancer, what symptoms to look for and what to do if ovarian cancer is 
suspected (Department of Health 2009, National Institute for Health and Clinical 
Excellence 2011). 
 
6 
 
1.3.4 Ovarian cancer symptoms  
The key symptoms of ovarian cancer are persistent abdominal distension (often 
referred to by women as ‘bloating’), feeling full (early satiety) and/or loss of appetite, 
pelvic or abdominal pain, and increased urinary urgency and/or frequency 
(Department of Health 2009, National Institute for Health and Clinical Excellence 
2011). Although symptoms are now advocated for ovarian cancer, debate still 
surrounds them due to their low positive predictive value (PPV). The symptoms have a 
PPV of less than 1%, except for persistent abdominal distension, which has a PPV of 2.5 
(Goff et al. 2007). The low PPVs associated with ovarian cancer symptoms could reflect 
the common every day nature of the symptoms, which may involve bodily sensations 
that women frequently experience as part of everyday life, and are therefore hard to 
attribute or identify as possible symptoms (Austoker 2009, Hamilton et al. 2009, 
Kirwan et al. 2002). Women tend to misattribute ovarian cancer symptoms to other 
causes such as ageing, the menopause and stress (Goff et al. 2000, Lockwood-
Rayermann et al. 2009b, Yawn et al. 2004). In order to help women and healthcare 
professionals discriminate between what may be general feelings and sensations and 
those which may be a possible symptom of ovarian cancer, the frequency, severity and 
persistency of symptoms are being emphasised (Austoker 2009, Department of Health 
2009). However, the messages regarding frequency and duration of symptoms are 
mixed, with clear clinical consensus on symptom frequency and duration that is 
indicative of ovarian cancer currently lacking. For example the National Institute for 
Health and Clinical Excellence (2011) guidelines state that if symptoms are 
“experienced more than 12 times per month” medical advice should be sought, while 
the Department of Health (2009) states that advice should be sought “if symptoms 
occur on most days”.  
 
A recurring theme in the literature is the lack of awareness that women have of the 
non-gynaecological symptoms of ovarian cancer (Bankhead et al. 2008, Goff et al. 
2000, Lockwood-Rayermann et al. 2009b). Women often report that they would 
expect symptoms of ovarian cancer to be gynaecological in nature (Cooper et al. 2011), 
possibly reflecting expectations of a disease of the ovaries to have symptoms in that 
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part of the body (Lockwood-Rayermann et al. 2009b). A challenge to ovarian cancer 
symptom awareness could therefore be to educate women about the non-
gynaecological nature of symptoms and to disentangle these symptoms from those 
associated with other conditions, such as irritable bowel syndrome (IBS) or the 
menopause (Goff et al. 2000, Lockwood-Rayermann et al. 2009b, Yawn et al. 2004). 
 
1.4 Early diagnosis in ovarian cancer: the NAEDI pathway 
The importance and potential benefits of earlier cancer diagnosis has been highlighted 
by the National Awareness and Early Diagnosis Initiative (NAEDI) which outlines how 
better cancer survival rates in the UK could be achieved through early diagnosis 
(Richards 2009a). The NAEDI model in Figure 1.1 conceptualises the diagnostic 
pathway and allows for different areas of the pathway to be identified and then 
targeted in order to ultimately bring about earlier cancer diagnosis and better 
prognostic outcomes.  
 
 
Figure 1.1. The National Awareness and Early Diagnosis initiative (NAEDI) pathway (Richards 
2009) 
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It can be seen that the model includes screening, but does not solely focus on it, 
reflecting that the majority of cancers in the UK are diagnosed as a result of symptoms 
experienced by the individual rather than through screening (Richards 2009b). Many 
people present to primary care with cancer symptoms, making it the first point of 
contact along the diagnostic pathway (Allgar and Neal 2005a, Allgar and Neal 2005b, 
Evans et al. 2014, Macleod et al. 2009).  A recent study of cancer symptomatic 
presentation in a UK population sample reported that for around 75% (n=177) of study 
participants, the first step towards cancer diagnosis was discussing symptom concerns 
with their GP (Simon et al. 2010). Awareness and presentation are key areas at the 
start of the NAEDI pathway, with the gate-keeping role of primary care shown in the 
pathway (see Figure 1.1). In ovarian cancer, there has been a move towards symptom 
awareness due to uncertainty regarding the clinical effectiveness of ovarian cancer 
screening (Menon et al. 2009) and low levels of ovarian cancer symptom awareness in 
the UK public (Cooper et al. 2012, Richards 2009a). 
 
Even if people do become aware that they are experiencing cancer symptoms, this 
does not necessarily mean that they will seek help for these symptoms. Barriers to 
presentation to healthcare services are often reported as an explanation for delaying 
presentation or not presenting at all. Perceived barriers cover and include service and 
personal barriers. Service barriers include expectations of the GP’s response, whether 
the GP will take concerns seriously and appointment processes (Eadie and MacAskill 
2008, Robb et al. 2009). Personal barriers include fear of what the doctor might find, 
symptom type, embarrassment and fear of diagnosis (Ramirez et al. 1999, Robb et al. 
2009). The relationship between perceived barriers and presentation is complicated 
and is mediated by other factors such as the nature of symptoms, GP reputation and 
the doctor–patient relationship (Eadie and MacAskill 2008). Vague symptoms have 
been associated with longer presentation times due to difficulty attributing symptoms 
to possible cancer (Goff et al. 2000). GP reputation and fear of the consultation have a 
more complex relationship with presentation. A positive doctor-patient relationship 
can facilitate presentation; however, if patients perceive that their GP will not take 
their concern seriously, this can lead to longer presentation (Smith et al. 2005b). 
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Unsurprisingly, endorsing more barriers has been shown to increase time to 
presentation to health services (Robb et al. 2009). 
 
1.5 Psychological background to ovarian cancer risk management strategies 
Women at increased genetic risk of ovarian cancer may use risk management 
strategies to manage their increased risk status (Howard et al. 2009). The main options 
of ovarian screening, RRSO and symptom awareness and presentation have been 
presented. Drawing on studies that examine the determinants of uptake of these risk 
management strategies can inform about the psychological background to being at 
genetic risk for ovarian cancer. When considering the psychological determinants of 
these risk management strategies, it is important to distinguish between screening and 
symptom awareness and presentation behaviours. Symptomatic presentation involves 
self-determined awareness and cues to action, whereas screening depends partly on 
external drivers, such as participation invites and reminders. Whilst screening uptake is 
a different behaviour to symptom awareness and presentation, findings from studies 
on predictors of screening uptake can be extrapolated to aid understanding of 
determinants of symptomatic presentation due to similar study populations. 
 
1.5.1 Psychological determinants of screening uptake 
Studies with women participating in familial ovarian cancer screening provide insight 
into how women at increased genetic risk may attempt to manage their risk status, 
and their use of screening as a strategy for maintaining psychological wellbeing. Higher 
levels of ovarian cancer worry have been reported to be associated with higher 
perceived risk in women with a family history (Lerman et al. 1994). Ovarian cancer 
worry and the number of affected relatives was found to be positively associated with 
ovarian cancer screening uptake in a sample of women at increased genetic risk for 
ovarian cancer (Schwartz, Lerman et al 1995). Similarly, Andersen et al. (2002) 
reported that women who were at increased genetic risk for ovarian cancer who 
engaged with ovarian cancer screening more frequently had higher levels of worry. 
The frequent engagement with screening by women with high levels of worry was 
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interpreted by Schwartz et al. (1995a) as an attempt by these women to reduce their 
levels of distress. However, the cross-sectional nature of this research needs to be 
considered when interpreting the results, as it is difficult to establish causality in such 
research. The role of worry and perceived risk in screening participation was also 
explored in a study of cancer related anxiety levels in women who were attending 
ovarian cancer screening (Hensley et al. 2003). Pre-menopausal women were reported 
to have higher levels of anxiety than post-menopausal women. Hensley et al. (2003) 
also observed that participants had high levels of perceived risk, with women who 
were pre-menopausal more like to overestimate their personal risk of ovarian cancer. 
 
Women at increased genetic risk of ovarian cancer are also at increased risk of breast 
cancer (Andersen et al. 2003a), therefore studies of breast cancer screening in women 
at increased genetic risk may also be useful for understanding the psychological 
determinants of ovarian cancer risk management strategies.  A longitudinal study by 
Diefenbach et al. (1999) reported that cancer worry was a predictor of mammography 
use in women at increased genetic risk for breast and ovarian cancer. In particular, 
moderate levels of worry were associated with greater participation in screening 
(Diefenbach et al. 1999). Andersen et al. (2003b) reported an inverted u-shaped 
relationship between worry and mammography use in women with a family history of 
breast or ovarian cancer, whereby those with lower or higher levels of worry were less 
likely to use mammography. This finding suggests that the relationship between worry 
and breast cancer screening uptake is not linear, and that high levels of worry can act 
as a barrier to screening uptake. However, again, the cross-sectional nature of the 
research needs to be acknowledged. A meta-analysis conducted by Hay et al. (2006) 
identified twelve prospective studies with a sample of women at increased risk for 
breast cancer, and reported that higher breast cancer worry was associated with more 
engagement with breast cancer screening, regardless of how worry was measured. The 
prospective nature of studies included in the meta-analysis enhances understanding of 
the role that worry plays in breast cancer screening uptake, and adds to the findings 
from studies on ovarian cancer screening suggesting that higher levels of cancer 
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related worry in women at increased genetic risk prompt greater engagement in 
cancer screening. 
 
The impact of participating in cancer screening for women at increased genetic risk is 
also important to consider, because in the absence of screening, the needs that were 
met by screening must be met in other ways. Participating in screening has been 
described by women as a proactive approach to ovarian cancer detection (Lifford et al. 
2013b) and therefore women may feel a sense of loss and helplessness in the current 
absence of routine screening. A prospective study that evaluated the psychological 
impact of familial ovarian cancer screening highlighted the importance of screening for 
women at increased genetic risk (Brain et al. 2012). Screening helped women to 
maintain psychological wellbeing, with considerable reassurance gained from being 
part of a screening programme which acted as a safety net (Brain et al. 2012). Feelings 
of reassurance and reduced distress as a result of participating in ovarian screening 
were similarly reported by Lancastle et al. (2011). Women at increased genetic risk of 
ovarian cancer may therefore need to seek out other sources of support in order to 
replace the proactive approach to cancer detection and reassurance that they 
previously gained through participation in screening. 
 
1.5.2 Psychological determinants of risk reducing salpingo-oophorectomy  
Although a proven method for reducing ovarian cancer risk, not all women elect for 
RRSO (Hensley et al. 2003). Studies that have examined the beliefs about risk 
management strategies in women who have chosen to have the procedure help to 
explain the possible determinants of this risk management option. Uptake of RRSO has 
been shown to be motivated by desire to reduce anxiety and worry, and to minimise 
the uncertainty surrounding potential cancer diagnosis at a later stage in life (Hallowell 
1998, Hurley et al. 2001, Meiser et al. 1999).  
 
A systematic review of 43 articles by Howard et al. (2009) identified three types of 
factors that influence risk management decisions in women at increased genetic risk of 
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developing ovarian cancer. The first set of factors related to medical and physical 
factors, such as BRCA1/2 status, age, parity and menopausal status. The consideration 
of age related factors demonstrates that risk management decisions are not made at 
one time point, but are re-evaluated as women progress through different stages of 
their life. The second set involved psychological factors, including perceived risk, 
worry, anxiety and distress. Again, this demonstrates how women may choose RRSO in 
order to reduce the worry and anxiety associated with their increased risk status. The 
final set concerned social factors, such as personal experiences of cancer in the family 
and family obligations (Goff et al. 2004), highlighting the importance of wider social 
contexts in risk management decisions. Some women who initially chose ovarian 
cancer screening as a risk management option later opt for RRSO. Reasons for 
discontinuing screening to undergo RRSO were explored by Lifford et al. (2013a). 
Interviews with a sample of women at increased genetic risk of ovarian cancer who 
were involved with UKFOCSS but who had elected for RRSO revealed varying factors 
that were catalysts to the decision to have RRSO. The main factors included abnormal 
screening results and age related factors (Lifford et al. 2013a). Again, this 
demonstrates how different risk management strategies are considered by women 
throughout their life. This highlights the importance of offering different risk 
management strategies, so that women can choose the best option for their personal 
circumstances.  
 
1.5.3 Psychological determinants of symptom awareness and presentation  
Studies in the general population have revealed low public awareness of cancer 
symptoms and the need to promote symptom awareness and early presentation to 
primary care (Robb et al. 2009, Wardle et al. 2001). However, there are no equivalent 
studies of symptom awareness in women at increased genetic risk of developing 
ovarian cancer, in whom awareness, attitudes and beliefs about ovarian cancer are 
likely to differ from those of the general population due to the tendency towards high 
levels of cancer-related worry and perceived risk (Andersen et al. 2002, Hay et al. 
2006, Kash et al 1992, Schwartz et al 1995). It could be expected that the increased 
saliency of health would lead to earlier symptomatic presentation; however, empirical 
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evidence is lacking regarding how heightened worry and perceived risk influence 
symptomatic presentation in women at increased genetic risk.  
 
In the absence of literature on symptom awareness and presentation in women at 
increased genetic risk of ovarian cancer, evidence regarding the psychological 
determinants of breast self-examination (BSE) can be considered. BSE can be 
considered a similar behaviour to symptomatic presentation, since it involves self-
determined awareness of breast symptoms which act as cues to action. Norman and 
Brain (2005) investigated breast self-examination in a sample of women who had a 
first degree relative diagnosed with breast cancer. Excessive self-examiners had higher 
levels of breast cancer worry and perceived severity (Norman and Brain 2005). 
Excessive breast self-examination was also observed among first-degree relatives of 
newly diagnosed breast cancer patients in a study by Epstein et al. (1997). High 
frequency of thoughts about breast cancer, high perceived risk and having two or more 
first degree relatives with breast cancer, were also associated with frequent BSE 
(Epstein et al. 1997). Confidence has also been reported as an important determinant 
of BSE, with low confidence in carrying out the behaviour associated with poor 
adherence to BSE (Kash et al. 1992). A study evaluating the psychological outcomes of 
breast cancer genetic risk assessment at 6-year follow up identified greater worry as a 
predictor of frequent BSE and higher perceived risk (Brain et al. 2011). Cancer worry at 
baseline was also identified as the strongest predictor of cancer worry at 6-year follow 
up, suggesting that emotional aspects of perceived risk are relatively stable over time 
(Brain et al. 2011). Findings from the BSE literature suggest that high levels of worry 
and perceived risk may prompt hyper-vigilant behaviour in women at increased 
genetic risk. However, as these studies focus specifically on breast cancer, the extent 
to which the findings generalise to the context of ovarian cancer is unknown.   
 
Evidence regarding the psychological determinants of ovarian cancer and breast 
cancer screening uptake and BSE support the proposition that women at increased 
genetic risk for ovarian cancer are more likely to over-present than delay with ovarian 
cancer symptoms. This behavioural pattern could be problematic not only in terms of 
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the individual’s psychological wellbeing, but also the potential impact on primary care 
services if women are frequently visiting their GP due to hyper-vigilance (Evans et al. 
2014). This also has implications for interventions that promote symptom awareness, 
with the potential that such interventions could lead to hyper-vigilance and over-
presentation in women at increased genetic risk. Understanding of the determinants 
of anticipated symptomatic presentation in women at increased genetic risk is needed 
so that interventions can promote appropriate presentation in this population without 
raising worry levels. 
 
1.6 Summary 
There is currently a gap in research concerning determinants of symptomatic 
presentation in women at increased genetic risk of ovarian cancer. General population 
studies have revealed low public awareness of cancer symptoms (Robb et al 2009, 
Wardle et al. 2001), however equivalent studies of ovarian cancer symptom awareness 
in women at increased genetic risk are currently lacking. There is evidence that genetic 
risk, levels of cancer worry and perceived susceptibility predict screening uptake 
(Andersen et al. 2002, Brain et al. 2011, Schwartz et al. 1995a,) but as yet, the impact 
of risk status on ovarian cancer symptomatic presentation is unknown. In the absence 
of a screening programme for ovarian cancer, symptom awareness in the context of 
increased genetic risk needs to be explored and understood. Once this is understood, 
work can be done to try and increase awareness and encourage appropriate 
presentation. Symptom awareness tools are a possible way to increase awareness and 
encourage appropriate presentation, potentially leading to earlier diagnosis (Evans et 
al. 2014). However, little is known about the number of symptom awareness tools 
already in existence, their content or development processes. The suitability of such 
materials for women at increased genetic risk is also unknown. There is concern that 
encouraging regular self-monitoring through diaries and checklists in women at 
increased genetic risk may lead to anxiety, hyper-vigilance, and potentially to 
unnecessary investigations (Brain et al. 1999, Fallowfield et al. 2010, Norman and Brain 
2005). In relation to women at increased genetic risk of ovarian cancer, the challenge is 
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therefore to promote symptom awareness without encouraging excessive self-
monitoring.  
1.7 Thesis  
1.7.1 Rationale 
There is a gap in understanding the feasibility and impact of symptom awareness as a 
risk management strategy for women at increased genetic risk of ovarian cancer. This 
lack of understanding is particularly concerning due to the current lack of routinely 
available ovarian cancer screening. As part of the Cancer Reform Strategy, the 
Department of Health is advocating public awareness of ovarian cancer to promote 
early presentation and improve cancer outcomes (Department of Health 2007). 
Symptom awareness is also a key recommendation in the NICE ovarian cancer 
management guidelines (National Institute for Health and Clinical Excellence 2011).  
 
Interventions to increase symptom awareness may be best aimed at women at 
increased genetic risk of ovarian cancer (Low et al. 2013a), as these women may have 
to rely on symptom awareness despite higher levels of worry associated with ovarian 
cancer risk. Currently there is a lack of understanding of levels of symptom awareness, 
or the determinants of symptomatic presentation in this population. Research needs 
to be undertaken to understand the likely presentation behaviour of women at 
increased genetic risk, because if they are likely to over-present with potential 
symptoms, interventions which aim to increase symptom awareness will need to 
address this behavioural response. Interventions should provide symptom information 
without impeding the psychological wellbeing of the individual or over-burdening 
primary care services. Currently there is a lack of theory-driven interventions, and it is 
essential that a clinical management approach based on symptom awareness is guided 
by research evidence.  
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1.7.2 Aims 
The aims of the PhD are (1) to understand the psychological determinants of 
symptomatic presentation in women at increased genetic risk of ovarian cancer, and 
(2) to develop a preliminary ovarian cancer symptom awareness tool.  
 
Objectives for the PhD are: (1) to identify relevant theory for awareness and 
presentation, and describe women’s knowledge, beliefs and attitudes towards ovarian 
cancer and the potential influence of risk on these factors; (2) to conduct a thorough 
search and evaluation of existing symptom awareness tools; (3) to identify the factors 
influencing early presentation behaviour in an increased genetic risk sample in 
comparison with an existing general population sample, and (4) to develop a 
preliminary ovarian cancer symptom awareness tool and examine its 
acceptability/usage with a sample of potential users and providers.  
 
The proposed studies follow the MRC complex interventions guidelines (Craig et al. 
2008b) in generating an evidence base for the preliminary development of an ovarian 
cancer symptom awareness tool for women at increased genetic risk of ovarian cancer. 
The MRC complex intervention guidelines state that intervention development should 
be done over four phases of development, feasibility/piloting, evaluation and 
implementation. As part of the development phase, the guidelines emphasise the 
importance of understanding existing interventions and developing a theoretical 
understanding of the area in question (Craig et al. 2008b, Jones et al. 2013). The 
proposed research represents theoretical/modelling phase work to generate this 
evidence base which will guide tool development (Craig et al. 2008b). It is anticipated 
that the current development and feasibility studies will form groundwork for follow-
on research to evaluate the clinical utility and actual implementation of the tool in 
primary care.  
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1.7.3 Study design  
In order to achieve the aims and objectives of the PhD, the project is split in to five 
phases involving mixed methods: 
Phase One will identify and evaluate existing ovarian cancer symptom awareness 
tools; 
Phase Two will examine ovarian cancer symptom awareness and anticipated 
presentation behaviour. Health beliefs including symptom knowledge, cancer beliefs, 
barriers to presentation and confidence in symptom detection will be explored in a 
sample of women at increased genetic risk versus a general population sample; 
Phase Three will explore the influence of genetic risk status on help seeking behaviour 
and the acceptability of an approach based on ovarian cancer symptom awareness 
using semi-structured interviews with a sample of women at increased risk; 
Phase Four will gain consensus on the symptom content and guidance to include in the 
tool based on empirical evidence (systematic literature search) and clinical evidence 
(virtual reference group of ovarian cancer experts);  
 Phase Five will utilise the information gathered in previous phases to develop a 
preliminary tool before user and provider feedback is gained using cognitive 
interviews. 
 
1.8 Thesis chapter plan 
The thesis continues in Chapter 2 with a description of the theoretical underpinning of 
the proposed research and description of previous literature which provides the 
rationale for the research. The subsequent chapters present the five phases of the PhD 
(Chapters 3-7) followed by an integrated discussion chapter (Chapter 8).
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2 Theoretical underpinning  
2.1 Chapter overview 
This chapter presents the theoretical underpinning of the research project. The 
psychology of awareness and symptomatic presentation behaviour will be discussed 
and health behaviour theories will be drawn upon. The importance of health behaviour 
theories in intervention development will be presented and relevant theories will be 
introduced. The application of this theoretical underpinning will then be explained in 
terms of the mixed method approach that will be used in subsequent chapters. 
 
2.2 Introduction  
As detailed in the previous chapter, the National Awareness and Early Diagnosis 
Initiative (NAEDI) outlined a pathway which aims to reduce cancer deaths by increasing 
awareness and early diagnosis (Richards 2009a). The first stage of this pathway 
consists of public awareness and/or beliefs about cancer. The development of such a 
pathway highlights the importance of awareness and beliefs about cancer and the 
important role they play in the cancer diagnostic pathway. The role of cancer 
awareness and beliefs has been explored frequently in the literature through the use 
of various participant populations and study methodology. These studies help create 
an understanding of the psychology of awareness and symptomatic presentation 
behaviours. Understanding of the psychology is important because once the 
determinants and beliefs surrounding awareness and presentation are understood, 
these can be targeted in interventions to increase awareness and promote timely 
presentation. This process is endorsed as part of the development process in the MRC 
complex intervention guidelines (Craig et al. 2008b). 
 
2.3 Health behaviour theories  
The research in this thesis concerns understanding awareness and anticipated 
symptomatic presentation behaviour in women at increased genetic risk of ovarian 
cancer and therefore it is important to draw upon theories that may help explain such 
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behaviour. A variety of health behaviour theories are used in research to understand 
and predict determinants of behaviour. When developing interventions it is important 
to identify the potential theoretical models so that the appropriate model is applied 
(Jones et al. 2013, Michie et al. 2005). When applied to intervention development, 
theories allow for the identification of salient beliefs that influence the target 
behaviour. These beliefs can then be targeted in order to maximise the likelihood of 
the target behaviour being carried out. Theoretical understanding is important to allow 
for identification of how the intervention is working and what elements of the 
intervention are causing change (Craig et al. 2008b). Through the use of a theoretical 
framework the components contributing to a target behaviour can be understood and 
mapped out, enhancing understanding of the target behaviour. Interventions that 
have a theoretical foundation are considered advantageous as they allow for 
systematic development based on best available evidence (Craig et al. 2008b). 
 
The importance of an explicit theory based approach to conceptualising anticipated 
presentation for a variety of cancers is emphasized in a systematic review by Walter et 
al. (2011). The review reported that most studies investigating patient presentation 
decisions in cancer diagnosis failed to use theory to guide study content and reporting. 
The absence of theory led to variation in definitions and study methods used in 
included studies, which consequently made comparisons between studies of different 
cancer sites and different medical systems/contexts very difficult (Walter et al. 2011).  
An overview of health behaviour theories that could be applied to symptom awareness 
and presentation in women at increased genetic risk of ovarian cancer is presented in 
the following section. 
2.3.1 Overview of theories 
Health behaviour theories can be used to help explain determinants of behaviour in a 
given health context. Different theories have slightly different focal points which 
allows for theoretical constructs that are most appropriate to the research being 
undertaken to be applied. Theories that have been widely applied to health behaviour 
include the Extended Parallel Processing Model (Witte 1992), Health Belief Model 
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(Rosenstock et al. 1988), Protection Motivation Theory (Rogers 1975), Social Cognitive 
Theory (Bandura 2004)  and Theory of Planned Behaviour (Ajzen 1991). 
Table 2.1 outlines the main theoretical constructs and the main focus of the theories. It 
can be seen from Table 2.1 that the theories include different constructs which 
determine behaviour and influence what populations/behaviours the theory can be 
best applied to.  
Table 2.1. Overview of health behaviour theories 
Theory Main constructs Theoretical focus 
Extended Parallel  
Processing Model 
 Threat appraisal 
 Fear 
 Disregard 
 Efficacy appraisal 
 Danger control (constructive 
response) 
 Fear control (defensive response) 
 Often used to assess 
behavioural impact of health 
risk information 
 Depending on the efficacy 
appraisal people will be 
motivated to engage in 
danger control or fear 
control 
Health Belief Model  Perceived susceptibility 
 Perceived severity 
 Perceived benefits 
 Perceived barriers 
 Cues to action 
 Self-efficacy  
 Developed to predict health 
behaviour 
 Involves threat perceptions 
and evaluation of behaviours 
to counteract this threat 
Protection 
Motivation Theory 
 Threat appraisal (severity, 
vulnerability, intrinsic and extrinsic 
rewards) 
 Coping appraisal (response costs, 
response efficacy and self-efficacy) 
 Often used to assess 
behavioural impact of health 
risk information 
 Threat and coping interact to 
influence motivation for risk 
reducing behaviour 
Social Cognitive 
Theory 
 Self-efficacy  
 Goals 
 Behaviour 
 Outcome expectations (physical, 
social) 
 Socio-structural factors (facilitator, 
impediments)  
 Focuses on expectancies of 
environmental cue 
 Motivation and action is 
based on situation outcome, 
action outcome and self-
efficacy 
Theory of Planned 
Behaviour  
 Attitudes 
 Subjective norms 
 Perceived behavioural control 
 Behaviour intention 
 Focuses on behavioural 
beliefs 
 Does not explicitly cater for 
emotional or arousal 
variables 
The Extended Parallel Processing Model (EPPM, Figure 2.1) (Witte 1992) and 
Protection Motivation Theory (PMT, Figure 2.2) (Rogers 1975) have commonalities, 
both focusing on threat appraisal (Table 2.1). However, there is an emphasis on 
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arousal in the EPPM that distinguishes it from the PMT. Although fear arousal is an 
integral part of EPPM, a review of the EPPM reported that fear has a weak effect on 
attitudes and behavioural intentions (Witte and Allen 2000).  
 
Figure 2.1. The Extended Parallel Process Model (adapted from Witte 1992) 
 
A meta-analysis of 12 studies that used the PMT in health related research reported 
that self-efficacy was the most consistent correlate of behavioural intention, and that 
coping appraisal variables collectively were reported to be more predictive than the 
threat appraisal variables (Milne et al. 2002). A criticism of both of these theories is the 
emphasis on the processing of threats in a careful manner in order for behaviours to 
be considered, which is potentially problematic due to people not always processing 
information this way. This could especially be the case for women at increased genetic 
risk of ovarian cancer, who may not process threats in a considered manner due to 
their increased risk status and possible heightened threat levels. The predictive ability 
of these models has also been questioned in the literature (Armitage and Conner 
2000). Specifically, the ability of the PMT to predict future behaviour has been 
reported as weak (Milne et al. 2002).  
 
22 
 
Figure 2.2. Protection Motivation Theory (adapted from Rogers 1975) 
Unlike the EPPM and PMT, self-efficacy is the main focus of Social Cognitive Theory 
(SCT, Figure 2.3) and is determined by the individuals’ beliefs about whether the given 
behaviour is in their control (Bandura 2004). The theory also includes wider influences, 
such as environmental cues, which act as either facilitators or barriers to behaviour. 
SCT also emphasises the importance of social systems surrounding the individual, with 
people in the individuals’ environment shaping and influencing beliefs (Bandura 2004). 
Self-efficacy has been reported to be the most predictive variable within the model 
(Armitage and Conner 2000). Self-efficacy could be important for women at increased 
genetic risk of ovarian cancer due to their inherited risk status potentially influencing 
their beliefs about the amount of personal control they have over behaviours.  
 
 
Figure 2.3. Social Cognitive Theory (model from (Bandura (2000)) 
 
The Health Belief Model (HBM, Figure 2.4) states that when faced with a potential 
health threat people consider their susceptibility and the severity of the health threat 
when deciding whether to act, as well as the benefits and barriers to carrying out the 
behaviour  (Conner and Norman 2005, Rosenstock et al. 1988). Studies have reported 
fewer perceived barriers and higher perceived susceptibility to be the strongest 
determinants of behaviour (Lashley 1987, Wyper 1990). Knowledge has also been 
reported to be an important determinant of behaviour in cancer contexts including 
breast self-examination and cervical screening (Burak and Meyer 1997, Lashley 1987). 
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The inclusion of susceptibility could make this theory particularly applicable to women 
at increased genetic risk of ovarian cancer as it enables exploration of the influence of 
their risk status on help seeking decisions. The construct self-efficacy, as discussed in 
the SCT was not included in the original HBM, but was later included in extended 
versions of the HBM (Rosenstock et al. 1997). A recent meta-analysis of 18 studies by 
Carpenter (2010) concluded that perceived barriers and perceived benefits were the 
most consistent predictors of behaviour. 
 
Figure 2.4. The Health Belief Model (from Stretcher & Rosenstock (1997) in Glanz et al (2008)) 
 
The Theory of Planned Behaviour (TPB, Figure 2.5) focuses on behavioural beliefs, with 
little attention paid to emotional or arousal variables (Table 2.1). Subjective norms and 
perceived behavioural control were identified as influencing intention in relation to 
testicular self-examination (Brubaker and Wickersham 1990). Subjective norms have 
also be shown to be strong determinants of intention for breast cancer screening 
attendance (Rutter 2000). However, the subjective norms construct has been reported 
to be a weak predictor of intentions in a meta-analysis on the efficacy of the TPB by 
Armitage and Conner (2001). The meta-analysis also reported that the TPB may be 
better at predicting intention and behaviour when applied to self-reported behaviour 
as opposed to observed behaviour (Armitage and Conner 2001). As emotional and 
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cognitive representations of risk are thought to be influential for women at increased 
genetic risk of ovarian cancer (Andersen et al. 2002, Brain et al. 1999, Kash et al. 1992), 
TPB may not be best applied in the current context. 
 
Figure 2.5. The Theory of Planned Behaviour (source Ajzen 1991) 
 
It is evident that there is some overlap in the constructs between the theories 
discussed, with this reflecting the considerations that need to be made when applying 
a theory to a health behaviour (Ogden 2003). Of the health behaviour theories 
presented, the HBM constructs could be best applied to explain awareness and 
anticipated symptomatic presentation in women at increased genetic risk of ovarian 
cancer. The focus on the benefits and costs of performing a behaviour, and the 
inclusion of the constructs perceived susceptibility and self-efficacy could make it 
particularly useful in the current context. In women at increased genetic risk of 
developing ovarian cancer, the impact that perceived susceptibility has on anticipated 
presentation is particularly important to understand.  As a result of the HBMs 
applicability when applied to ovarian cancer awareness and anticipated symptomatic 
presentation, the HBM will be the main theory used to guide the research in this 
thesis. The HBM is presented in more detail in the following section. 
 
2.3.2 Choice of theory 
The HBM has been widely used in health behaviour research and has been used for 
predicting the likelihood of actual and hypothetical behaviours in a variety of cancer 
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contexts (Cohen 2006, Grunfeld et al. 2002, Kash et al. 1992, Norman and Brain 2005, 
Sohl and Moyer 2007). The model has also been frequently used in the development of 
interventions over the past 40 years (Jones et al. 2013). The HBM focuses on personal 
characteristics and cognitive processes in order to explain the likelihood of a behaviour 
being carried out (Wyke et al. 2013). The HBM comprises theoretical constructs 
including knowledge, self-efficacy, perceived benefits, barriers, severity and 
susceptibility, threat and cues to action (Rosenstock et al. 1997). 
 
2.3.3 Constructs of the Health Belief Model 
The conceptualisations of HBM constructs are shown in Figure 2.4. Constructs are 
grouped under the headings Individual Perceptions, Modifying Factors and Likelihood 
of Action. 
 
Perceived threat is an important construct within the model (see Figure 2.4). The HBM 
states that perceived threat and its emotional consequents predict health belief action 
(Jones et al. 2013). Individual perceptions comprise how individuals perceive their 
susceptibility to, and the severity of, the health problem. The construct of perceived 
susceptibility is important in encouraging health related behaviour. The more 
susceptible people perceive themselves to be, the more likely they will engage in 
behaviour to reduce that risk  (Rosenstock et al. 1988). Perceived susceptibility is 
closely linked to perceived severity and relates to the perceived seriousness of the 
disease (Rosenstock, Strecher et al. 1997).  Perceived benefits comprise both medical 
and psychosocial benefits of engaging in health promoting behaviours (Rosenstock et 
al. 1997).  Perceived barriers consist of practical barriers to performing the behaviour 
as well as the psychosocial costs associated with performing the behaviour, and 
judgements as to whether the new behaviour is better than current behaviours 
(Rosenstock et al. 1997). Perceived benefits and barriers are grouped under the 
‘likelihood of action’ heading, as it is the consideration of the benefits and barriers that 
determine the likelihood of the behaviour being carried out. Perceived benefits and 
barriers are integral to behaviour uptake, with behaviour more likely to be conducted 
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if more benefits are perceived to carrying it out than barriers (Conner and Norman 
2005, Rosenstock et al. 1988). It is therefore important to highlight the benefits of 
presenting with possible symptom concerns, whilst at the same time addressing and 
minimising barriers. 
 
 Cues to action are needed for people to engage in behaviour that address the health 
threat and can take various forms, including a physical symptom, health education 
leaflets, direct guidance from a health care professional, mass media and influences of 
significant others. Modifying factors are personal variables that influence the health 
behaviour, such as age, education, symptom knowledge and self-efficacy. The HBM 
hypothesises that these constructs influence the likelihood of behaviour (Rosenstock 
et al. 1997). 
 
When applied to anticipated ovarian cancer symptomatic presentation, the HBM 
specifies that those who perceive themselves to be susceptible to ovarian cancer, and 
believe ovarian cancer to be a serious threat are more likely to be motivated to engage 
in behaviours that are targeted towards this threat. The HBM will be used in this thesis 
to help identify salient health beliefs in women at increased genetic risk of ovarian 
cancer and a general population sample, which will lead to an understanding of 
awareness and anticipated presentation in different risk populations. Once identified, 
these determinants can be included and targeted in an intervention that addresses 
these issues. It is anticipated that the HBM will guide intervention components aimed 
at encouraging appropriate symptomatic presentation whilst maintaining 
psychological wellbeing in women at increased genetic risk of developing ovarian 
cancer. 
 
2.4 Anticipated presentation and barriers 
It is important to draw on existing literature about awareness and symptomatic 
presentation in order to make predictions for the present research based on best 
available evidence. When presentation times are discussed in the literature, the 
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potential contributors to longer presentation are sometimes attributed to the patient, 
and are termed ‘patient delay’ (Andersen et al. 1995). Patient delay refers to the time 
after the individual notices a sign or symptom to the time taken to seek medical advice 
(Andersen et al. 1995). However, in recent formulations, this term is viewed as 
somewhat judgemental due to the negative connotations and blame associated with 
the term “delay”, thus “patient interval” is now preferred (Walter et al. 2011). 
Contributors to this decision to seek medical advice can be explored using the 
concepts of the HBM that have previously been described. 
 
Drawing on existing literature will enable understanding to be gained on how the 
constructs have worked in other populations or contexts. This could aid understanding 
of the complex relationship between awareness and presentation. Cancer awareness 
involves not only increasing knowledge about symptoms, but also increasing 
confidence and motivation to present promptly in the presence of such symptoms 
(Forbes et al. 2011). Empirical research can be drawn on to determine whether or not 
there is evidence for the constructs outlined by the HBM for reflecting determinants of 
awareness and anticipated presentation. Literature from the wider cancer context will 
be considered due to the current lack of research in samples of women at increased 
genetic risk of ovarian cancer.  
 
2.4.1 Population studies of cancer symptom awareness and presentation  
The focus on awareness and beliefs in cancer demonstrates that delayed presentation 
is thought to be associated with poorer survival (Macleod et al. 2009, Ramirez et al. 
1999). A population based survey of public awareness of cancer in Britain was 
conducted by Robb et al. (2009). Multivariate analysis revealed an association between 
higher symptom awareness and shorter anticipated presentation, suggesting that 
symptom awareness directly translates to shorter presentation times (Robb et al. 
2009). The most commonly endorsed barriers to presentation were difficulty getting 
an appointment, worry about wasting the doctor’s time and worry about what the 
doctor might find (Robb et al. 2009). In line with the HBM, the endorsement of more 
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barriers was associated with longer anticipated presentation. These findings suggest 
that improving cancer symptom awareness and reducing barriers could lead to earlier 
presentation. Robb et al. (2009) also reported that those who were more educated 
were more likely to report longer anticipated presentation.  
 
Differences in cancer awareness and beliefs were explored in an international study of 
cancer survival differences in six countries (Australia, Canada, Denmark, Norway, 
Sweden and the UK ) (Forbes et al. 2013). There was a lack of difference between 
symptom awareness between the countries, however differences were found in 
cancer beliefs. The UK, which has the poorest cancer survival outcomes out of the 
participating countries, had the lowest awareness of the age related risk of cancer. The 
UK population also reported more negative beliefs towards cancer and endorsed more 
barriers to anticipated presentation compared to the other countries, with worry 
about wasting the doctor’s time the most prominent barrier (Forbes et al. 2013). These 
findings suggest that a focus on improving the doctor-patient interaction in primary 
care is needed in order to help reduce barriers to presentation. As outlined by the 
HBM, reducing such barriers and negative beliefs could bring about early anticipated 
presentation, which in turn could improve survival outcomes. 
 
The data from the UK countries within the Forbes et al. (2013) study (England, 
Northern Ireland and Wales) was also analysed separately to provide more of an 
insight into the patterns of cancer awareness and beliefs held by the UK population 
(Quaife et al. 2013). Analysis indicated that higher education was associated with 
better recognition of individual cancer symptoms. Better recognition of cancer 
symptoms was related to earlier anticipated presentation times, whereas endorsing 
the belief that it would be difficult to see a doctor was associated with longer 
anticipated presentation times (Quaife et al. 2013), again, demonstrating the negative 
impact of endorsing barriers to presentation as outlined by the HBM.   
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UK population sample data from Simon et al. (2010) retrospectively examined 
associations between symptom awareness and longer anticipated presentation times. 
Participants were asked whether they had been to see a doctor with symptoms they 
thought might have been cancer within the previous three months. Better symptom 
knowledge helped people recognise symptoms, which in turn reduced appraisal and 
presentation delays (Simon et al. 2010), highlighting the potential modifying role of 
symptom knowledge on behaviour, as outlined by the HBM. More positive attitudes 
were reported to reduce presentation delay (Simon et al. 2010). Similar findings were 
also reported in a synthesis of 32 qualitative studies by Smith et al. (2005b), where the 
most common determinant of longer anticipated presentation was poor symptom 
recognition.  
 
2.4.2 Ovarian cancer awareness and presentation 
Few research studies have been conducted that focus on awareness and symptomatic 
presentation in ovarian cancer. Lockwood-Rayermann et al. (2009) investigated 
awareness of ovarian cancer risk factors and symptoms in a general population sample 
in the USA. Similar to studies concerning general cancer symptom awareness, low 
levels of ovarian symptom awareness were reported. Those who were less educated 
had poorer levels of awareness of ovarian symptoms and risk factors ( Lockwood-
Rayermann et al. 2009). However, whilst this study provides insights to symptom 
awareness specific to ovarian cancer, it did not explore the potential influence of 
ovarian cancer symptom awareness on anticipated presentation. 
 
A UK study investigating the influence of symptom awareness on anticipated 
presentation conducted by Low et al. (2013b) reported a lack of association between 
awareness of gynaecologic cancer symptoms and anticipated presentation.  These 
findings contrast with those of studies examining the relationship between general 
cancer symptom awareness and anticipated presentation (Quaife et al. 2013, Robb et 
al. 2009) and could be indicative of different mechanisms underlying these processes 
which are specific to ovarian cancer.  The historic view that ovarian cancer is an 
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asymptomatic disease (Goff et al. 2007) could lead to a lack of connection between 
symptoms and anticipated presentation because people do not associate symptoms 
with ovarian cancer (Cooper et al. 2011, Goff et al. 2000, Lockwood-Rayermann et al. 
2009). An alternative explanation for the lack of association could be that ovarian 
cancer awareness is indirectly associated with anticipated presentation. It could be 
that symptoms alone are not always enough to warrant seeking medical advice, with 
awareness influencing anticipated presentation through other mechanisms (Smith et 
al. 2005b). The indirect influence of symptom knowledge is outlined in the HBM, 
where symptom knowledge is described as indirectly influencing anticipated 
presentation through other components of the model, including perceived threat and 
perceived benefits and barriers to presentation (see Figure 2.4). More research needs 
to be done to understand the relationship between awareness and presentation for 
ovarian cancer in order for this process to be fully understood. 
 
2.4.3 Contributors to longer presentation in ovarian cancer 
Awareness about cancers may be influenced by public awareness campaigns (Eadie 
and MacAskill 2008, Forbes et al. 2011), with this evident in more common cancers 
which are paired with large-scale public campaigns, such as being breast awareness 
and anti-smoking campaigns (Redeker et al. 2009). People may have knowledge about 
well-known cancers but often possess little knowledge about less well known cancers 
(Stubbings et al. 2009). In the wider cancer context, some symptoms of cancer are 
viewed as cues to action because of the specificity of the symptom as an indicator of 
cancer (e.g., breast lump, irregular bleeding, and mole). These symptoms are often 
termed ‘red flag’ symptoms (Macleod et al. 2009) because they are easily recognised, 
and therefore can be more readily attributed to possible cancer (Ramirez et al. 1999, 
Robb et al. 2009). However, in the case of ovarian cancer, the main signs and 
symptoms are less specific and could be attributed to many other reasons e.g. diet, 
lifestyle, Irritable Bowel Syndrome, diverticulitis (Austoker 2009, Goff et al. 2000, 
Hamilton et al. 2009). 
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A possible explanation for the patient interval in presentation in ovarian cancer could 
be that these symptoms may be attributed to a benign condition or not taken 
seriously, and therefore are not perceived as red flags or cues to action. In ovarian 
cancer this could be particularly relevant for the non-pelvic symptoms which are vague 
in nature (Fitch et al. 2002, Goff et al. 2000). Non-recognition of the importance of 
symptoms has been reported as a determinant of presentation in the wider cancer 
context (Bish et al. 2005, Macleod et al. 2009, Quaife et al. 2013). This is echoed by 
Smith et al. (2005b) who reported that it is not just knowledge or recognition of 
symptoms that is important, but also the interpretation of them that plays an 
important role in presentation. 
 
Issues surrounding attribution of symptoms of ovarian cancer have been highlighted in 
the literature. Goff et al. (2000) asked women diagnosed with ovarian cancer to recall 
symptoms and presentation experiences in a survey included in an ovarian cancer 
newsletter. Women who had experienced non-pelvic symptoms such as fatigue, 
gastrointestinal or urinary symptoms were significantly more likely to have ignored 
their symptoms. Symptoms were also commonly misattributed to benign causes such 
as menopause, ageing and daily stressors (Goff et al. 2000). However, it should be 
noted that participant bias may be a problem in this study as the recruitment pool 
consisted of subscribers to a newsletter, and the sample may therefore not be 
representative of people not yet diagnosed with ovarian cancer or those at other 
stages of diagnosis and treatment. Another potential problem is recall bias, with the 
time elapsed from diagnosis to time of participation an important factor influencing 
the accuracy with which participants recall information relating to experiences before 
their diagnosis. It was reported that 50% of participants received their diagnosis more 
than two years prior to the study, which is arguably too long to expect people to 
accurately recall symptoms experienced. In addition, participants in this study were 
not asked about family history of ovarian cancer or risk status, therefore it is not 
known whether the sample included women at increased risk of ovarian cancer. 
Therefore the applicability of these findings for women at increased genetic risk is not 
known. Similarly, Evans et al. (2007) reported delays in presentation as a result of 
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misattributing symptoms of ovarian cancer to stress, menopause or benign conditions 
and not recognising symptom seriousness. Again, neither the risk status of the 
participants, nor the time lapse from diagnosis to participation was stated, limiting the 
conclusions that can be drawn from these data.  
 
The UK Collaborative Trial of Ovarian Cancer Screening (UKTOCS) is a large scale study 
in the UK that is evaluating the effectiveness of ovarian cancer screening. Data were 
gathered on awareness of ovarian cancer risk factors alongside beliefs and attitudes 
towards screening (Fallowfield et al. 2010). Less than half of women recognised the 
increased risk of developing ovarian cancer after the menopause, even though in 
postmenopausal women 90% of ovarian cancers develop sporadically (Menon et al. 
2009). Lack of awareness of the age related risk of cancer could therefore be a barrier, 
and could be especially problematic if older people have poorer symptom knowledge 
(Fallowfield et al. 2010). Misconceptions concerning ovarian cancer are frequently 
reported in the literature, with many women falsely believing that the cervical smear 
test detects ovarian cancer (Cooper et al. 2011, Jones et al. 2010, Lockwood-
Rayermann et al. 2009, Meisel et al. 2013, Tiller et al. 2005). Similar misconceptions 
also arose in the UKTOCS study, where there were beliefs that an abnormal smear test 
was indicative of ovarian cancer (Fallowfield et al. 2010). Such erroneous beliefs are 
problematic, especially when they concern detection because women may believe 
they are having a form of ovarian cancer screening, when in fact they are not. If people 
believe they are being monitored for the presence of a disease, they may not pay 
attention to bodily changes that could be indicative of the disease because they 
believe that potential problems will be detected by ‘screening’. These misconceptions 
could be due to confusion with other cancers or diseases, and highlight the need for 
clarity and education in relation to ovarian cancer.  
 
From these studies it can be seen that awareness and beliefs play a role in the cancer 
diagnostic pathway and that these beliefs reflect the constructs of the HBM.  However, 
the research to date has not included those at increased genetic risk of ovarian cancer, 
hence it is difficult to determine what pattern of beliefs or levels of awareness within 
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this population, or how these influence presentation with possible ovarian cancer 
symptoms. 
 
2.5 Impact of increased genetic risk status on symptom awareness and 
presentation  
The previous study findings are useful for understanding possible barriers to 
presentation and cancer awareness in the general population, however a different 
pattern may be seen in those at increased genetic risk. At risk populations for specific 
cancers may possess more knowledge about the disease, may have different beliefs, 
such as increased worry, and endorse different barriers as a result of their risk status 
and perceived susceptibility (Fallowfield et al. 2010). The importance of risk status is 
highlighted in the HBM through the inclusion of the ‘perceived susceptibility’ construct 
(Rosenstock et al. 1988).  
 
Fatalistic beliefs regarding cancer outcomes could possibly contribute to delay in both 
the general population and those at increased genetic risk (Beeken et al. 2011, Robb et 
al. 2009, Von Wagner et al. 2011). However, these beliefs may be more prominent in 
women at increased genetic risk who may have experienced ovarian cancer in family 
members diagnosed with the disease. If people have had negative experiences with 
ovarian cancer these beliefs could lead to a circular process whereby negative 
outcome expectancies could cause delayed presentation, which in turn leads to later 
stage at diagnosis and is then related to poorer outcomes (Von Wagner et al. 2011). 
Fear of cancer could lead to irrational responses to cancer symptoms and 
consequently, delayed presentation (Eadie and MacAskill 2008). In such a scenario, 
delays in presentation could therefore be attributed in part to a combination of poor 
symptom awareness and possessing negative beliefs towards cancer (Grunfeld et al. 
2002), with this also supported by the HBM.  
 
Experience with illness could also act as a cue to action (Andersen et al. 2004, 
Lockwood-Rayermann et al. 2009, Von Wagner et al. 2011). Experience with cancer 
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and fear of cancer could therefore influence symptom appraisal and presentation 
behaviour in different ways (Eadie and MacAskill 2008). Women at increased genetic 
risk of ovarian cancer have often seen family members diagnosed, and these 
experiences could shape their own beliefs about ovarian cancer ( Lockwood-
Rayermann et al. 2009, Tiller et al. 2005, Trask et al. 2001). Fallowfield et al. (2010) 
reported that women who had a family member affected by ovarian cancer had better 
knowledge of the disease compared to those without this experience. Personal 
experience has also been shown to be influential in breast cancer awareness (Absetz et 
al. 2003). The personal experience that many women at increased genetic risk of 
ovarian cancer have had may influence aspects of their own beliefs and behaviours 
about the disease, and can be conceptualised as ‘cues to action’ within the HBM (see 
Appendix 2). Andersen et al. (2009) suggest that an individual’s understanding of 
bodily sensations relating to a specific cancer are nested within the social and cultural 
context of the individual. The personal experiences women at increased genetic risk of 
ovarian cancer have had may therefore influence their own perceptions of the signs 
and symptoms of disease. 
 
The empirical studies presented are useful in exploring the relationship between 
symptom awareness and anticipated presentation and provide evidence for the utility 
of the HBM constructs in the current context. The studies also highlight the gap in 
research concerning determinants of symptomatic presentation in women at increased 
genetic risk of ovarian cancer. In order to understand the possible influence of 
increased genetic risk status on awareness and presentation in ovarian cancer, 
research needs to be undertaken with the target population ideally in comparison with 
a general population sample. Educational materials can then be created with the aim 
of maximising awareness and reducing potential barriers to presentation in different 
risk populations.  
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2.6 Foundations to mixed method approaches 
Different methodological approaches will ensure that salient health beliefs for 
awareness and symptomatic presentation for women at increased genetic risk of 
ovarian cancer can be explored and represented in a draft symptom awareness tool. 
The multiple approaches to answering the research question offered by the mixed 
method approach will allow for an inclusive understanding of the research question. A 
mixed method approach will  allow for the MRC complex intervention guidelines to be 
followed, ensuring thorough theoretical and modelling phases of development, 
including identifying the evidence base and identifying/developing appropriate theory 
(Craig et al. 2008b). The use of mixed methods will also help to generate a strong 
evidence base for the preliminary ovarian cancer symptom awareness tool. Complex 
interventions are often used in public health and are commonly used for education 
purposes that have health consequences (Craig et al. 2008a). The MRC guidelines 
propose that a strong theoretical understanding is crucial through all stages of 
development, allowing for insight to be gained regarding how the intervention causes 
change, how to identify strong and weak determinants of change, and how to 
determine and effectively measure the active ingredients within the intervention that 
are causing change (Craig et al. 2008a). The theoretical foundations therefore have 
reach beyond the development of the intervention and are also crucial for 
understanding and evaluating the impact of the intervention.  
 
As the PhD phases progress, the mixed methods approach enables the findings from 
previous phases to be drawn upon in order to guide subsequent phases. This will allow 
the symptom awareness tool to be developed based on rigorous methods which were 
carried out using a sample of likely tool users and providers. The use of different 
methods will lead to a thorough understanding of awareness and anticipated 
symptomatic presentation in women at increased genetic risk of ovarian cancer, and 
will also permit comparisons to a general population sample to be made. The 
philosophical foundations of a mixed method approach enables the problem context 
to be explored from multiple angles. Sequential phases will allow for the research to 
be more specific and tailored to what is important to the target population. 
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Phase One will identify existing ovarian cancer symptom awareness tools using a 
systematic search method and will evaluate the quality, content and format of these 
tools. This evidence will then be utilised in later phases of the PhD, when the draft tool 
is being created. The systematic search follows the MRC complex intervention 
guidelines, which state that researchers should understand what is already known 
about similar interventions and what methods were used to create them (Craig et al. 
2008b).  
 
A survey guided by the HBM will be carried out in Phase 2 with women at increased 
genetic risk of ovarian cancer and compared to an existing dataset consisting of a 
general population sample. The analysis of the quantitative survey data from two 
different risk populations will enable the identification of the mechanisms underlying 
awareness and anticipated presentation in women at increased genetic risk of ovarian 
cancer in comparison to those in a general population sample. For example, emotional 
barriers may be more salient in determining awareness/anticipated presentation in the 
context of increased genetic risk. The research will be undertaken to develop a 
theoretical understanding of the determinants of anticipated symptomatic 
presentation and will lead to an understanding of how a change in anticipated 
presentation may be achieved. This process will help develop the rationale for the 
intervention (Craig et al. 2008a) and will allow for identification of any determinants 
that are unique to women at increased genetic risk of developing ovarian cancer and 
those which are shared with the general population sample. Identifying common and 
unique determinants is important because interventions may work best if they are 
tailored to personal circumstances (Craig et al. 2008b). The data collection method for 
this phase of work will be advantageous as quantitative research allows for large 
amounts of data to be gathered without geographic restrictions and in short time 
frames (Black 1994, Johnson and Onwuegbuzie 2004). It is therefore useful for 
studying large numbers of people in a standardised way. Quantitative research allows 
for testing of theories, as well as for testing hypotheses made prior to data analysis. 
However, such methods can be restrictive as respondents are usually restricted to 
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answers based on pre-determined response options. Therefore, if the researcher has 
not accurately reflected response categories it could lead to oversights (Green and 
Thorogood 2013, Johnson and Onwuegbuzie 2004). The testing of hypotheses could 
also be too narrow, with confirmation bias a potential problem associated with 
quantitative methods.    
 
Qualitative, semi-structured interviews will be conducted in Phase 3 in order to further 
explore salient health beliefs as outlined by the HBM in Phase Two. A sample of 
women at increased genetic risk of ovarian cancer from Phase Two will be invited to 
participate in the interviews which will also explore the acceptability/feasibility of a 
risk management approach based on ovarian cancer symptom awareness. Using the 
quantitative findings from the previous phases to influence and inform the qualitative 
phase is an advantage of the mixed method approach (Johnson and Onwuegbuzie 
2004). In qualitative research responses are not restricted, so that participants can 
express their own understanding and meanings of the topic area (Black 1994, Green 
and Thorogood 2013). Qualitative research allows for smaller numbers of participants 
to be understood in detail, and can be particularly useful when the subject matter is 
sensitive, complex or personal in nature (Smith 1996). Unlike quantitative research, 
which traditionally tests a hypothesis, qualitative research has an emphasis on 
hypothesis generation based on what the participants deem to be important (Black 
1994, Green and Thorogood 2013). Due to traditionally small sample sizes, the findings 
may not be as generalisable as those from quantitative studies (Johnson and 
Onwuegbuzie 2004, Keeble et al. 2014). Qualitative research can also be a time 
consuming process, both in terms of data collection and analysis. As the data involves 
unrestricted responses, the analysis of data is less systematic and is more susceptible 
to researcher bias. Mixed method approaches allow for a blend of traditional 
quantitative and qualitative research approaches. Combing the two approaches in 
subsequent phases lets the researchers draw on the strengths, and minimize the 
weaknesses of each method (Johnson and Onwuegbuzie 2004). Another consequence 
is the potential for stronger conclusions to be made based on the combining the 
findings from different phases, with different methodologies.  
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Phase Four will gain consensus on the symptom content to include in the tool based on 
empirical evidence (systematic literature search) and clinical evidence (virtual 
reference group of ovarian cancer experts). The systematic search method allows for 
the best available information regarding symptoms which are indicative of ovarian 
cancer to be identified and synthesised and presented to a group of ovarian cancer 
experts in order to elicit their clinical expertise and opinion. Both sets of evidence can 
then be synthesised in order to guide choices about what symptom information to 
present in the awareness tool.  
 
Finally, the findings from these phases can be synthesised for the development of the 
preliminary tool in Phase Five. The draft tool will then undergo user testing with 
cognitive interviews with a sample of the target population and potential providers, 
with this process providing a further opportunity to involve stakeholders in the 
development process (Craig et al. 2008a). Cognitive interviews will involve presenting 
participants with the draft tool and then applying cognitive interview techniques to 
elicit understanding of the tool and opinion on content. The feedback and opinions will 
then be considered, with any potential changes made in order to create the final tool. 
 
2.7 Conclusion 
The present chapter has demonstrated how theory will form an integral part of the 
PhD and has proposed how the HBM will be used to develop a symptom awareness 
tool that addresses the specific needs of women at increased genetic risk of ovarian 
cancer. Research has been presented that helps to define the problems for ovarian 
cancer symptomatic presentation and an underlying theory has been presented (Craig 
et al. 2008b, Smith et al. 2012). The gap in research on ovarian cancer awareness and 
anticipated presentation in women at increased genetic risk has also been highlighted. 
Whilst the relationship between awareness of symptoms and presenting to get 
medical advice is not simple, it is known that delaying getting medical help after 
noticing symptoms is likely to lead to poorer prognosis (Allgar and Neal 2005b, 
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Austoker et al. 2009, Richards 2009a). It is therefore important to educate women 
about what the symptoms of ovarian cancer are, what to do in their presence and also 
to try to reduce the fear and barriers relating to consultation (Smith et al. 2005b). The 
described mixed method approach will lead to the development of a tool that is the 
product of theoretically based research involving the target audience. The research 
discussed in this chapter has explored the determinants of symptom awareness, in 
addition to the potential personal and service facilitators and barriers to presentation 
in the context of the HBM. Levels of awareness, and facilitators and barriers to 
presentation in women at increased genetic risk are not currently understood, and as 
discussed, these beliefs could be different in this population due to their risk status.   
 
This chapter has demonstrated how the use of the HBM throughout the phases will 
allow for a deep understanding of the constructs within the model that are influencing 
ovarian cancer awareness and anticipated presentation. As the thesis progresses, the 
project will start to identify what constructs should be targeted in the intervention, 
and how they can be best incorporated into the intervention. This will lead to the 
development of a theoretically driven and empirically based symptom awareness tool 
which addresses the specific needs of women at increased genetic risk of ovarian 
cancer.
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3 A systematic search of ovarian cancer symptom awareness tools 
 
3.1 Chapter overview 
When creating an intervention it is an important first step to identify and evaluate 
what interventions already exist. A systematic search of ovarian cancer symptom 
awareness tools is presented, followed by a critical appraisal of the content and quality 
of identified tools. An appreciation of the strengths and limitations of existing tools, 
particularly in relation to theoretical grounding is emphasised in the MRC complex 
intervention guidelines (Craig et al. 2008b) and will assist in developing an ovarian 
cancer symptom awareness tool for women at increased genetic risk.  
 
3.2 Introduction 
3.2.1 Background to ovarian cancer symptom awareness tools 
Symptom awareness tools are an increasingly popular method of sharing information 
about a specific topic, due to the low cost associated with production and the ease at 
which large populations can be reached (Evans et al. 2014). In the context of ovarian 
cancer, there has been a move towards symptom awareness due to the uncertain 
effectiveness of screening programmes (Menon et al. 2009) and low levels of ovarian 
cancer symptom awareness in the UK public (Cooper et al. 2012, Richards 2009a). 
Symptom awareness tools provide information about ovarian cancer symptoms and 
encourage women to seek medical advice if symptoms are experienced. 
 
A wide variety of ovarian cancer symptom awareness tools exist, yet there is a lack of 
research into the content and evaluation of such tools. Little is known about the range 
and quality of information in awareness tools that are available to women, especially 
those who search for information about ovarian cancer symptoms on the internet. In 
the context of the PhD, whether a symptom awareness tool exists that is specifically 
aimed at women at increased genetic risk of ovarian cancer is of particular interest. 
Women at increased genetic risk may have different health beliefs about ovarian 
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cancer compared to women in the general population and a tool for this population 
may need to be targeted at specific beliefs. Potential differences in those at increased 
genetic risk include higher levels of ovarian cancer worry (Andersen et al. 2002, Kash et 
al. 1992), different barriers to presentation and different attitudes towards ovarian 
cancer, such as negative cancer beliefs (Bennett 2009, Ramirez et al. 1999). These 
differences could be a result of increased saliency of health threat (Schwartz et al. 
1995) and perceived susceptibility in women at increased genetic risk (Brain et al. 
1999, Schwartz et al. 1995). 
 
The lack of evaluation of existing tools may not be specific to ovarian cancer symptom 
awareness, with Abraham et al. (2007) suggesting that “there appears to be a general 
dearth of research into the content of health promotion and patient information 
leaflets”(p36). Ideally, health information should be theory based and have undergone 
an extensive development process particular to the specific health issue (Craig et al. 
2008b). If an assessment of the quality and content of a tool has not been carried out, 
little is known about the quality of the information provided to users.  
 
3.2.2 Theoretical background to ovarian cancer symptom awareness tools 
In terms of evaluating existing symptom awareness tools the most relevant theoretical 
components of the HBM will be perceived susceptibility, perceived severity, cues to 
action, perceived benefits and perceived barriers. Perceived threat cannot be directly 
assessed in an evaluation of existing tools because it arises as a result of Individual 
Perceptions, with these constructs varying according the individual characteristics 
(Rosenstock et al. 1988). Similarly, Modifying Factors will not be evaluated due to 
these constructs depending on the individual who is reading the material. Mapping the 
content of the identified symptom awareness tools on to the HBM will reveal whether 
the tools include constructs that the theory states will increase the likelihood of a 
behaviour being carried out. Specifically, this will be whether the tools are likely to 
achieve their aim of increasing symptom awareness and/or early symptomatic 
presentation.  
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3.2.3 Symptom content 
Content of symptom awareness tools can be guided by the latest medical and 
government guidelines. Regulated government guidelines, which are medically and 
scientifically grounded are not only useful to guide the content of symptom awareness 
tools, but can also help medical professionals access standardised information in order 
to aid their daily practice. Such guidelines are particularly important when the history 
of ovarian cancer is taken into account, with its transition from a “silent killer” (Goff et 
al. 2007) to the “disease that whispers”(Twombly 2007) with recognisable symptoms 
(Bankhead et al. 2008, Goff et al. 2007, Hamilton 2009). 
 
Although the symptoms identified by the Department of Health (2009) and National 
Institute for Health and Clinical Excellence (2011) guidelines are very similar, clear 
guidance on what to do if these symptoms are experienced is lacking. This information 
concerning how long a symptom should be experienced for and with what frequency 
of occurrence reflects the lack of clinical consensus on symptom duration and 
frequency. The National Institute for Health and Clinical Excellence (2011) guidelines 
state that if symptoms are “experienced more than 12 times per month” medical 
advice should be sought, with the Department of Health (2009) stating that advice 
should be sought “if symptoms occur on most days”. The message regarding frequency 
and duration of symptoms that are experienced is therefore unclear and it will be 
important to identify symptom guidance provided in existing ovarian cancer symptom 
awareness tools.  
 
3.2.4 Systematic searches 
Systematic searches may involve searching academic databases as well the grey 
literature in order to identify available content on a specific topic (Liberati et al. 2009). 
Searching academic databases enables journals, unpublished articles and abstracts to 
be identified that are relevant to the search terms entered. The identified articles can 
then be screened for their relevance to the topic in question before the articles are 
synthesised to provide results which summarise the literature in the area. However, as 
there is little published information surrounding ovarian cancer symptoms awareness 
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tools, it was considered necessary to search other sources. Many people turn to the 
internet in search of health information (Cooper et al. 2011), with health related 
websites amongst the most widely used (Wilson and Risk 2002). This is reflected in the 
increasing number of patients asking doctors in consultations about information they 
have found on the internet (Bass 2003). The presence of information on the internet is 
potentially problematic in terms of health professionals not knowing what information 
patients have had access to, with this exacerbated by the lack of regulation over 
information that is shared on the internet. This could lead to potential variation in the 
quality and content of information that is freely available to large amounts of people. 
It was therefore considered relevant to systematically search the internet as well as 
the academic literature for symptom awareness tools. 
 
3.2.5 Critical appraisal of ovarian cancer symptom awareness tools 
Ovarian cancer symptom awareness tools have not previously been systematically 
identified and evaluated, hence it is useful to refer to existing validated extraction and 
evaluation forms to aid this process. Michie et al. (2005) set out theoretical domains 
for investigating the implementation of evidence based practice in the context of 
behaviour change, which is in essence what ovarian cancer awareness tools should aim 
to do: provide women with information concerning symptoms that is based on 
research evidence. The validated theoretical framework aids the identification of 
theoretical constructs that are involved in behaviour change, such as knowledge, 
beliefs, skills and motivation (Michie et al. 2005). If symptom awareness tools are to 
increase awareness or promote timely symptomatic presentation it is important to 
identify whether behaviour change constructs are incorporated into existing tools.  
 
The International Patient Decision Aid Standards (IPDAS) Collaboration provides a set 
of criteria which assess the quality of decision support technologies (Elwyn et al. 2006). 
The criteria are assessed in a simple checklist format to facilitate quick, easy and 
comparable data collection. Although symptom awareness tools are not considered a 
decision aid, some of the IPDAS criteria are relevant as they capture information on 
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content, development processes and whether the tools have been guided by theory 
(Elwyn et al. 2006). Zaza et al. (2000) developed a “Data Abstraction Form” for 
standardized extraction of data from articles, with this process increasing consistency, 
validity and reliability, whilst reducing bias in the extraction process. The form consists 
of 26 items which describe the characteristics of the intervention and 23 items which 
assess the quality of the studies’ execution (Zaza et al. 2000). The distinction of two 
sections highlights that information not only needs to be gathered on tool content, but 
also on the quality of the execution of this information. Although these extraction 
forms were not created specifically for cancer symptom awareness tools, the 
systematic approach to the extraction of information regarding the quality of 
information can be applied to awareness tools. These validated sources will be 
integrated to aid data extraction in the present study.  
 
A new form was created for this systematic search as existing forms would not have 
captured all information that needed to be extracted. The inclusion of items from 
Michie et al. (2005) in the extraction form allowed identification of theoretical 
constructs. The IPDAS criteria (Elwyn et al. 2006) helped influence items which capture 
information on content, effectiveness and the developmental process, with the form 
from Zaza et al. (2000) helping ensure items covered both the content of the tool and 
the quality with which the tools execute this information. Drawing from these existing 
forms, which were created based on rigorous methods, enabled data to be 
systematically extracted and summarized. 
 
3.2.6 Aims of the present study  
A search was conducted in order to identify existing ovarian cancer symptom 
awareness tools. The specific aims were to (1) systematically review existing ovarian 
cancer symptom awareness tools, (2) evaluate the quality and content of existing tools 
using a bespoke checklist that was adapted from existing sources, (3) map the 
identified tools on to the theoretical components of the HBM, and (4) make 
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recommendations for a proposed symptom awareness tool for women at increased 
genetic risk. 
 
3.3 Methods and Design 
3.3.1 Definitions 
For the purpose of this search, symptom awareness tools were defined as educational 
materials such as leaflets, factsheets, pamphlets, videos and posters (Chung et al. 
2007) which are related to ovarian cancer and include symptoms of ovarian cancer. 
3.3.2 Development of a search protocol 
A comprehensive search strategy was developed to ensure that the maximum number 
of tools was identified. The search consisted of two components to ensure that all 
possible tools were identified and was developed with the help of SysNet (Cardiff 
University Systematic Review Network). First, a systematic search of databases was 
conducted using PsychInfo, Medline and Embase, with relevant studies identified 
through titles and abstracts. A systematic search of the internet was carried out 
separately as it was anticipated that most of the tools would be hosted on websites. 
The protocol for the internet search (i.e. ‘grey literature’) consisted of a list of search 
terms which were generated in order to reflect what terms women may use when 
looking for information regarding ovarian cancer symptoms. As this type of search is 
different to the usual systematic search process, a pilot study was conducted in order 
to test the feasibility of the grey literature search protocol. 
 
3.4 Materials 
3.4.1 Grey literature search strategy 
Pilot study 
A pilot search was conducted to ensure that the grey literature search strategy was 
comprehensive. This pilot was run on five consecutive days from Monday 15th April 
2012 to determine whether the search needed to be run on multiple days. The search 
was run on Google, BING, Yahoo and ASK, as these accounted for 90% of search 
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engines used in the UK at the time of the study (Hitwise 2012). All four search engines 
were included to establish whether they all needed to be included in the full search. 
The search term ovarian cancer symptoms was typed in to each of the above 
mentioned search engines, with all generated website results on the first three pages 
extracted to a database. This process was repeated on each of the five days for the 
four search engines. A summary of the website’s name was entered into the database 
in order to easily identify the order in which the websites appeared on consecutive 
days, and to identify whether any new results were generated by the different search 
engines. The terms were typed with and without speech marks. Speech marks were 
used because if the term ovarian cancer symptoms was entered, the search would pick 
up any information where either the word ovarian or cancer or symptoms was 
mentioned, whereas if "ovarian cancer symptoms" was searched it would only 
generate results for the whole term as written. However, as members of the general 
public may not search this way, the search was also run without speech marks.  
 
In order to check consistency between search results generated by the different search 
engines the ‘BEAT symptom checker’ was chosen as a benchmark. This tool was the 
first website result on Google on day one of the pilot. The search results showed that 
the BEAT tool was generated in the search results for all four search engines, with the 
placement of this tool being consistent on each day the search was run (see Table 3.1). 
Decisions about how many days the search should be run were made based on column 
three in Table 3.1, which shows the number of new websites generated by each search 
engines on days 2-5 that were not identified in the search on day one. At first glance, 
this number of new websites may be interpreted such that the search should be 
conducted on consecutive days; however, these websites were all found at the end of 
the third page of results, and none of these websites were relevant to the search 
criteria. These findings suggested that there was little to be gained by running the 
search on consecutive days. Few new tools were found on the third page of search 
results and therefore it was decided to use only the first two pages of results in the full 
search. This complements research suggesting that 70% of internet users will not 
search beyond the second page of search results (Ryan et al. 2006).  
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Table 3.1. Websites generated by Google, Bing, Yahoo and Ask in the pilot search of grey 
literature 
Search 
engine 
Number of 
websites 
generated 
on day 1 
Number of websites 
generated on days 2-5 
that were not 
identified on day 1 
Position of NHS 
Live Well (where 
BEAT tool was 
found) 
Number of websites 
generated that were 
not identified by 
Google 
Google 36 7 1 n/a 
Bing 38 1 8 15 
Yahoo 40 2 8 3 
Ask 32 9 9 21 
 
When looking at the content of the search results differentiated by search engine, 
Yahoo generated the least number of different results compared to Google (Column 
five, Table 3.1), in contrast ASK generated the most different links compared to 
Google. However, these were not relevant results with most being sponsored results 
(such as Omega supplements) or were non sponsored and irrelevant (such as London 
Bridge Hospital). These pilot findings influenced the number of search engines that 
were included in the full search (column five, Table 3.1). BING provided additional 
relevant website results to those that were generated via Google. Although ASK 
generated 21 different websites to Google, only three of these were actually related to 
ovarian cancer. Paired with the statistic that Google powers 84% of UK searches, BING 
accounts for 4%, Yahoo 2% and ASK 2% (Hitwise 2012), this suggests that it would be 
beneficial just to include Google and Bing. The inclusion of BING is important as in 
America, BING and Yahoo account for around 20% of searches and Google 67% 
(Hitwise 2012).  
 
Generating search terms for grey literature search 
In order to generate grey literature search terms, contact was made with ovarian 
cancer charity Target Ovarian Cancer who provided information on the search terms 
used by visitors to their website (www.targetovariancancer.org.uk).  The search terms 
were generic, with the top three out of 50 terms being symptoms ovarian cancer, 
ovarian cancer symptoms and signs of ovarian cancer. The only specific term used was 
pelvic pain, with no other references to individual symptoms used. Target Ovarian 
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Cancer also received site visits from people searching for information in relation to 
ovarian cysts and their signs and symptoms. 
 
In addition to the search terms provided by Target Ovarian Cancer, an electronic 
survey was sent to members of staff in the Cochrane Institute of Primary Care and 
Public Health in the School of Medicine at Cardiff University asking "If you wanted to 
gain information about the symptoms of ovarian cancer, what would you type in to a 
search engine (eg Google), to find such information?”. Respondents were encouraged 
to reply with as few or as many search terms as they felt necessary. The most 
frequently used term was "ovarian cancer symptoms". In contrast to search terms 
provided by Target Ovarian Cancer, many respondents indicated that they would 
search for the symptoms they were experiencing. The combined information from 
Target Ovarian Cancer and the departmental survey led to a list of 25 terms which 
would be used in the grey literature search (Appendix 1). 
 
3.4.2 Academic database search strategy 
The search strategy for the academic database search was developed with the help of 
SysNet. The search strategy is provided in Appendix 2.  
 
Critical appraisal 
A data extraction form was created to allow for reliable and consistent extraction of 
data from identified tools. The form integrated aspects of existing checklists and 
extraction forms (Elwyn et al. 2006, Michie et al. 2005, Zaza et al. 2000). The extraction 
form was designed to extract sufficient information to evaluate the tools, with sections 
comprising characteristics of the source, provision of information, communication, 
format, symptoms, risk information and medical guidance (see Appendix 3).  
 
The draft extraction form was appraised by project supervisors, with alterations and 
expansions made as a result of this review process. Changes were made to incorporate 
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items which covered classification of information, descriptive information about the 
intervention as well as quality of the source and execution quality of the tool (Zaza et 
al. 2000). Additional items included length of time to complete, number of pages, a 
brief description of the website (charity, NHS etc) and adding the URL to the extraction 
form. The extraction form was piloted for quality assurance, by completing the 
extraction process on the BEAT symptom checker. The extraction form (see Appendix 
3) was designed to be self-explanatory and easy to use, as well as allowing consistent, 
standardised and reliable accumulation of data. 
 
Double rating 
To ensure the reliability of the extraction form and to reduce rater bias, nine of the 
extractions (23%) were double rated. Only three discrepancies were found across all 
nine double extractions involving 80 items per extraction form, suggesting that the 
form was clear and robust. The discrepancies were minor, arising from oversights of 
information, such as not noting the presence of a picture, overlooking a version date 
and forgetting to put “leaflet” in tool format. Once these differences had been 
discussed, 100% agreement was achieved. 
 
3.4.3 Theoretical content 
Items from the extraction form that mapped on to the HBM (Rosenstock et al. 1997) 
were identified allowing for a score out of 14 to be given to each tool. A higher score 
reflected more theoretical construct coverage in that tool and allowed for the 
identification of underlying theoretical constructs that were implicit in the tools to be 
identified. The 14 items reflected the HBM constructs perceived susceptibility, 
perceived severity, perceived benefits, perceived barriers and cues to action 
(Rosenstock et al. 1997) (see Appendix 6).  
 
50 
 
3.4.4 Inclusion/exclusion criteria 
Tools were included if they were English language, included symptoms of ovarian 
cancer, and concerned either symptom awareness or presentation to a health 
professional with symptoms. Included tools were educational materials such as 
leaflets, factsheets, pamphlets, videos and posters which were related to ovarian 
cancer and included symptoms of ovarian cancer. Tools that did not meet these 
inclusion criteria were excluded. When more than one version of a tool was identified, 
the most recent version was retained.  
 
3.5 Results  
The following section covers (1) tool descriptions and (2) tool content and quality, 
which will lead to (3) tool symptom content and (4) mapping the theoretical content of 
the tools. 
 
3.5.1 Tools identified from systematic search  
Each website identified in the search was searched exhaustively to determine whether 
they hosted an awareness tool. The flow diagram of tool identification is presented in 
Figure 3.1. A total of 2,000 websites were identified and searched in the grey literature 
search. Once duplicates were removed 388 website remained. Of these, 350 were 
excluded as they did not meet the inclusion/exclusion criteria, leaving 38 eligible tools 
(see Figure 3.1). The database search identified 3,102 articles. Screening of title and 
abstracts for relevance led to the exclusion of 3,079 articles. Twenty three full text 
articles were assessed for eligibility, with this leading to a further 22 articles excluded 
due to not meeting the inclusion/exclusion criteria (see Figure 3.1).  
 
The total number of included tools was 39. All 39 authors were contacted to ask for 
any additional information they wished to provide about the tools. Responses were 
received from 15 authors (38%), with this additional information included in the 
“Author” column of the data extraction form. 
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Grey literature search    Academic database search 
 
Figure 3.1. Flow diagram of tool identification in grey literature search and database search 
(oc= ovarian cancer) 
3.5.2 Tool descriptions 
The 39 tools (see Appendix 4) included leaflets (12) were most popular, followed by 
diaries (9), factsheets (4), quizzes (4), flyers (2), bookmarks (2), wallet sized card (1), 
symptom checker (1), slideshow (1), diagram (1), TV commercial (1) and risk calculator 
(1). The tools originated in five different countries; USA (17), UK (11), Australia (7), 
Canada (3) and New Zealand (1). The majority of tools were hosted on charity websites 
(n=28, 72%). 
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3.5.3 Tool content and quality 
A summary of tool content is shown in Table 3.2. Contact information was provided in 
82% (n=32) of cases (see Table 3.2), with a further 15% (n=6) providing contact details 
on the website hosting the tool. Contact information was not found for extraction 39 
(tool identified in Mahon (1996) via database search), nor could a website for the tool 
be found. References to academic papers as sources for information provided within 
the tool were included in five (13%) tools, with a further 14 (36%) providing this 
information on their website. The majority of tools (n=25, 64%) were printable (see 
Table 3.2). Images or diagrams were used in 21 (54%) tools, with two (5%) tools using a 
personal account of symptom experience within the tool (Table 3.2). Funders who 
contributed to the tools were mentioned by seven (18%). A version number or date of 
last modification was present in 12 (31%) tools. Twenty three tools (59%) included 
numerical information in the form of percentages, frequencies or probabilities. Only 19 
(49%) tools that provided numerical information did so in a consistent format. An 
information standard approval was present in 10% of tools (extractions 20, 21, 22 and 
25). Three tools (8%) clearly stated the target audience: (“Ashkenazi Jews” (extraction 
12), “the UK population” (extraction 18) and “women of average risk” (extraction 33). 
 
Table 3.2. Characteristics of identified ovarian cancer symptom awareness tools 
Tool name Images/ 
Diagram 
Printable References Contact 
information 
Funders Version 
number 
1. Australia awareness 
Brochure 
 ✓ ✓ ✓ ✓ ✓ 
2 Early detection 
Australia 
✓ ✓  ✓   
3. Dr Oz ✓ ✓  ✓   
4. Australia symptom 
diary 
 ✓ ✓ ✓  ✓ 
5. OC: Australia 
factsheet 
✓ ✓  ✓ ✓ ✓ 
6. TV advert ✓   ✓   
7. No one knows your 
body like you do 
✓ ✓  ✓ ✓ ✓ 
8. It’s time to shout 
out  
✓ ✓  ✓   
9. OC Canada 
Knowledge Centre 
      
10. Think Ovarian!   ✓  ✓  ✓ 
11. NZ Gynaecological 
leaflet  
✓ ✓  ✓  ✓ 
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12. Ashkenazi 
Inheritance: 
✓ ✓  ✓  ✓ 
13. BEAT Symptom 
Checker 
✓      
14. BEAT Symptom 
Tracker 
✓   ✓   
15. Detecting OC: 
CRUK 
✓ ✓  ✓   
16. OC diary: 
Innermost secrets 
 ✓  ✓   
17. Ovarian Cancer 
Action diary 
   ✓  ✓ 
18. Qrisk Ovary ✓  ✓   ✓ 
19. Remember the 
Symptoms 
✓ ✓  ✓   
20. Swollen tummy?  ✓ ✓  ✓  ✓ 
21. Target quiz    ✓   
22. What women need 
to know…  
✓ ✓  ✓   
23. 15 Symptoms 
women ignore 
✓      
24. Break the silence 
conversation starter 
 ✓  ✓   
25. CDC diary ✓ ✓  ✓  ✓ 
26. NOCC Bookmark  ✓  ✓  ✓ 
27. NOCC Quiz       
28. Ova-1 calendar  ✓  ✓   
29. Ova-1 quiz    ✓   
30. OC symptoms  ✓ ✓ ✓   
31. OC warning signs ✓      
32. OCNA app    ✓ ✓  
33. OCNA symptom 
diary 
✓ ✓ ✓ ✓ ✓  
34. OCNA factsheet  ✓  ✓   
35. OAK Symptom 
Card 
 ✓  ✓   
36. Ovations for the 
future 
✓   ✓   
37. WCN 
understanding your 
risk 
 ✓  ✓ ✓  
38. WCN womens 
guide 
 ✓  ✓ ✓  
39. Mahon (1996) 
paper 
✓      
N(%) 21 (54%) 25 (64%) 5 (13%) 32 (82%) 7 (18%) 12 (31%) 
 
3.5.4 Peer reviewed articles  
One tool was identified in a peer reviewed article via the database search (see Figure 
3.1), and two tools identified via the grey literature search were also accompanied by 
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peer reviewed articles. A description of the content in the associated academic papers 
will be presented in the following section. An explanation for why these two additional 
tools were not included in the database search is also provided. 
 
(1) The Gynecologic Symptom diary (extraction 25) was identified in the grey literature 
search and was accompanied by three articles by the Centre for Disease Control (CDC) 
(Cooper et al. 2011, Rim et al. 2011, Trivers et al. 2011). These three papers were 
identified in the database search. However, as the grey literature search was 
conducted first, these papers had already been identified when the tool was identified 
in the grey literature search. Subsequently, these three papers were excluded from the 
database search due to duplication, with this represented in the extraction process as 
‘already identified via grey search =3” (see Figure 3.1). These papers provide 
information on the rationale and processes leading up to the tool development. The 
papers detail how CDC identified poor knowledge of an array of gynaecological and 
non-gynaecologic symptoms as part of a national general population HealthStyles 
survey (Trivers et al. 2011). These findings, along with a literature review (Rim et al. 
2011) led CDC to consider developing the symptom diary. As part of the development 
of the diary, focus groups (n=132) were held with women from the general population 
in four American cities (Cooper, Polonec et al. 2011). The articles outline that the 
diaries development was guided by Social Cognitive Theory (Bandura 2004). The focus 
groups further explored the signs, symptoms and risk factors of gynaecologic cancers 
that women were unfamiliar with (Cooper et al. 2011). These findings contributed to 
the content of the CDC “Inside Knowledge: Get the facts about gynaecologic cancer 
campaign”. This is a national campaign for the USA which covers cervical, ovarian, 
uterine, vaginal and vulvar cancers (Rim et al. 2011).  
 
(2) QriskOvary (extraction 18) is a risk calculator for developing ovarian cancer that 
was identified in the grey literature search. This risk calculator uses an algorithm based 
on responses that are entered in order to generate a risk status for developing ovarian 
cancer. This tool met the study inclusion criteria as it explicitly asks about symptoms 
that have been experienced.  It was developed to be used by clinicians but can also be 
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filled out by non-clinicians as it is freely accessible on the internet. The algorithm used 
in the QriskOvary calculator has also featured in a journal article (Hippisley-Cox et al. 
2007), with this paper focusing on the mathematical capabilities of the formulas used 
to predict the risk of developing ovarian cancer. As the paper focuses on the risk 
algorithm and does not include symptom content relevant to this search, it was not 
identified in the database search.  
 
(3) The database search identified one eligible paper (Mahon 1996) which contained a 
leaflet designed to educate women visiting the Cancer Screening Centre in St Louis 
about early detection of ovarian cancer (extraction 39). The paper details that the 
leaflet was developed following requests from women attending the centre who asked 
for information about recommendations for gynaecological cancer screening (Mahon 
1996). No theory is stated for the development of the leaflet, instead the leaflet was 
developed by the clinical team to meet the specific need in their working environment 
based on information requests by women (Mahon 1996). Before use, the leaflet was 
reviewed by 17 nurses, a medical oncologist, a pathologist, a gynaecologist, 13 women 
who used the centre and staff from the public relations office (Mahon 1996). 
 
3.5.5 Information on ovarian cancer symptoms  
The number of ovarian cancer symptoms included in each tool was noted (see Table 
3.4). If symptoms were duplicated in a tool, only the first occurrence was counted. The 
average number of symptoms was eight (SD 4, range 3-25). A breakdown of the 
symptoms included in each tool is provided in Appendix 5. It was not possible to 
collate the overall frequency of each individual symptom due to differences in wording 
or phrases used, such as “abdominal or back pain”, “increase in abdominal size or 
bloating”, “abdominal bloating and feeling of fullness” and “difficulty eating/feeling full 
quickly”. Each of these phrases was counted as one symptom as it was presented in 
the same statement and was presented separately from other symptoms within the 
tools. As most symptoms were presented in this way, it was not possible to count each 
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individual occurrence due to overlap within the phrases and the different wording 
used. 
 
Referring back to the key symptoms stated in the Department of Health (2009) and 
National Institute for Health and Clinical Excellence (2011) guidelines it can be seen 
that the wording of symptoms differed between guidelines. However, it was possible 
to extract words that were used in both guidelines i.e. “bloating”, “pelvic or abdominal 
pain” and “full”. Instances of these phrases in the tools could then be counted to 
ascertain if the tools were using similar words to the guidelines to describe symptoms. 
Due to the issues associated with inconsistent terminology, only those symptoms 
which matched this wording used in the clinical guidelines were counted. It can be 
seen in Table 3.3 that this wording occurred frequently in the tools, with 95% (n=37) 
using the term “bloating”, 69% (n=27) using the phrase “abdominal pain and/or pelvic 
pain” and 87% (n=34) using the word “full”. 
 
Table 3.3. Presence of three key symptoms in identified tools 
Tool name Bloating Pelvic and/or 
abdominal pain 
Full  
1. Australia awareness Brochure ✓ ✓ ✓ 
2 Early detection Australia ✓ ✓  
3. Dr Oz ✓ ✓ ✓ 
4. Australia symptom diary ✓ ✓ ✓ 
5. OC: Australia factsheet ✓ ✓ ✓ 
6. TV advert ✓  ✓ 
7. No one knows your body like you do ✓  ✓ 
8. It’s time to shout out  ✓  ✓ 
9. OC Canada Knowledge Centre ✓   
10. Think Ovarian!  ✓   
11. NZ Gynaecological leaflet  ✓ ✓ ✓ 
12. Ashkenazi Inheritance: ✓ ✓ ✓ 
13. BEAT Symptom Checker ✓ ✓ ✓ 
14. BEAT Symptom Tracker ✓ ✓ ✓ 
15. Detecting OC: CRUK ✓  ✓ 
16. OC diary: Innermost secrets ✓ ✓ ✓ 
17. Ovarian Cancer Action diary ✓ ✓ ✓ 
18. Qrisk Ovary    
19. Remember the Symptoms ✓ ✓ ✓ 
20. Swollen tummy?  ✓ ✓ ✓ 
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21. Target quiz ✓  ✓ 
22. What women need to know…  ✓ ✓ ✓ 
23. 15 Symptoms women ignore ✓ ✓ ✓ 
24. Break the silence conversation 
starter ✓ ✓ ✓ 
25. CDC diary ✓   
26. NOCC Bookmark ✓ ✓ ✓ 
27. NOCC Quiz ✓ ✓ ✓ 
28. Ova-1 calendar ✓  ✓ 
29. Ova-1 quiz ✓ ✓ ✓ 
30. OC symptoms ✓ ✓ ✓ 
31. OC warning signs ✓  ✓ 
32. OCNA app ✓ ✓ ✓ 
33. OCNA symptom diary ✓ ✓ ✓ 
34. OCNA factsheet ✓ ✓ ✓ 
35. OAK Symptom Card ✓ ✓ ✓ 
36. Ovations for the future ✓ ✓ ✓ 
37. WCN understanding your risk ✓ ✓ ✓ 
38. WCN womens guide ✓ ✓ ✓ 
39. Mahon (1996) paper   ✓ 
 37 (95%) 27 (69%) 34 (87%) 
 
3.5.6 Guidance on symptomatic presentation  
Twenty three (59%) tools provided specific information about time frames in which 
women should act on potential ovarian symptoms and present to a medical 
professional. This information varied, with such guidance informing women to seek 
medical help after symptoms had been present for two weeks all the way up to and 
over a month (see Table 3.4). Vague information which directs women to simply visit 
the doctor if they are experiencing symptoms was often included. Seven (18%) tools 
incorporated information which aimed to facilitate the interaction between patient 
and doctor (see Table 3.4). These sections provided a list of questions for women to 
ask their doctor at the appointment, with some encouraging women to fill out their 
own answers to the questions and others having the questions as prompts to 
encourage discussion.  
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Table 3.4. Number of symptoms and symptom guidance information in identified tools 
Tool name Number of 
symptoms 
Symptom 
time frame 
Frequency of 
symptoms 
“new for you”, 
“not normal” or 
“unusual” 
1. Australia awareness 
Brochure 10 2 weeks On most days ✓ 
2 Early detection Australia 
10   ✓ 
3. Dr Oz 
4 2 weeks  ✓ 
4. Australia symptom diary 10 4 weeks 12 times  
5. OC: Australia factsheet 
10   ✓ 
6. TV advert 
7   ✓ 
7. No one knows your body like 
you do 7   ✓ 
8. It’s time to shout out  
11 2 weeks  ✓ 
9. OC Canada Knowledge 
Centre 9 3 weeks  ✓ 
10. Think Ovarian!  
9 3 weeks 
1 or more 
symptom  
11. NZ Gynaecological leaflet  
11 2 weeks  ✓ 
12. Ashkenazi Inheritance: 
3 A month 12 days  
13. BEAT Symptom Checker 
4    
14. BEAT Symptom Tracker 
25    
15. Detecting OC: CRUK 9 A month Several times ✓ 
16. OC diary: Innermost secrets 11 A month Most days  
17. Ovarian Cancer Action diary 
7 A month Most days  
18. Qrisk Ovary 6    
19. Remember the Symptoms 
8  
Occur on most 
days ✓ 
20. Swollen tummy?  7 A month 12 times ✓ 
21. Target quiz 4  Most days  
22. What women need to 
know…  3  Most days ✓ 
23. 15 Symptoms women 
ignore 4 
More than a 
few weeks   
24. Break the silence 
conversation starter 16 2 weeks 
2 or 3 of these 
symptoms  
25. CDC diary 
6 2 weeks   
26. NOCC Bookmark 
10 2 weeks Daily  
27. NOCC Quiz 
8    
28. Ova-1 calendar 
10 4 weeks  ✓ 
29. Ova-1 quiz 4    
30. OC symptoms 
9 
More than a 
few weeks  ✓ 
31. OC warning signs 
12    
32. OCNA app 
4   ✓ 
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33. OCNA symptom diary 
4 A month 12 days  
34. OCNA factsheet 
10    
35. OAK Symptom Card 
10 
More than a 
few weeks Almost daily  
36. Ovations for the future 4 2 or 3 weeks Daily  
37. WCN understanding your 
risk 10 2-3 weeks Almost daily ✓ 
38. WCN womens guide 10 2-3 weeks Almost daily ✓ 
39. Mahon (1996) paper 4    
 
3.5.7 Theory Mapping 
One tool (extraction 25) was explicitly guided by Social Cognitive Theory. However, as 
previously stated, content of all tools was mapped on to the HBM in order to identify 
the theoretical coverage.  The mapping of relevant items from the data extraction 
form on to the HBM was achieved through discussion with the supervisory team and 
led to the identification of 14 items which covered the HBM constructs. The theoretical 
coverage of the tools is provided in Appendix 6.  
 
Perceived susceptibility: Four items that mapped on to the construct of perceived 
susceptibility were covered to varying degrees by the tools. Risk factors were well 
covered, with 27 (69%) tools including some information of this nature, whereas a 
personal risk status was only generated in three (8%) tools. Ways to reduce risk and 
information regarding family history were included in 11 (28%) and 10 (26%) tools 
respectively. Ten tools (26%) failed to cover any items that related to perceived 
susceptibility. In contrast, two tools (extractions 32 and 37) included information 
relating to all four of these items.  
Perceived severity: One item reflected this construct, with 26 (67%) tools providing 
facts about ovarian cancer. 
Perceived benefits: Three items reflected the construct of perceived benefits. The most 
well covered of these was ‘directly suggesting places to get information’, which was 
addressed in 31 (79%) tools and referred readers to additional resources about the 
disease which provided information about the importance of early disease diagnosis. 
The benefits of symptom awareness was addressed in 20 (51%) tools, and confidence 
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was addressed in 14 (36%) tools. Eight tools (21%) covered all three of these items and 
four tools (10%) did not cover any of these items. 
Perceived barriers: Of the three items which related to the construct of perceived 
barriers, dispelling myths was the item with the most extensive coverage, with 23 
(59%) tools including information of this nature. Fifteen (38%) included information 
about the vague nature of the symptoms of ovarian cancer, with nine (23%) including 
information that reduced fear or distress relating to ovarian cancer symptoms and help 
seeking. Four tools (10%) included information on all three items, with ten tools (26%) 
not including information on any of these items. 
Cues to action: Three items make up the cues to action construct. Information 
regarding symptom duration was provided in 23 (59%) tools, with 18 (46%) tools 
providing information regarding symptom frequency. Only 15 (38%) tools provided 
information regarding both symptom duration and frequency. Thirteen (33%) tools 
failed to provide information about either item. Information about when to re-visit the 
GP with symptom concerns was the least covered item, with this included in 11 (28%) 
of tools. All three items were included in 8 (21%) tools, and 13 (33%) tools failed to 
include any of these items. 
 
Two tools had the most extensive theoretical construct coverage, with the Australia 
Awareness Brochure (extraction 1) and the ‘Swollen Tummy?’ leaflet by UK based 
charity Target Ovarian Cancer (extraction 20) both covering 12 of 14 theoretical 
constructs of the HBM (Appendix 6). The two constructs that were not covered by 
these two tools were both from Perceived Susceptibility. A personal risk status was not 
generated by either tool. The Australian Awareness Brochure also did not address 
family history, whilst the Target Ovarian Cancer leaflet did not include information 
about how to reduce risk. Most of the tools had less extensive theoretical coverage, 
with an average score of 6.2 (SD 2.8). Four tools had the least theoretical construct 
coverage (extraction 6, 23, 28 and 39), each covering only two items.  
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3.6 Discussion  
The present study was the first study that systematically identified, reviewed and 
evaluated existing ovarian cancer symptom awareness tools. The search identified a 
wide variety of ovarian cancer symptom awareness tools, with variation observed in 
evidence base, format, content and theoretical coverage. The majority of tools were 
found on websites, particularly charity websites, with very few tools featuring in peer 
reviewed articles.  
 
3.6.1 Tool content and quality  
A variety of tool formats were identified, with leaflets and symptom diaries the most 
popular. Whilst varying formats were observed, the majority of tools were printable, 
possibly reflecting the importance of physical copies of information to users. The use 
of diagrams, pictures or personal narratives are possible ways of making tools more 
user friendly (Baumeister and Newman 1994), with such techniques used to varying 
degrees by the tools. Some tools incorporated a section providing information to 
facilitate the interaction between patient and doctor. The presence of such initiatives 
could reflect a possible anticipated lack of confidence that women have in the 
consultation process. The use of these sections in tools could be a way to address the 
potential barriers to presentation that have been reported in population based 
awareness and presentation studies, such as confidence in talking to the GP and 
feeling embarrassed (Robb et al. 2009). Most of the tools used numerical information 
to aid information exchange, but the majority failed to provide this numerical 
information in a consistent format. Discrepancies between using percentages, 
frequencies and probabilities could lead to confusion for the reader, with consistent 
formats advantageous (Edwards et al. 2013). 
 
Country of origin is an important piece of information to include in tools because the 
guidelines for ovarian cancer detection and healthcare systems may vary by country. It 
is therefore important to state country of origin to make it clear to the reader whether 
the information is relevant to their healthcare context. This is highlighted by the tools 
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identified in this search originating from five different countries. Paired with the 
finding that most tools were found on the internet, this means that people can 
remotely access information which may not be relevant to them due to country 
specific differences.  Similarly, the majority of tools did not state their target audience. 
In such cases it could be assumed that the tools are aimed at the general population. 
Clarification of the target audience is particularly important as different groups of 
women may have different information needs and preferences in relation to ovarian 
cancer symptom awareness and presentation. For example, emotional barriers may be 
more salient in women at increased genetic risk (Kash et al. 1992), as they may be 
more concerned about the disease as a result of their risk status. The problems arising 
as a result of omitting country of origin and target audience could be easily rectified by 
including a short statement on the tools. 
 
The name of funders who contributed to the tool development was expected to have 
been higher considering the amount of tools originated in the USA, which has a health 
service that is heavily influenced by pharmaceutical and insurance companies. A 
similar lack of information was found for sources of information for tool content. 
When information is provided on the internet this information is particularly important 
as it can be hard to determine the credibility of information unless sources are 
explicitly identified. Whilst references for sources of information was lacking in the 
majority of tools, contact information had much better coverage. Contact information 
allows users to find out more about the information within the tool and is best placed 
on the tool itself, as if other websites host the tool, or if the tools are printed, this 
information could be lost. As two thirds of the tools in this search were printable, this 
scenario could occur.  An additional internet specific problem for tools is that it is not 
always easy or obvious to identify how old the information is. Whereas information 
materials that are distributed in community areas or doctors surgeries may be updated 
and old materials removed, this is not always the case with the internet. A way to 
overcome this is to provide a version number or date on the tool. The majority of 
identified tools failed to provide a version number or date and as a result people 
reading the tools may not know the relevance of the information they are reading. 
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3.6.2 Ovarian cancer symptom coverage 
On average, many more symptoms were included in tools than the number of 
symptoms stated in current UK guidelines. Including so many symptoms could be 
overwhelming and deemed excessive considering the current National Institute for 
Health and Clinical Excellence (2011) guidelines state four key symptoms of ovarian 
cancer, and the Department of Health Key Messages (2009) state three. One tool 
included 25 symptoms, when realistically it would not be feasible to ask women to 
remember or track the presence of all 25 symptoms. Even tracking the average of eight 
symptoms could be burdensome and potentially anxiety provoking. Including fewer 
symptoms that reflect the key symptoms could improve the focus of the tool, with this 
possibly increasing the chance of users remembering the symptom information within 
the tool. 
 
The search identified that the description of symptoms within tools was not 
standardised, with large variation observed between tools in the wording of 
symptoms. A wide variety of phrases were used to convey what should be the same 
information. This was further demonstrated by the results of the search for the 
presence of the key symptom terms as highlighted in the UK guidelines. To identify the 
coverage of key symptoms within the tool the instances of these exact phrases were 
counted. It could be argued that counting the instances of these exact phrases is unfair 
for tools which included these three symptoms but used different phrasing. However, 
having so many different ways of describing a symptom is problematic because it is 
likely to create confusion, both in health professionals and the public. The use of 
consistent terms for symptoms could considerably reduce this problem.  
 
3.6.3 Guidance on ovarian cancer symptomatic presentation 
The emphasis on symptoms of ovarian cancer representing a change from normal state 
was often used. This type of guidance shifts the responsibility of identifying symptoms 
to the individual and encourages them to know their bodies and become familiar with 
what is normal for them. Similar techniques have been employed in breast cancer 
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awareness, with women encouraged to know their bodies as opposed to conducting 
ritualistic self-breast examinations (Austoker et al. 2009, Forster et al. 2013). However, 
it may be hard to convey this change from normal to the GP if the individual is not very 
confident. Some tools utilise symptom diaries which could help women feel more 
confident in discussing the symptoms they have experienced. However, the use of 
symptom diaries could also lead women to become fixated on possible symptoms, 
with this having possible negative psychological consequences and leading to hyper-
vigilance (Epstein et al. 1997, Norman and Brain 2005). Symptom diaries and tracking 
of symptoms could be particularly problematic for women at increased genetic risk of 
developing ovarian cancer, as due to their risk status these women may be more alert 
to bodily changes, and may associate such changes more readily with possible ovarian 
cancer (Kash et al. 1992). This scenario emphasises the importance of providing clear 
information about ovarian cancer symptoms, as well as additional information such as 
symptom frequency and duration. It is important for women to know what to do if the 
symptoms are experienced and when to seek medical advice if concerned about 
possible symptoms.  
 
In the majority of identified tools, there was a lack of specific, action orientated 
guidance for symptomatic presentation. As discussed, such information is important in 
enabling women to know whether and when to act if they are experiencing symptoms. 
This means that while all of the identified tools attempted to raise awareness of the 
symptoms of ovarian cancer, they have not directly encouraged awareness to be 
translated into presentation (if symptoms are experienced). Providing information on 
what specific behaviours to carry out, and how to carry out such behaviours, is an 
imperative part of a successful health intervention (Soames Job 1988). The absence of 
guidance about symptomatic presentation is concerning in the context of ovarian 
cancer, due to the vague nature of the symptoms and the frequency with which they 
will naturally occur in most women at some time in their life as part of everyday bodily 
changes (Bankhead et al. 2008, Hamilton et al. 2009). This finding highlights the need 
for clear medical consensus on symptom frequency and duration information.  It could 
be argued bad practice to simply make women aware of the symptoms without 
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providing information on what to do if they are experienced. Without such 
information, fear could be increased (Ruiter et al. 2003, Soames Job 1988). 
 
3.6.4 Theory mapping 
There was varying coverage of HBM theoretical constructs within the tools, with 
information relating to cues to action having the poorest coverage. Whilst risk factors 
for ovarian cancer were the most well covered item relating to the construct perceived 
susceptibility, the appropriateness of the risk factors presented may be dependent on 
the target audience. If the target audience are at increased genetic risk and have 
undergone genetic assessment to determine their risk, there may be less need to 
provide information on risk factors such as the role of the BRCA1/2 genes. This 
example highlights the importance of identifying and understanding the target 
audience in order to create an effective tool. In addition, the possible psychological 
impact of including risk factor information in the absence of medical supervision needs 
to be considered. Provision of facts about incidence and mortality rates for ovarian 
cancer can highlight the severity of the disease. In the context of symptom awareness 
tools, ovarian cancer statistics may encourage people to be more aware of symptoms 
or to act in a more timely fashion if they are experienced; however, they could 
discourage people due to fear or worry.  Benefits and barriers were covered by most of 
the tools, although items relating to reducing fear/distress were not well covered. 
Benefits and barriers are areas that could be easily included if tools are developed 
based on theory because the theoretical understanding of the determinants of 
awareness and presentation of the target audience would outline the benefits and 
barriers perceived by that population. 
 
Of the tools that had the most extensive theoretical construct coverage, neither 
provided a personal risk status. Awareness of personal risk status is important as the 
HBM outlines that people are more likely to engage in health behaviours if they 
believe they are personally susceptible (Rosenstock et al. 1988). However, it is a 
complex process to accurately generate a personal risk status of developing ovarian 
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cancer and would not be feasible for most tools. It would also be unethical to provide 
this information in a stand-alone awareness tool, as this type of information should be 
provided in consultation with a medical professional.  
 
3.6.5 Study limitations 
A limitation of the current search, is that it is out dated almost immediately. Since the 
search was conducted, the CDC national campaign for gynaecological cancers has 
added to its materials, with an ovarian cancer symptom awareness tool now included 
in the campaign. While this is a positive step for theory based ovarian cancer symptom 
awareness tools, the tool development was based on methods including American 
women from the general population and the information provided may not be 
relevant to the UK context or women at increased genetic risk. 
 
Whilst it was deemed necessary and appropriate to use a newly constructed data 
extraction form, it was not validated. Documentary analysis may be a useful method to 
consider when similar searches are carried out in the future (Sixsmith and Murray 
2001). Documentary analysis allows for systematic and detailed analysis of identified 
written materials and benefits from enabling researchers to analyse documents which 
take different formats and have varying content (Appleton and Cowley 1997, Sixsmith 
and Murray 2001). Due to the current search being the first systematic search of 
symptom awareness tools, the search protocol and data analysis were driven by 
experience with traditional systematic reviews and the research objectives (to identify 
and evaluate existing ovarian cancer symptom awareness tools). Based on the type of 
tools that were identified in this current study, with hindsight, documentary analysis 
could have been applied and should be considered in similar searches in the future. 
Documentary analysis would enable a systematic and structured analysis of tools, 
which could complement the systematic nature of the identification of tools (Appleton 
and Cowley 1997). 
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A further limitation could be the search strategy itself, as it aimed to identify existing 
tools via peer reviewed articles and the internet. This search method could therefore 
have excluded tools that are physically available in places such as GPs, hospitals and 
support groups. Whilst it was anticipated that most tools of this nature would also be 
hosted on websites, it was not feasible to identify tools that may exist in purely 
physical formats in such places. 
 
The use of UK guidelines for symptom information could also be a limitation, especially 
considering that the identified tools originated from five different countries. However, 
the symptoms in country-specific guidelines are comparable to those for the UK and as 
the research concerns awareness in UK women, it was decided that the UK guidelines 
should be the main focus. This enables the findings to contribute to the development 
of a symptoms awareness tool that will be directly relevant for the target population. 
 
3.6.6 Implications and future research 
Very few of the ovarian cancer symptom awareness tools identified in the current 
search had an explicit theoretical foundation. When the tools were mapped on to the 
HBM to identify theoretical groundings, none of the tools addressed all of the 
theoretical constructs. This could reflect potential inefficiency in identified tools to 
increase symptom awareness and encourage timely presentation. 
 
In order to be effective, symptom awareness tools should not only state the symptoms 
of ovarian cancer, but also provide information about what to do if symptoms are 
experienced. This could be an important step in translating symptom awareness into 
presentation. This search has highlighted that multiple ovarian cancer symptom 
awareness tools exist and that they are not consistent. If tools are created, based on 
guidelines such as the MRC guidelines for complex interventions (Craig et al. 2008b) 
and described in full, then the formula for creation can be replicated, whereby the 
successful components can be followed and unsuccessful ones avoided (Jones et al. 
2013).  In future, collaborations between governments, researchers and charities could 
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lead to well-developed information being easily delivered to the target populations. 
This would be especially useful due to many of the tools being found on charity 
websites, and the increasing use of the internet when searching for health information 
(Cooper et al. 2012). Such collaborations could be a possible for overcoming the flaws 
that were found in many of the tools, such as failure to identify the target audience, 
presence of potentially overwhelming number of symptoms, and failure to elaborate 
or action plan if symptoms are experienced.  
 
3.6.7 Summary  
The present search has highlighted that although a variety of symptom awareness 
tools already exist there is currently no theory based awareness tool for women at 
increased genetic risk of ovarian cancer. Development of a tool for women at 
increased genetic risk would enable the information needs of this population to be 
addressed, at the same time as raising awareness and encouraging appropriate 
symptomatic presentation without increasing distress. The needs of women at 
increased genetic risk will be explored in subsequent chapters, with surveys and 
interviews used to explore awareness, beliefs, confidence and worry in relation to 
ovarian cancer. In order to identify whether the health beliefs are unique to women at 
increased genetic risk, health beliefs will also be explored in relation to a sample of 
women from the general population.  It is essential to understand the needs of the 
specific target audience so that they can be addressed within the tool, with 
interventions that follow this process more likely to be successful (Austoker et al. 
2009). 
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4 Determinants of anticipated presentation with ovarian cancer symptoms in 
women from different risk populations 
 
4.1 Chapter overview 
Previous literature on awareness, presentation and beliefs about cancer has focused 
mainly on the general population. Few studies have been conducted involving samples 
of people at increased genetic risk for ovarian cancer, where symptoms are vague 
(Evans et al. 2007). A cross-sectional questionnaire study is presented that tests the 
ability of the Health Belief Model (Rosenstock et al. 1988) to identify variation in 
anticipated time to presentation to primary care with ovarian cancer symptoms. The 
determinants of anticipated presentation to a healthcare professional with suspected 
ovarian cancer symptoms in a sample of women at increased genetic risk of ovarian 
cancer was compared to determinants identified in a general population sample. The 
findings will be used to guide the content of a symptom awareness tool with tailored 
content for women at increased genetic risk of ovarian cancer. 
 
4.2 Introduction  
A study that explores and compares the determinants in an increased genetic risk 
population and a general population sample would allow for recommendations to be 
made based on contributors to anticipated presentation that are unique to each 
group. This exploration process is important as interventions are more likely to be 
effective if they are relevant to the user (Craig et al. 2008b). Understanding of 
anticipated presentation behaviour will also provide insight into what the possible 
impact on health services would be if awareness is increased, and early presentation is 
promoted.  
 
4.2.1 Health Belief Model constructs 
Cancer worry relates to thoughts of developing the disease and the impact these 
thoughts have on mood and daily function (Andersen et al. 2007). Worry is thought to 
70 
 
play an important part in help seeking decisions for women at increased genetic risk of 
ovarian cancer, and its conceptualisation within health behaviour theory is therefore 
important. Although the original HBM does not explicitly include the construct ‘worry’, 
it can be incorporated into the model through the concept of perceived threat. In 
previous studies, perceived threat has been the combination of perceived 
susceptibility and perceived severity (Glanz et al. 2008, Rosenstock et al. 1988). 
However, the operationalization of the perceived threat concept allows for the 
integration of the concept ‘worry’. The role of worry in the HBM is discussed by Hay et 
al. (2005), where worry is considered to be an affective representation of perceived 
susceptibility. Hay et al. (2005) conducted a review of empirical literature on the role 
of cancer worry in screening, in which theoretical approaches to understanding and 
conceptualising worry were discussed. Cancer worry was proposed as an aspect of 
susceptibility or severity, with measures of worry embedded within susceptibility or 
severity (Hay et al. 2005). Worry was therefore incorporated into the HBM in the 
current study (see Figure 4.1). 
 
The conceptualisation of the constructs in the HBM are shown in Figure 4.1. Constructs 
are grouped under the headings Individual Perceptions, Modifying Factors and 
Likelihood of Action. Individual perceptions are linked to the outcome of anticipated 
presentation (likelihood of behaviour) indirectly via perceived threat. Perceived threat 
is a latent, unobserved variable, and is the combination of the Individual Perceptions 
items. Individual Perceptions items are perceived susceptibility and ovarian cancer 
worry (see Figure 4.1).  
 
In the HBM, knowledge (also known as symptom recognition) is a modifying factor that 
is indirectly linked to the outcome via the other HBM components. Confidence in 
symptom detection represents the construct of self-efficacy, and is also a modifying 
factor linked to the outcome via other HBM components. Demographic variables 
including age, education level, relationship status, and ethnicity are also modifying 
factors that have indirect effects on the outcome through the other HBM constructs. 
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Figure 4.1. The Health Belief Model, adapted for this study from Rosenstock et al. (1997) 
Cues to action are linked to outcome indirectly via perceived threat, with cues 
increasing perceptions of threat. Perceived benefits and barriers to presenting with 
suspected ovarian cancer symptoms are a measure of likelihood of action, with this 
construct linked directly to outcome. In summary, the HBM proposes that two 
variables directly influence likelihood of anticipated presentation behaviour: (1) 
perceived threat, and (2) the belief that the benefits of carrying out the action 
outweigh the barriers. 
 
4.2.2 The role of worry in the HBM 
Explanations for the patient interval in ovarian cancer presentation can be considered 
based on the HBM model. The impact of worry should be considered both in terms of 
women’s psychological wellbeing as well as the potential over burdening of the health 
system by women concerned about possible symptoms (Evans et al. 2014). If worry is 
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determining presentation it is important to identify mechanisms through which this 
can be reduced or managed, so that ovarian cancer symptom information can be given 
to women without harming their psychological well-being. The role that worry plays in 
presentation to primary care with suspected ovarian cancer symptoms in an increased 
genetic risk sample is not currently known. Evidence suggests that a higher level of 
ovarian cancer worry is associated with higher perceived risk in women with a family 
history (Lerman et al. 1994). Ovarian cancer worry and the number of affected 
relatives has been found to be positively associated with ovarian cancer screening 
uptake in women at increased risk for ovarian cancer (Andersen et al. 2002, Schwartz 
et al. 1995a). For women at increased genetic risk of ovarian cancer, worry may 
therefore be a contributor to symptom-driven presentation times. Although it is 
possible to extrapolate from studies of ovarian cancer screening uptake, specific 
research needs to be undertaken in order to understand the nature and direction of 
the influence of worry on symptomatic presentation to primary care in women at 
increased genetic risk. 
 
4.2.3 Gaps in knowledge  
The need for a test of the entire HBM model for anticipated presentation of ovarian 
cancer symptoms will be addressed in the current study. Structural equation modelling 
(SEM) will be used to test the HBM model and to identify correlates of anticipated time 
to presentation. SEM is a statistical technique that allows for the simultaneous test of 
multiple causal relations (Kline 2011) and can be used to test theoretical models such 
as the HBM in novel health contexts. SEM is an advantageous method as it allows for a 
deeper exploration of the relationships between variables than standard regression 
analysis. Particularly, SEM allows for theoretical models to be tested, for simultaneous 
analysis to be conducted, and for latent (unobserved) variables to be modelled.  
 
4.2.4 Aims of the present study  
The HBM was used to identify correlates of anticipated presentation in a sample that 
included women at increased genetic risk of ovarian cancer and women drawn from 
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the general population. As there is evidence for health beliefs to be different among 
different risk populations (Chapter 2), the study also aimed to test whether the model 
was invariant across two risk groups. If the model is adequate the determinants of the 
two risk groups will be explored separately in order for comparisons to be made. In 
order for this to be achieved, a dataset comprising women from the general 
population (who are at, or near population risk) and women at increased genetic risk 
of ovarian cancer was analysed. Practically, this could aid decisions about whether 
tailored interventions are needed for the general population and women at increased 
genetic risk.  Based on research in other health contexts and empirical evidence, it was 
expected that the HBM would be a good fit for anticipated symptomatic presentation 
behaviour in ovarian cancer. It was hypothesised that susceptibility and worry would 
form part of the same latent construct. The increased genetic risk group were 
hypothesised to differ from the general population group on the HBM constructs, with 
higher levels of worry, knowledge, perceived susceptibility, perceived threat, benefits 
and barriers to presentation, more personal experience with ovarian cancer, and 
earlier anticipated time to presentation than the general population group. The model 
was hypothesised to be invariant by group.  
 
4.3 Methods  
Recruitment and study procedures are presented separately below for the increased 
genetic risk and general population samples. Ethical approval for the study was 
received from Cardiff University School of Medicine Research Ethics Committee (see 
Appendix 7). 
4.4 Increased genetic risk sample 
4.4.1 Participants 
Participants were recruited by the PhD student from the database of participants in 
PsyFOCS (psychological evaluation of familial ovarian cancer screening) or via an 
ovarian cancer charity (Ovacome). PsyFOCS was the psychological partner study of 
UKFOCSS, a large scale UK clinical study involving over 200,000 women which aimed to 
evaluate the effectiveness of screening in women at increased genetic risk for ovarian 
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cancer (Jacobs et al. 1999). From the UKFOCSS sample, 3224 women were invited to 
participate in PsyFOCS, which concerned the psychological and behavioural impact of 
ovarian cancer screening for women at increased familial risk of ovarian cancer (Brain 
et al. 2012). A total of 1,999 women participated in PsyFOCS, all of whom were 
identified as being at increased risk of familial ovarian cancer based on a detailed 
pedigree-based assessment carried out at familial cancer clinics. Of the PsyFOCS 
sample, 446 participants accepted the offer of an end of study summary, which 
included an opportunity to register interest in a further study on ovarian symptom 
awareness. Further participants were recruited from the UK based charity Ovacome, 
which included a piece about the study in the letters section of their summer 2012 
newsletter. The piece asked readers to register interest in receiving information on 
research concerning ovarian cancer symptom awareness via an email address. Twenty 
nine people registered interest in this way. 
4.4.2 Inclusion/exclusion criteria 
Respondents who indicated that they had had a procedure to remove one or both 
ovaries were excluded from analysis due to the potential confounding influence on 
their awareness and beliefs as a result of this reduction in ovarian cancer risk.  
4.4.3 Procedures 
Survey data were collected from October-December 2012. A study pack including an 
information sheet, consent form, questionnaire (see Appendix 8) and stamped pre-
addressed return envelope was sent to women who had registered interest in taking 
part in the study. A web address for the online version of the survey was also included 
in the study pack for those who wished to complete it electronically. 
 
4.5 General population sample 
4.5.1 Participants  
Women aged over 50  years were recruited using random probability sampling as part 
of the International Cancer Benchmarking Partnership (Forbes et al. 2013). Computer 
assisted telephone interviews were completed by 1,043 women.  
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4.5.2 Inclusion/exclusion criteria 
Women aged over 50, residing in Wales and able to give verbal consent were included. 
Women who had a personal diagnosis of ovarian cancer, or who had had their ovaries 
removed were excluded from this sample in a screening question at the start of the 
questionnaire (Brain et al. 2014). 
4.5.3 Procedures 
Random probability sampling was used to achieve a population-representative sample 
using electronic telephone directories as the sampling frame. Where more than one 
person was eligible, the Rizzo method was used to randomly select one person to be 
interviewed, thereby giving an equal chance of selection to all eligible people living in 
the household (Rizzo et al. 2004). Survey data were gathered by trained interviewers 
using computer assisted telephone interviews (see Appendix 9 for questionnaire). 
Recruitment and data collection was outsourced to the company IPSOS-MORI. 
 
4.5.4 Measures  
Individual perceptions 
Perceived susceptibility 
Perceived susceptibility was measured using the question “Compared to most other 
women your age, how likely do you think it is that you will get ovarian cancer at some 
time in your life?” (adapted from Tyndel et al. (2007). Responses were: much less 
likely, a little less likely, about the same, a little more likely, and much more likely. 
Ovarian cancer worry 
Ovarian cancer worry was measured with the Ovarian Cancer Worry Scale (Andersen 
et al. 2007), which is an adaptation of the Cancer Worry Scale (Lerman et al. 1991). The 
Ovarian Cancer Worry Scale consists of three questions, which assess frequency of 
worry (“How often, if at all, do you worry about getting ovarian cancer someday?”), 
the impact this has on mood (“How often, if at all, does your worry about getting 
ovarian cancer affect your ability to perform your daily activities?”) and the impact on 
daily functioning (“How often, if at all does your worry about getting ovarian cancer 
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affect your ability to perform your daily activities?”). Questions were answered on a 
five point scale, where 1=not at all, 2=rarely, 3=sometimes, 4=often and 5=almost all 
the time, giving the scale a range of 3-15. (Cronbach’s α for increased genetic risk 
sample =0.80, for general population = 0.69). 
 
Modifying factors 
Knowledge (Ovarian cancer symptom awareness) 
Eleven statements were included in the questionnaire to assess ovarian cancer 
awareness and were adapted from the ovarian cancer awareness measure (CAM) 
(Simon, Wardle et al. 2012). The question “Do you think the following could be a sign 
of ovarian cancer?” was followed by 11 symptoms, with the response options of ‘yes’, 
‘no’ and ‘don’t know’. Responses ‘no’ and ‘don’t know’ were combined, with 
responses coded as 1=yes and 0=no, creating a knowledge score from 0-11. The 11 
symptoms were: a persistent pain in the abdomen, a persistent pain in the pelvis, 
vaginal bleeding after the menopause, persistent abdominal bloating, increased 
abdominal size on most days, not wanting to eat because feel persistently full, 
difficulty eating usual amounts of food on most days, passing more urine than usual, a 
change in bowel habits, extreme tiredness and back pain. Items were adapted from 
the validated ovarian CAM (Simon et al. 2012b) and included less common symptoms 
(change in bowel habit, fatigue, back pain) to reflect the UK Department of Health’s 
‘Key Messages’ on ovarian cancer for health professionals and the public (Department 
of Health 2009). 
Self-efficacy (confidence in symptom detection) 
Confidence in symptom detection was measured using the question “How confident 
are you that you would notice a symptom of ovarian cancer?” Scores ranged from 1 
(not at all) to 4 (very confident) (Simon et al. 2012b).  
Demographic variables  
Participants provided their age in years and the highest level of education they 
attained (coded as: up to 16 years old, post 16 (e.g. BTEC, NVQ, HND, HNC, A levels), 
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undergraduate college or university, graduate or post graduate school, other) and their 
relationship status (married or cohabiting, in a relationship but not married or 
cohabiting, widowed and not living with another partner, divorced and not living with 
another partner, single). Participants indicated their ethnic origin (“How would you 
describe your ethnic origin?”) according to the following categories: 
English/Welsh/Scottish/ Northern Irish/British, Irish, Gypsy or Irish Traveller, White 
and Black Caribbean, White and Black African, White and Asian, Indian, Pakistani, 
Bangladeshi, African, Caribbean, Arab, Chinese and Other.  
 
Cues to action 
Personal experience with ovarian cancer 
Increased genetic risk group: The external cue of experience with ovarian cancer was 
measured with the question “Have you, or any friends or family members been 
diagnosed with ovarian cancer?” Response options were; yes (self), yes (friend or 
family member; if yes to this option, what is your relationship to this person?), and no. 
Those who responded ‘yes self’ were excluded as this sample does not include women 
diagnosed with cancer. The responses were then coded as 0= no ovarian cancer 
experience, 1= ovarian cancer experience. 
General population group: Women were asked “Have you, or any friends or family 
members that are close to you, ever been diagnosed with ovarian cancer?” Those who 
indicated that they had had a diagnosis of ovarian cancer were not given the survey. 
Response options were coded as 0= no experience of ovarian cancer and 1= 
experience of ovarian cancer.   
 
Likelihood of action (perceived benefits and barriers) 
Eleven items were used to develop scales for perceived benefits and barriers (Brain et 
al. 2014, Forbes et al. 2013, Simon et al. 2012b). For eight of the items, participants 
were asked to “indicate whether any of the following might put you off going to the 
doctor if you thought you had a symptom of ovarian cancer”. The eight items were (1) I 
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would be too embarrassed, (2) I would be too scared, (3) I would be too worried about 
wasting the doctor’s time, (4) I would have too many other things to worry about, (5) I 
would be worried about what the doctor might find, (6) I wouldn’t feel confident 
talking about my symptom with the doctor, (7) it would be difficult for me to get an 
appointment and (8) I would be too busy to make time to go to the doctor. The 
response options for these eight items were yes often (code =3), yes sometimes (code 
= 2) and no (code =1). For the remaining three items, participants were asked “please 
indicate how much you agree or disagree with each statement”. The statements were 
(9) If ovarian cancer is diagnosed early, it can be treated more successfully, (10) If 
found early, ovarian cancer can often be cured and (11) going to the doctor as quickly 
as possible after noticing a symptom of ovarian cancer could increase chances of 
surviving. The response options for these items were strongly disagree (code = 1), tend 
to disagree (code = 2), tend to agree (code=3), strongly agree (code =4).  
 
Likelihood of behaviour (Anticipated presentation time) 
Participants were asked “If you had a symptom that you thought might be a sign of 
ovarian cancer, how long would it take you to go to the doctors from the time you first 
noticed the symptom?”(Simon et al. 2012b). Response options were; I would go as 
soon as I noticed, up to one week, over one week up to two weeks, over two weeks up 
to three weeks, over three weeks up to four weeks, and more than a month.  
Responses were re-coded as ‘0= I would go as soon as I noticed, no delay’ and ‘1= any 
delay, up to a week to more than a month’.  
 
4.5.5 Data analysis 
Data screening identified one participant reporting a score of 15 for ovarian cancer 
worry (sample mean = 6.15 (SD= 1.94)). This case was removed from analysis due to 
varying from the mean and standard deviation of the rest of the sample. The case was 
removed in screening and cleaning and therefore was not included in the data analysis. 
Sample characteristics and descriptive statistics are presented for the two risk groups 
separately in order to show the profiles of the two risk groups. Separate principal 
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components analyses with varimax rotation on a priori HBM items were conducted for 
the two groups in order to identify the salient factors contributing to the HBM scales 
for each risk group. 
 
The increased genetic risk sample (N=283) and general population sample (N=1,043) 
were combined (N=1,326) for an overall test of the structural relations in the HBM 
model. Initially, a measurement model was created in order to observe whether 
perceived susceptibility and ovarian cancer worry were part of the same latent trait 
complex perceived threat. A full structural equation model (SEM) was then used to 
examine relations between this latent complex and other constructs. Specifically, a 
SEM was computed investigating whether individual perceptions, modifying factors, 
perceived threat, cues to action and likelihood of action predicted the behavioural 
outcome of anticipated time to presentation. Constructs were subject to preliminary 
screening to test the normality of the distributions before fitting the model. All 
constructs met the assumptions of normality. A baseline model was created, with the 
same parameters used for configural models for analysis of invariance. The invariance 
tests examined equivalence of model parameters (intercept, regression coefficients, 
means, covariance and residuals) between the two risk groups. 
 
Fit of the overall model was determined from five fit indices:  (1) chi-square (CMIN) not 
significant at the 0.05 level of significance indicates a model with good fit (Byrne 2009); 
(2) relative chi-square (CMIN/df) with a ratio within 3:1 indicates good fit (Kline 2011); 
(3) a comparative fit index (CFI) and (4) Tucker-Lewis Index (TLI) greater than 0.95 
indicates a model with good fit (Hu and Bentler 1999), (5) a standardised root-mean 
square error of approximation (RMSEA) close to 0.06 indicates good fit (Hu and Bentler 
1999). 
4.6 Results  
Results are presented in the following sections covering (1) sample characteristics, (2) 
principal components analysis (PCA) of HBM items, (3) SEM for all participants, and (4) 
SEM for increased genetic risk and general population groups separately. 
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4.6.1 Response rate in the increased genetic risk group 
The questionnaire was sent to 475 women, of whom 164 (35%) did not return the form 
and 28 (6%) were excluded due to having undergone a procedure to remove their 
ovaries. The final sample was 283, giving a final response rate of 63%. Twenty nine 
respondents were recruited from the Ovacome newsletter (10%) and the remaining 
254 (90%) participants from the PsyFOCS recruitment pool. Four participants 
completed the electronic version of the survey.  
 
4.6.2 Response rate in the general population  
As a result of the data collection method, it is hard to estimate true response rates for 
this sample (Brain et al. 2014). Random digit dialling means it is not possible to 
estimate the number of eligible participants. Of the 1385 female respondents, 315 
were excluded due to a personal history of ovarian cancer or having had a procedure 
to remove one or both ovaries. The final sample was 1043. 
 
4.6.3 Sample characteristics of the two risk populations  
Sample characteristics for both risk groups are provided in Table 4.1.  All comparisons 
were significantly different. The majority of the increased genetic risk group 
respondents were over 50, were married or cohabiting and were educated beyond age 
16. The general population responders were mainly in the 50-69 years old age bracket, 
and there was an almost even split of participants who were married or cohabiting and 
not married or cohabiting. Most of the general population sample was educated up to 
age 16.  
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Table 4.1. Sample characteristics and comparison statistics of the increased genetic risk and 
general population 
Variable 
 
Increased 
genetic risk 
(n=283) 
General population 
(n=1043) 
Statistic  
Age, years n (%) m=52.87 
(sd=10.40) 
m=64.53 (sd=9.49) t(1313)=-17.86, 
p<0.001 
   30-49 123 (44%)   
   50-69 135 (48%) 735 (71%)  
   70+ 
 
22 (8%) 300 (29%)  
Relationship status n(%)   x
2
(1)=53.81, p<0.001 
   Married or cohabiting 209 (74%) 515 (49%)  
 
Education n(%) 
   
x
2
(2)=66.11, p<0.001 
   Up to 16 81 (29%) 570 (56%)  
   Secondary 105 (37%) 254 (25%)  
   Degree and above 
 
96 (34%) 197 (19%)  
Anticipated time to presentation n 
(%) 
m=0.59 (sd=0.49) m=0.51 (sd=0.52) x
2
(5)=30.38, p<0.001 
I would go as soon as I noticed 115 (41%) 507 (51%)  
Up to 1 week 46 (17%) 239 (24%)  
Over 1 up to 2 weeks 43 (16%) 101 (10%)  
Over 2 up to 3 weeks 23 (8%) 51 (5%)  
Over 3 up to 4 weeks 28 (10%) 57 (6%)  
More than a month 
 
22 (8%) 43 (4%)  
 Confidence in symptom detection n 
(%) 
m=2.20 (sd=0.70) m=2.34 (sd=0.93) t(586)=-3.01, p<0.01 
  Not at all 41 (14%) 213 (21%)  
  Not very 151 (54%) 350 (34%)  
  Fairly  85 (30%) 347 (34%)  
  Very  
 
5 (2%) 108 (11%)  
Perceived susceptibility n (%) m=4.21 (sd=0.71) m=2.40 (sd=0.95) t(579)=-34.04, 
p<0.001 
  Much less likely 2 (1%) 194 (21%)  
  A little less likely 1 (0.5%) 276 (29%)  
  About the same 30 (11%) 392 (41%)  
  A little more likely  144 (53%) 69 (7%)  
  Much more likely 
 
94 (34.5%) 17 (2%)  
Experience with OC n (%)   x
2
(1)=437.36, 
p<0.001 
   Yes 257 (91%) 238 (22%) 
 
 
Symptom knowledge m (sd, range) 
 
6.1 (0-11, 2.6) 6.9 (0-11, 2.7) t(1324)=--4.28 
,p<0.001 
Worry m (sd, range) 6.2 (1.9, 3-12) 5.3 (1.4, 4-12) t(495)=-6.24, p<0.001 
Note: valid % reported in cases where data were missing. OC= ovarian cancer  
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Under half of the increased genetic risk sample (41%) anticipated presenting 
immediately after noticing a possible ovarian cancer symptom, with 51% of the general 
population anticipating presenting immediately. When asked about confidence levels 
in detecting possible symptoms of ovarian cancer, 32% of the increased genetic risk 
group, and 35% of the general population group felt confident. Only 2% of the 
increased genetic risk group and 11% of the general population reported feeling ‘very 
confident’ in detecting a symptom. The majority of the increased genetic risk sample 
(88%) perceived that they were more likely to get ovarian cancer compared to other 
women of the same age, with only 1% perceiving they were less likely to get ovarian 
cancer. Only 9% of the general population perceived that they were more likely to get 
ovarian cancer compared to other women of the same age.  Most of the increased 
genetic risk respondents had personal experience of ovarian cancer (friend or family), 
whereas most of the general population sample had no personal experience of ovarian 
cancer. The average ovarian cancer worry score for the increased genetic risk sample 
was significantly higher than that in the general population sample. 
 
4.6.4 Knowledge of ovarian cancer symptoms 
The most frequently recognised ovarian cancer symptom was persistent abdominal 
bloating (n =247, 89%) for the increased genetic risk group, and vaginal bleeding after 
the menopause (n= 912, 92%) for the general population group (see Figure 4.2 for all 
symptoms). Passing more urine than usual was least recognised by both the increased 
genetic risk (n=76, 28%) and general population (n= 334, 38%) groups. The general 
population group had significantly better symptom knowledge (reported in Table 4.1), 
with an average knowing of 6.9 of symptoms, versus the increased genetic risk group 
knowing 6.1 symptoms. 
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Figure 4.2. Recognition of individual ovarian cancer symptoms for both risk populations (valid 
% presented in cases where data were missing) 
 
4.6.5 Principal components analysis of HBM items 
Increased genetic risk group 
Four factors were extracted which explained a total 63.12% of the variance (see 
Appendix 10). The factors were labelled Perceived Barriers (26.60% of variance, 
eigenvalue 3.19, Cronbach’s a=0.72, range 6-8, mean score 7.94, sd=2.17), Perceived 
Benefits (16.42% of variance, eigenvalue 1.97 Cronbach’s a= 0.81, range 3-12, mean 
score 10.04, sd=1.90), Fear (11.57% of variance, eigenvalue 1.39 r=0.72, p<0.001) and 
Perceived Susceptibility (8.52%, eigenvalue 1.02).  Fear referred to fear of what might 
be discovered (see Factor III in Appendix 10), therefore the purpose of SEM, the factor-
derived scales for fear and perceived barriers were combined to create a Perceived 
Barriers construct (8 item scale Cronbach’s a= .75). As the HBM defines the likelihood 
of action as perceived benefits minus barriers, calculations were made in SPSS version 
20 creating a likelihood of action scale which ranged from -15 to 4. Scores at the 
negative end of the likelihood of action scale represented more perceived barriers 
than benefits, and scores at the positive end of the scale indicated more perceived 
benefits than barriers. 
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General population group 
Four factors were extracted which explained 57.84% of the variance (see Appendix 11). 
The factors were labelled Emotional Barriers (23.96% of variance, eigenvalue 2.88, 
Cronbach’s a=0.67, range 5-15, mean score 6.02, sd=1.65), Practical Barriers (15.71% 
of variance, eigenvalue 1.89, Cronbach’s a=0.59, range 3-9 mean score 3.51, sd=1.02), 
Perceived Benefits (9.78, eigenvalue 1.17, Cronbach’s a= 0.68, range 3-12 mean score 
10.94, sd=1.29) and Perceived Susceptibility (8.39% of variance, eigenvalue 1.01). The 
emotional barriers and practical barriers were combined to create a perceived barriers 
construct for use in SEM (8 item scale Cronbach’s a= .72). The Likelihood of Action 
scale was created in the same way as for the increased risk group (range -10 to 4). 
 
4.6.6 Structural equation modelling for total sample 
Prior to the SEM, a measurement model was created in order to observe whether 
perceived susceptibility and ovarian cancer worry were part of the same trait complex. 
The measurement model showed the conceptualisation of the perceived threat 
component. The other components of the HBM were then added in order to create the 
structural model. The measurement model, consisting of perceived susceptibility, 
ovarian cancer worry and the latent variable perceived threat can be seen embedded 
in the structural model in Figure 4.3. The full structural equation model for the total 
sample is shown in Figure 4.3. The goodness of fit statistic was significant (x
2=115.68, 
df=11, p<.05), indicating a bad fit. Fit indices were CFI=.90 and RMSEA=.09, indicating 
marginal good fit, with TLI=.66 and relative chi-square x2/df= 10.52 indicating bad fit 
(see Appendix 12 for correlation matrix of model variables). 
 
Perceived susceptibility and ovarian cancer worry were both significant indicators of 
perceived threat in the measurement model. The likelihood of action construct, which 
consists of perceived benefits and barriers, was significantly negatively correlated with 
anticipated presentation. Participants who perceived more benefits than barriers to 
presentation were therefore more likely to report earlier anticipated presentation. 
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Older participants perceived significantly more benefits than barriers to presentation, 
and perceived significantly lower threat. 
 
Figure 4.3. The Health Belief Model applied to anticipated presentation to medical professional with 
potential ovarian cancer symptoms for all participants. Values displayed are standardised regression 
weights (      ), covariances  (     ) and percentage of variance accounted for. *p<0.05. **p<0.01, 
***p<0.001. Grey font indicates paths with no significant associations.  
 
Participants reporting higher self-efficacy perceived significantly more benefits than 
barriers to presentation, and also had lower perceived threat. Participants with more 
personal experience of ovarian cancer had higher levels of perceived threat. There was 
no significant correlation between perceived threat and anticipated presentation. 
Knowledge was not significantly correlated with either perceived threat or likelihood 
of action; however, it was positively correlated with self-efficacy. Covariances for 
personal experience were not significantly correlated with variables within the model. 
Age, knowledge and self-efficacy accounted for 13% of the variance in perceived 
benefits minus barriers. The constructs of the HBM predicted 6% of variance in 
anticipated presentation. 
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4.6.7 Tests of invariance across the two risk populations  
Analysis of invariance was carried out to identify differences in fit between the 
increased genetic risk and general population groups. The increased genetic risk and 
general population data were analysed simultaneously in a configural model with the 
same parameters as the baseline model. Goodness of fit statistics for the configural 
model were x2(118.28), df=24, p<.001, x2/df= 4.93, CFI=.77, RMSEA=.05. Constraints 
were then applied to the parameters to test invariance in loadings and structure across 
groups (see Table 4.2). Δx2 indicated invariance for model 1, indicating that when the 
structural weights (i.e., path coefficients) were constrained the model was variant 
between groups. When other constraints were successively added (intercepts, means, 
covariances, residuals, see Models 2-5) the model was invariant. ΔCFI indicated the 
model was not invariant across groups for all models. These results indicated that 
model fit could be poor because the nature of associations among variables (path 
coefficients) differed between the increased genetic risk and general population group. 
 
Table 4.2. SEM invariance analysis across different risk populations  
 x2 Df Δx2 Δdf CFI ΔCFI 
Configural model 118.28 24   .77  
Model 1 132.57 32 14.29 8 .75 .02 
Model 2 201.47 33 83.19* 9 .58 .19 
Model 3 793.96 37 675.68* 13 .00 .77 
Model 4 1076.58 47 958.30* 23 .00 .77 
Model 5 1236.45 49 1118.17* 25 .00 .77 
Note. Δx
2 
=difference in x
2 
between models; Δdf= difference in degrees of freedom between models; ΔCFI = 
difference in CFI between models. Numbers in bold indicate goodness of fit. Model 1= constrained structural 
weights. Model 2= constrained structural weights and intercepts. Model 3 = constrained structural weights, 
intercepts and means. Model 4= constrained structural weights, intercepts, means and covariance’s. Model 5 = 
constrained structural weights, intercepts, means, covariance’s and residuals.  *p<.05. 
 
4.6.8 Structural equation modelling for separate groups 
Due to the tests of invariance indicating that the model did not hold its meaning across 
groups, separate SEMs were tested in the individual groups to identify model 
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differences between the two risk groups.  The results of the increased genetic risk SEM 
and the general population SEM are presented together in Figure 4.4. 
 
Figure 4 4. The Health Belief Model applied to anticipated presentation to medical professional with 
potential ovarian cancer symptoms for increased genetic risk (top coefficient)  and general population 
participants (bottom coefficient). Values displayed are standardised regression weights (      ), 
covariances (      ) and percentage of variance accounted for. *p<0.05. **p<0.01, ***p<0.001. Grey font 
indicates paths with no significant associations. Italic font represents the increased genetic risk group. 
Non italic font represents the general population group. 
 
4.6.9 SEM model fit in increased genetic risk group 
The goodness of fit statistic was significant at the .05 level (x
2=23.54, df=12, p<.05), 
indicating bad fit. The relative chi-square (x
2/df=1.96) was under the recommended 3:1 
range and indicated good fit. The CFI=.92 indicated marginal good fit, RMSEA=.06, 
good fit, and TLI=.76 a bad fit. The observed relationships between the variables in the 
increased genetic risk model are provided in the correlation matrix in Appendix 13. 
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The constructs of the HBM predicted 14% of variance in anticipated presentation for 
the increased genetic risk group (see Figure 4.4). Perceived threat was determined by 
perceived susceptibility and ovarian cancer worry, with both of these variables being 
significant indicators of perceived threat in the measurement model. High perceived 
threat was associated with earlier anticipated presentation in this group. Age was 
positively correlated with likelihood of action (benefits minus barriers), with older 
participants perceiving significantly more benefits than barriers to presentation. Age 
was significantly negatively correlated with perceived threat, with older participants 
having lower perceived threat. Higher self-efficacy was associated with perceiving 
significantly more benefits than barriers to presentation. 
 
Higher self-efficacy was also significantly associated with lower perceived threat. 
Again, knowledge was not significantly correlated with either perceived threat or 
likelihood of action. However, a significant positive covariance of knowledge with self-
efficacy was observed. Personal experience was not significantly correlated with 
perceived threat, but those with personal experience had significantly higher self-
efficacy. Age, knowledge and self-efficacy accounted for 10% of the variance in the 
likelihood of action construct, perceiving more benefits than barriers was significantly 
associated with immediate presentation. 
 
Analysis of invariance was carried out for the dichotomous demographic variables 
marital status and education level. Both groups (married and not married) were 
analysed simultaneously in a configural model with the same parameters as the 
baseline model. Goodness of fit statistics for the configural model were; x2(34.13, 
df=24, p=.08, x2/df= 1.42, CFI=.93, RMSEA=.04. Constraints were then applied to the 
parameters to test invariance and structure across groups (see Appendix 15). Again, to 
test for invariance across education status, both groups (highly educated and not 
highly educated) were analysed simultaneously in a configural model with the same 
parameters as the baseline model. Goodness of fit statistics were x2(33.49, df=24, p= 
.09, x2/df= 1.40, CFI=.92, RMSEA= .04. Constraints were then applied to the parameters 
to test invariance and structure across groups (see Appendix 16). 
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4.6.10 SEM model fit in general population 
For the general population group, the goodness of fit statistic was significant at the .05 
level (x
2=26.31, df=12, p<.05), indicating a bad fit. The relative chi-square (x
2/df=2.19) 
was under the recommended 3:1 range that indicates good fit. Other fit indices were 
CFI=.92 and RMSEA=.04, indicating marginally good fit, with TLI=.72 indicating a bad fit. 
The relationships between the variables used in the general population model are 
provided in the correlation matrix in Appendix 14. The constructs of the HBM 
predicted 3% of variance in anticipated presentation for the general population group 
(see Figure 4.4). 
 
In the general population group, only perceived susceptibility was a significant 
determinant of perceived threat. The correlation between perceived threat and 
anticipated presentation was not significant in this group. Age was negatively 
correlated with perceived threat, with older participants having lower perceived 
threat. High self-efficacy was associated with perceiving more benefits than barriers to 
presentation. Knowledge was significantly correlated with likelihood of action in the 
general population, with knowledge amplifying the benefits of presenting. Age, 
knowledge and self-efficacy accounted for 5% of the variance in the likelihood of 
action construct, similarly to the increased genetic risk group, perceiving more benefits 
than barriers to presentation was associated with earlier anticipated presentation in 
the general population group.  
 
4.6.11 Summary of model fit for the three structural models 
The fit indices for the three structural models can be seen in Table 4.3. Fit indices 
indicated that the model fit best when applied to the increased genetic risk sample. 
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Table 4.3. Goodness of fit according to fit indices for Health Belief Model structural models for 
total sample, increased genetic risk sample and general population sample 
 Comparative 
fit index (CFI) 
Standardised root 
mean square error 
(RMSEA) 
Tucker-Lewis 
Index (TLI) 
Relative chi 
square (x
2
/df) 
Total sample 
(n=1326) 
0.90 0.09 0.66 10.52 
Increased genetic 
risk sample (n=283) 
0.92 0.06 0.76 1.96 
General population 
sample (n=1043) 
0.92 0.04 0.72 2.19 
 
4.7 Discussion  
The HBM was used to test theoretical determinants of anticipated symptomatic 
presentation in a sample of women comprising two risk populations. The evidence 
from the present study suggests that the HBM is a good model to use in identifying 
determinants of anticipated presentation with potential ovarian cancer symptoms. 
Tests of invariance across the two risk groups showed, however, that the model was 
not invariant across the two risk groups, indicating that the constructs of the HBM 
influencing anticipated presentation differ according to whether women are at risk for 
ovarian cancer. This was the first study to explore the nature of perceived threat and 
its influence on action was found to differ according to risk status. Perceived threat 
comprised both affective (worry) and cognitive (susceptibility) aspects in women at 
increased genetic risk, but only cognitive aspects in the general population sample. In 
those at increased genetic risk, the affective component of risk perception 
predominated, and may override cognitive aspects of anticipated presentation 
behaviour. Overall, the current findings support the need for a symptom awareness 
tool with tailored content for women at increased genetic risk of ovarian cancer.  
 
4.7.1 Is the Health Belief Model a useful model? 
Structural equation modelling provided evidence that the constructs proposed by the 
HBM are important determinants of anticipated presentation to a medical professional 
with suspected ovarian cancer symptoms. However, the HBM predicted a greater 
proportion of the variance in anticipated presentation for the increased genetic risk 
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group (14%) than for the general population (3%). Tests of invariance indicated that 
the difference between the two groups was as a result of differences in the magnitude 
of path coefficients in the model, rather than differences in levels of predictors (e.g. 
mean susceptibility). The path differences suggest that health beliefs in women at 
increased genetic risk are determined by perceived threat, with affective 
representations of this latent variable important in this population.  
 
The varying model fit could be explained in terms of the study populations. The model 
may not fit the general population so well because it does not represent the health 
beliefs of this group, or their notion of threat, as well as it does for the increased 
genetic risk group. The inclusion of perceived susceptibility and ovarian cancer worry 
in the HBM could mean that the theory is directly relevant to women at increased 
genetic risk of ovarian cancer, as the theory accounts for the impact of their increased 
risk status. The HBM proposes that when faced with a potential health threat, people 
consider their susceptibility to and the severity of the health threat when deciding 
whether to act, (Rosenstock et al. 1988), with such considerations more salient in 
those at increased genetic risk. This could also explain the greater proportion of 
variance in anticipated presentation that was accounted for by the model in women at 
increased genetic risk.  
 
4.7.2 What is perceived threat?  
Perceived threat is an integral component of the HBM and was shown to vary 
according to risk context. Findings suggest that whilst cognitive and affective 
components are determinants of perceived threat, it is the affective component that is 
the predominant influence on anticipated presentation in the context of increased 
genetic risk. In the increased genetic risk group, high levels of perceived susceptibility 
(cognitive) and high levels of ovarian cancer worry (affective) were demonstrated in 
those with high perceived threat.  Perceived threat is therefore associated with both 
cognitions and emotions in the increased genetic risk group, but only cognitions in the 
general population.  
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Previous operationalizations of perceived threat have focused on the cognitive aspects 
of perceived threat by including perceived susceptibility and severity (Glanz et al. 2008, 
Rosenstock et al. 1988), whereas the current study has operationalized perceived 
susceptibility and ovarian cancer worry. Aspects of affective components of threat are 
embedded in perceived susceptibility and severity (Hay et al. 2005), however the 
inclusion of a variable focused on the affective component of threat in this study 
means that it explicitly includes both cognitive and affective components of threat. 
This study has demonstrated that including an affective threat variable can help 
increase understanding of the role perceived threat plays in help seeking behaviour, in 
particular anticipated symptomatic presentation. In future research, both affective and 
cognitive components of perceived threat should be considered, with worry and 
susceptibility particularly important considerations in increased risk samples.   
 
4.7.3 What predicts anticipated presentation?  
Perceived threat was found to influence anticipated presentation behaviour in 
different ways, depending on risk status. In the increased genetic risk group, high 
perceived threat was associated with earlier anticipated presentation, whereas in the 
general population the influence of perceived threat was not significant. This suggests 
that it is both the cognitive and affective representations of perceived threat that are 
influencing anticipated presentation with ovarian cancer symptoms. The HBM outlines 
that higher perceived threat increases the likelihood of engaging in behaviour that is 
likely to manage/reduce this threat (Rosenstock et al. 1988). The present findings 
elaborate this further by demonstrating that the affective component of threat may be 
a greater motivator for those at increased genetic risk.  A possible explanation is that 
those with high worry present to the doctor with symptoms in attempts to manage 
their worry. However, due to the cross-sectional nature of the research it is hard to 
infer causality. This pattern of results complements research on familial ovarian cancer 
screening uptake, where worry is a key determinant of screening uptake (Andersen et 
al. 2002, Schwartz et al. 1995a). Whilst it is hard to put a value on an “appropriate 
level” of worry, or infer causality, the current study findings suggest that cancer-
related worry experienced in the increased genetic risk sample is higher or more 
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salient than in the general population, and is a key determinant of anticipated 
presentation.  
 
It is also difficult to conceptualise appropriate levels of delay. In the current study, a 
dichotomous no delay/any delay presentation cut off was used. This was chosen as any 
delay in presentation may be deemed problematic, based on survival rates for earlier 
detection and earlier diagnosis of ovarian cancer (Quaye et al. 2008). This choice of cut 
off means that findings from the current study will allow a deeper understanding of 
the health beliefs and determinants of presentation in those who anticipate presenting 
immediately, and those who anticipate waiting for any length of time.  
 
4.7.4 Which components of the HBM are relevant for anticipated presentation?  
Factor analysis for the HBM scales revealed a similar pattern of underlying constructs 
for the two risk groups, with the exception of barriers. For the increased genetic risk 
group, the extracted factors for barriers differentiated fear of the discovery of ovarian 
cancer, whereas for the general population the extracted factors differentiated 
practical barriers involving time constraints. This differentiation has implications for 
education and awareness tools about ovarian cancer, providing support for the need 
to tailor tool content according to risk status. 
 
Personal experience was not a significant determinant of perceived threat in either risk 
group. It was anticipated that participants who were at increased genetic risk would 
have familial experience with ovarian cancer that would influence their perceived 
threat. The only notable influence of personal experience of ovarian cancer in the 
increased genetic risk group was in combination with self-efficacy, suggesting that 
having close relatives who have experienced ovarian cancer is more influential on 
learning than having friends or distant relatives who have experienced it.  
 
There was no significant association between knowledge and perceived benefits and 
barriers in the increased genetic risk group, although an association was observed for 
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the general population. However, knowledge was still important in the increased 
genetic risk group, influencing anticipated presentation indirectly via self-efficacy 
(women with greater knowledge had more self-efficacy). In turn, self-efficacy was 
identified as being a significant determinant of perceived threat. Women at increased 
genetic risk with lower self-efficacy had higher perceived threat. Symptom awareness 
could therefore influence anticipated presentation indirectly via self-efficacy, and 
improving confidence could be a mechanism for translating awareness to presentation. 
Those with higher self-efficacy also perceived more benefits than barriers to 
presentation. This is consistent with predictions of the HBM, which state that the 
likelihood of action is higher if the individual perceives more benefits to the behaviour 
than barriers to carrying it out (Becker 1974). 
 
Older participants in the increased genetic risk group perceived more benefits than 
barriers to presentation. Older participants in both risk groups reported lower levels of 
perceived threat, with lower levels of perceived threat associated with longer 
presentation times. This finding is particularly interesting in light of the risk of 
developing ovarian cancer increasing with age (Quaife et al. 2013). Younger people 
reporting higher perceived threat could reflect media attention surrounding the 
diagnosis of cancer in high profile, young celebrities.  
 
The lack of a direct association between ovarian cancer symptom awareness and 
anticipated presentation that was observed in the current study was also reported by 
Low et al. (2013b), and could be indicative of mechanisms underlying these processes 
which are specific to ovarian cancer. Modelling using the HBM suggests that ovarian 
cancer awareness (or knowledge) is indirectly associated with anticipated 
presentation, with awareness influencing anticipated presentation through 
mechanisms such as self-efficacy, perceived benefits and barriers to presenting, and in 
women at increased genetic risk perceived threat. 
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4.7.5 Study limitations  
The cross-sectional nature of the study design and use of intent-to-present have 
implications regarding the temporal stability and interpretation of the current findings. 
Prospective research would allow real symptoms and presentation behaviour to be 
measured, and could provide a more accurate understanding of women’s appraisal 
process when deciding whether to present to primary care with ovarian cancer 
symptom concerns.  
 
In the current study, a higher percentage of women anticipated presenting in a shorter 
time frame than has been reported in the literature concerning actual presentation. 
The Royal College of General Practitioners national audit of cancer diagnosis in primary 
care (RCGP 2011) reported that 50% of ovarian cancer patients present within one 
month of developing symptoms. Goff et al. (2000) also reported that women who had 
been diagnosed with ovarian cancer took an average of 2-3 months before seeking 
medical advice. The differences could reflect discrepancies between anticipated and 
actual presentation (Low et al. 2013a, Sheeran 2002). It could also reflect a problem 
with the measure used in the current study, as anticipated time to presentation may 
not be an accurate representation of actual presentation time (Andersen et al. 2009, 
Robb et al. 2009). Results in the current study indicated that women from the general 
population had higher symptom awareness and anticipated presenting in shorter time 
frames than the increased genetic risk sample (see Table 4.1). This counter-intuitive 
finding could reflect beliefs held by women at increased genetic risk, such as beliefs 
that ovarian cancer is an asymptomatic disease. Women at increased genetic risk could 
have their perceptions about the disease shaped by their family members (Andersen et 
al. 2009), with negative experiences of the disease in family members potentially 
influencing personal beliefs about the disease. The observed difference between the 
two risk populations could also reflect that women at increased genetic risk rely on 
screening as their main detection strategy and therefore place less emphasis on 
symptom awareness and symptomatic presentation. 
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The use of a dichotomous variable for anticipated presentation could also obscure 
nuance in this variable. The categories chosen for the anticipated presentation variable 
were “immediate presentation” versus “any delay”. Since there is no clinical consensus 
on the optimal time to present with ovarian cancer symptoms, in addition to the 
notion that degree of delay is not as important as presence of delay, this cut off was 
considered acceptable. Of the increased genetic risk sample, 41% reported that they 
would anticipate presenting immediately after noticing a symptom, compared to 51% 
of the general population sample. Based on these results, having a cut off reflecting 
those anticipating presenting “immediately” and those with longer anticipated 
presentation enables recommendations to be made based on those who have high 
levels of perceived threat. It also seems reasonable to propose an "immediate 
presentation" versus "any delay" dichotomy, as there is currently little data to support 
fine grained differences between waiting for a week, month etc. 
Symptom recognition scores were aggregated in the current study, whereas better 
understanding may be gained if symptoms are examined on an individual basis, or if 
knowledge of ‘red flag’ Versus ‘non red flag’ symptoms are explored. However, the 
sample was too small to examine symptom recognition in this way. A further limitation 
relating to symptom recognition is that while the measure in the current study informs 
about the ability of respondents to recognise potential symptoms, it is not informative 
about the participant’s understanding of these symptoms. The symptom question does 
not inform about the processes women may go through when appraising and 
interpreting a symptom, or if indeed the participants are simply guessing whether 
symptoms are indicative of ovarian cancer.  The appraisal process is important to 
understand in cancer awareness because it is the cognitive process through which 
people generate a sense of susceptibility, and therefore may help researchers to better 
conceptualise “delay” (Andersen et al. 2009) and the role of cognitions and emotions 
in help seeking behaviour.  
 
The potential lack of sample representativeness should also be acknowledged, as the 
increased genetic risk sample was mainly recruited from a pool of those who had 
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participated in UKFOCSS and its psychological partner study, PsyFOCS. These women 
may therefore have different levels of ovarian cancer worry and symptom awareness 
than women who did not take part. However, PsyFOCS data suggested that non-
completers had higher levels of ovarian cancer worry, therefore levels of worry may 
have been under-represented in the current sample (Brain et al. 2012). Some women 
were also recruited from Ovacome and there may have been differences according to 
recruitment source, however, as only a small number were recruited from Ovacome it 
was not possible to examine the potential effects of recruitment source. Thus the 
findings may not be generalisable to all women who are at increased risk for ovarian 
cancer. A further concern is the different sampling methods that were used. The 
increased genetic risk sample was an opportunity sample whilst the general population 
sample was a population representative sample. The cases and controls not being 
drawn from the same population is a known problem for cohort studies (Mann 2003). 
In addition, it was not possible to confirm the actual risk status of the general 
population sample. Group differences should be noted as a possible explanation of 
differences observed in the SEM. The demographic profiles of the two samples could 
explain differences observed, therefore it could be variables including age and 
education level rather than cancer awareness, that caused the observed effects. 
 
4.7.6 Application of findings 
The present findings have highlighted that cognitive and affective components of 
perceived threat differ according to risk group, providing justification for tailored 
health information for those at increased genetic risk in order to address the potential 
influence of high levels of cancer-related worry on anticipated presentation in this 
population. Educational information should be provided for women at increased 
genetic risk of ovarian cancer that focuses on minimising the impact of worry on the 
cognitive aspects about what to do in the presence of symptoms. Educational 
information should consider the potential for over-presentation in women at increased 
genetic risk and include guidance and information on specific time frames in order to 
educate women on appropriate presentation times.  
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The current findings have identified some common health beliefs for the two risk 
populations (self-efficacy associated with knowledge and perceiving more benefits and 
barriers, and perceiving more benefits than barriers associated with earlier anticipated 
presentation), as well as unique health beliefs for women at increased genetic risk (the 
make-up of perceived threat and the association with anticipated presentation). The 
findings of the SEMs also suggest that women from the general population could 
benefit from symptom information and education about presentation times. Therefore 
tailored content that addresses the specific needs of women at increased genetic risk 
could be embedded within a tool which also contains information that is relevant to 
women from the general population. This may prove effective as it allows for an all-
inclusive approach to education on ovarian cancer awareness, whilst still addressing 
the specific issues that are unique to women at increased genetic risk, such as ovarian 
cancer worry.  The principal components analysis revealed similar health belief 
constructs in the two risk populations, with the main exception of barriers. These 
different barriers for the increased genetic risk population could be addressed in the 
tailored content that is specific for women at increased genetic risk. The acceptability 
of an all-encompassing awareness tool, which also has specific content for women at 
increased genetic risk can explored in later phases of this research project. 
 
Barriers to presentation have also been reported in UK population samples, where 
worrying about wasting the doctor’s time and embarrassment were significant barriers 
to presentation (Forbes et al. 2013, Simon et al. 2010). The presence of these barriers 
seen in other study populations could therefore reflect British approaches and beliefs 
to healthcare.  However, the present study has shown that women at increased 
genetic risk also have the added psychological burden of their risk status, with fear and 
worry relating to visiting the doctor a barrier to presentation. An intervention which 
includes tailored content for women at increased genetic risk could be a way for these 
differing barriers and the specific psychological burdens for women at increased 
genetic risk to be addressed. 
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The current findings are applicable to clinicians and health professionals who interact 
with women at increased genetic risk of ovarian cancer, as the psychological impact of 
risk status has been highlighted. GPs should be aware of the potential for heightened 
cancer worry when consulting with increased risk populations. This awareness could 
also allow for GPs to make potential recommendation or referrals to places for women 
to discuss the impact of their risk status and help manage or reduce their worry levels. 
 
4.7.7 Future research 
Prospective research that examines actual behaviour and that disentangles causal 
direction is an important next step in this research field. Such research could also help 
increase understanding of the interplay between affective and cognitive 
representations of threat. The current study has justified the need for information 
tools to be developed which contain content tailored according to risk. However, the 
need remains for firm clinical evidence regarding symptom duration and thresholds. 
While such clinical information is still developing, the work in the current study has 
provided insight in to the health beliefs of women at increased genetic risk of ovarian 
cancer, and how these compare to a general population sample. This research has 
developed a theoretical understanding of anticipated presentation with ovarian cancer 
symptoms and has led to an understanding of how change in anticipated presentation 
may be achieved. This understanding forms the theoretical foundation (Craig et al. 
2008b) for the development of an ovarian cancer symptom awareness tool that has 
core content for all women and tailored content specific for the needs of women at 
increased genetic risk of ovarian cancer. 
 
4.7.8 Summary 
Findings justify the need for an ovarian cancer symptom awareness tool that has 
specific content that is tailored to the needs of women at increased genetic risk. In 
those at increased genetic risk, the affective component of risk perception (worry) may 
override cognitive aspects. An understanding of the determinants of perceived threat 
have been identified, and attention can now be paid to how perceived threat can be 
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reduced or managed. This will allow ovarian cancer information to be given whilst 
maintaining the psychological well-being of the individual. This is important as the 
psychological well-being of those at increased risk needs to be maintained in the 
absence of routine ovarian screening.
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5 A qualitative study exploring the influence of ovarian cancer experience on 
anticipated presentation in women at increased genetic risk of ovarian cancer. 
 
5.1 Chapter overview 
The present chapter reports a qualitative study with women at increased genetic risk 
of ovarian cancer, in which women’s perceptions of ovarian cancer symptom 
awareness and symptomatic presentation were explored. This study was conducted to 
further understand the unique health beliefs that were identified for this population in 
the survey (Chapter 4) and to guide decisions regarding the content of a symptom 
awareness tool with tailored content for women at increased genetic risk of ovarian 
cancer.  
 
5.2 Introduction  
Understanding health beliefs is crucial for a risk management approach based on 
symptom awareness. Theoretical constructs that are identified as important can be 
incorporated into an awareness tool aimed at encouraging timely symptomatic 
presentation. Perceived threat was identified as an important health belief, with the 
determinants of perceived threat differing according to risk status. The affective 
component of perceived threat (ovarian cancer worry) was associated with how 
women at increased genetic risk perceived their risk, their health beliefs and 
anticipated symptomatic presentation. A richer understanding of the influence of 
perceived threat on emotions and behaviour is therefore needed.  
 
The affective (worry) component of perceived threat is of particular interest as high 
levels of worry could lead to hyper-vigilance and therefore the potential influence of 
threat on behaviour also needs to be understood in order to provide guidance to 
women and manage their expectations. This is important as the psychological 
wellbeing of those at increased genetic risk needs to be maintained in the absence of 
routine screening. This behavioural pattern could be problematic not only in terms of 
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the individual’s psychological wellbeing, but also the potential impact on primary care 
services if women are frequently visiting their GP due to hyper-vigilance.  
 
Other health beliefs that were identified as important determinants of earlier 
anticipated presentation for women at increased genetic risk of ovarian cancer 
included high self-efficacy and perceiving more benefits than barriers to presentation 
(Chapter 4). These constructs identified in Chapter 4 were also explored in greater 
depth to ascertain whether they should be incorporated into a symptom awareness 
tool with tailored content for women at increased genetic risk.  
 
5.2.1 Qualitative methods 
Qualitative methods enable a deeper and more personal responses than can be gained 
through quantitative methods (Green and Thorogood 2013). Qualitative methods are 
particularly useful when the subject matter is reflective and emotionally evocative 
(Smith 2007), for example the impact of personal experiences of ovarian cancer within 
the family. Interpretative Phenomenological Analysis (IPA) is idiographic, inductive and 
interrogative, and is a well-developed qualitative approach to health psychology 
research (Smith 2004). 
 
IPA aims to explore personal lived experiences and how people make sense of these 
experiences, with individual perceptions of objects or events an integral part of the 
theory (Smith 2004). This type of analysis involves trying to understand potential 
relationships between health status, health beliefs and behaviour (Smith 1996) and is 
recommended for small samples of around 5-10 participants (Smith 2004, Smith 2007). 
IPA is similar to thematic analysis in drawing out themes and patterns across 
participants; however, IPA also focuses on the unique aspects of participants’ own 
experiences (Smith 2004).  
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5.2.2 Aims of the present study 
The aim of the present study was to gain further insight into women’s experiences and 
perceptions of symptom management in the context of living with a family history of 
ovarian cancer, and the proactive or preventative behaviours they may adopt in the 
absence of routine ovarian screening. Semi-structured qualitative interviews were 
carried out with women at increased genetic risk were used to further explore the 
concept of perceived threat, in particular the affective component of risk perception 
and its influence on anticipated symptomatic presentation. Perceived benefits and 
barriers to presentation, as well as the acceptability of symptom awareness as a risk 
management strategy were also explored. Topics relating to opinions of symptom 
awareness tools are important as user acceptability is a crucial step in intervention 
development (Craig et al. 2008b). The use of qualitative methods, and particularly IPA, 
allowed for elaboration and exploration of how women’s personal experiences of 
ovarian cancer have shaped their perceptions and beliefs about the disease and its 
management. 
 
5.3 Methods  
5.3.1 Participants  
Participants were women who had taken part in the earlier study on determinants of 
anticipated presentation with ovarian cancer symptoms (see Chapter 4) and who had 
agreed to take part in future research studies about ovarian cancer symptom 
awareness. A purposive sample was selected to reflect a range of anticipated 
presentation times and level of worry. Specifically, those who anticipated presenting 
immediately, those who anticipated delaying a week and those who anticipated 
delaying for over three weeks were selected. Geographical proximity was also 
considered due to the face-to-face nature of the interviews, therefore women who 
lived within two hours travelling distance of the Cardiff research base were invited to 
participate. In total, 20 women agreed to be interviewed out of 32 invited (65%). 
Recruitment stopped when 8 interviews had been completed (25%) as it was felt that 
the data had achieved its goal of representing perceptions about symptom awareness 
104 
 
in women at increased genetic risk of ovarian cancer (Brocki and Alison 2006). It was 
felt that at this point in recruitment there was coherence in responses and that the 
accounts given by participants could be discussed in relation to the research question 
and could be extrapolated to relevant psychological theory (Brocki and Alison 2006). 
For the remaining 12 women who agreed to participate but were not included in the 
data analysis, 7 could not be contacted in order to arrange an interview time and the 
remaining 5 respondents were contacted, informed that the study was no longer 
recruiting and were thanked for their interest in the study. 
 
5.3.2 Interview topic guide 
The main topics were ovarian cancer symptom appraisal, facilitators and barriers to 
symptomatic presentation, ways to reduce barriers, and acceptability of symptom 
awareness tools (see Appendix 17). The content of the topic guide was guided by the 
findings of previous chapters. At the end of the interview participants were asked 
about the advantages and disadvantages of symptom awareness tools. Participants 
were then shown two examples of symptom awareness tools that had been identified 
through the systematic search (Chapter 3). These were shown after opinions of 
symptom awareness tools had been explored in order to ensure that these initial 
opinions were unprompted.  
 
A total of four tools were used in interviews in order to reflect the diversity of tools 
that were identified (see Chapter 3), with each participant shown two tools in order to 
maximise the feedback on different tool formats. Copies of the tools can be seen in 
Appendix 18-21. On presentation of the first tool, question 11 from the topic guide 
(see Appendix 17) was explored, and then this process was repeated with the second 
tool. Tool 1 was a leaflet developed by Target Ovarian Cancer, which was identified as 
one of the most comprehensive awareness tools in the systematic search (Chapter 3). 
Tool 2 was a fact sheet called ‘It’s time to shout out’ and was chosen because the 
illustrations within the tool highlighted a visual approach to awareness tools. Tool 3 
was a symptom diary created by Ovarian Cancer Action. This tool was chosen as an 
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example of an interactive symptom awareness tool. The final tool was from the ‘Be 
Clear on Cancer’ campaign by Cancer Research UK. This tool was not publically 
available at the time of the systematic search, and was included to represent an up to 
date symptom awareness tool. 
 
5.3.3 Procedure 
Cardiff University School of Medicine Research Ethics Committee provided approval for 
this study (see Appendix 22). Participants were sent an invitation letter, information 
sheet and consent form. Those who wished to take part in the interview study 
returned the signed consent form. Once consent had been obtained, the researcher 
called participants to answer any questions about the research study and arrange a 
time for the interview. At the time of the interview, participants completed a further 
consent form and were given the opportunity to ask any questions. Semi-structured 
interviews were conducted in the participants’ own homes, with the content of the 
interviews informed by the topic guide. Other topics that arose during interviews were 
explored through the use of probes and prompts. The interviews were audio recorded 
and transcribed verbatim. The average length of the interviews was 35 minutes (range 
21-61 minutes). 
 
5.3.4 Analysis  
Transcripts were analysed using Interpretative Phenomenological Analysis (IPA) (Smith 
2004). Each anonymised transcript was read and re-read, and was analysed with 
themes noted for each transcript. This process was repeated until all themes within 
transcripts had been identified and noted. Once the themes that represented the 
different thoughts and feelings about a particular topic had been identified, the themes 
were clustered into superordinate themes. Abstraction was then used to identify links 
between emergent themes. A name was then given to each superordinate theme that 
reflected the themes within the cluster (Smith 2004). Three transcripts were 
independently coded by another researcher, with discrepancies resolved through 
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discussion. The data were then entered into NVivo 8 qualitative analysis software 
package (QSR International Pty Ltd 2008). 
 
Quotes presented in the following section represent examples of the identified themes. 
Insertions to clarify topic content are denoted by square brackets. The removal of 
irrelevant information within the quotes is denoted by “….”. The characteristics of each 
participant are presented in parentheses after each quote in the following order: 
participant number (p1-p8), anticipated time to presentation (immediate, one week, 
over three weeks) and worry (w3-w8). 
5.4 Results  
5.4.1 Sample characteristics 
Sample characteristics are provided in Table 5.1. Participants were aged 41-77 years, 
were mostly educated up to secondary level, and had been in ovarian screening 
between one and ten years.  
 
Table 5.1. Age, education, screening years, anticipated presentation and ovarian cancer worry 
levels of participants  
Participant  Age Education level Years in 
ovarian 
screening 
Anticipated 
presentation time 
Ovarian 
cancer worry 
1 70 Up to age 16 6 Immediately 3 
2 77 Secondary 4 Immediately 6 
3 56 Secondary 1 Up to 1 week 5 
4 41 Degree and above 1 Up to 1 week 3 
5 68 Secondary 10 Over 3 weeks, up to 4 5 
6 54 Degree and above 5 Immediately 4 
7 50 Secondary 2 Immediately 7 
8 44 Secondary 6 4+ weeks 8 
 
5.4.2 Emergent themes 
Key themes that were identified in included personal and familial experiences, 
personal barriers and facilitators, system barriers and facilitators, ovarian cancer 
symptom information sources, symptom monitoring behaviour, sources of support, 
sources of worry and tool format. 
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5.4.3 Personal and familial experiences 
Most women discussed memories and personal experiences of ovarian cancer 
diagnosis in their family members. These experiences had a strong influence on their 
own perceptions of ovarian cancer, both in terms of recognising symptoms and disease 
progression once diagnosed. Women would compare themselves to the family 
member who had been diagnosed and would use this experience as an information 
source. 
       I suppose because of my sister having no symptoms… (p2, immediate, w6) 
… ‘cause I know when my cousin got it, she didn’t even realise, realise that she had it 
[ovarian cancer]. (p5, over 3 weeks, w5) 
In some cases, diagnosis of ovarian cancer within the family was bringing up bad 
memories which influenced thoughts and feelings about their own ovarian cancer risk 
on a regular basis.  
    …I think you do get good days and you do get bad days, you know it still hurts now and we're 
talking six years down the line. (p7, immediate, w7) 
    It’s [ovarian cancer] horrible, I’ve seen it first hand and it’s not nice at all… I mean because if 
you’ve seen somebody suffering from it, you think to yourself, I’d never want to be in that 
situation because it’s horrible. (p6, immediate, w4) 
 
Some women described these experiences as making them act quickly and be more 
aware of ovarian cancer. In such instances, the negative memories of ovarian cancer in 
relatives were a driving force, as women were anticipating swift action in order to 
avoid the same experience themselves.  
I mean if you’ve been down the road before, you know… you just wouldn’t waste time, 
would you, because time is precious. (p6, immediate, w4) 
… having gone through it all [with Mother and Grandmother who had ovarian cancer] I 
know roughly what to look for and if there’s anything amiss then to go and find out 
straightaway. (p1, immediate, w3) 
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5.4.4 Personal barriers  
The most commonly endorsed barrier to presentation was the vague nature of the 
symptoms of ovarian cancer. The vague nature made it difficult for women to 
distinguish potential symptoms of cancer from common physical sensations. 
The only time you find out there’s something wrong is when it’s advanced and it’s too late 
then.  (p3, 1 week, w5) 
It can be scary sometimes, because you can look at everything and think, ‘I’ve got that, I’ve 
got that.’ (p8, over 3 weeks, w8) 
They call it the silent killer for one reason. All the symptoms are there but they don’t know 
about it. They think oh well, it could be a period, it could be this, it could be that, it could be 
what I’ve eaten. (p6, immediate, w4) 
The nature of the symptoms was frequently mentioned in relation to age. Many 
women felt that as they were getting older, they were finding it harder to distinguish 
between what might be a symptom of ovarian cancer and what was part of the natural 
ageing process. 
I mean, any young person like you, if you started to get those then you would really start to 
worry, wouldn’t you? Someone my age, you say, well, okay I’ll get back ache and get wind a 
lot, you know, and I get changes in bowel movements so, you know they’re always 
changing. (p2, immediate, w6) 
‘cause feeling bloated is what you feel like when you know, you go through the menopause. 
(p5, over 3 weeks, w5) 
 
The nature of ovarian cancer symptoms and pre-existing medical conditions were also 
discussed, as women found it hard to differentiate the symptoms of ovarian cancer 
from those associated with other benign conditions. 
Feeling full, tummy pain, swollen tummy, it can all be relative to IBS really. I mean I only 
know because I’ve got IBS (laughs) so that could be relevant to that. (p1, immediate, w3) 
… that would be difficult for me, change of bowel habit, because I’ve got a stoma, it’s very 
different, so that’s a difficult one, you know. (p3, 1 week, w5) 
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Fear of diagnosis was also explored. Participants expressed concerns that experiencing 
symptoms may mean that they automatically have ovarian cancer. This barrier was 
related to previous familial diagnosis of ovarian cancer and the implications for 
personal risk of developing the disease.  
There’s some days and I think I’m definitely going to get it. It’s in my history and everything 
like that, and it’s just a matter of time really. (p8, over 3 weeks, w8) 
If you've experienced even one of those symptoms, you know, your mind is just going to go 
frantic because you automatically think, I've got that, and you know, and every human is 
going to do that [go frantic.] (p7, immediate, w7) 
 
5.4.5 Personal facilitators  
Symptoms were frequently mentioned in relation to personal barriers for 
presentation, but were also commonly endorsed as facilitators to presentation. 
Women considered symptoms and bodily changes to be very important, with the 
perception that being aware of their own bodies would make it easier to spot any 
changes. 
If I started to have any symptoms which I thought were unusual, I would immediately go to 
my doctor. (p2, immediate, w6) 
If something was different from every day I would… I wouldn’t waste time. I’d go and get it 
checked straight away. (p6, immediate, w4) 
 
Once the symptoms or bodily changes had been noticed, participants felt that they 
would act quickly and seek medical advice. 
If I started to have any symptoms which I thought were unusual, I would immediately go to 
my doctor. (p2, immediate, w6) 
I think based on the symptoms that I know I’d pick up the phone straightaway [and make an 
appointment.] (p4, 1 week, w3) 
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Personal risk status was mentioned as a facilitator to presentation in the presence of 
symptoms. Participants reported that they would act quickly due to their concerns 
relating to their increased risk status.  
If I had any signs or symptoms yes, knowing the family history, I would go straight away. 
(p1, immediate, w3) 
I would think, ‘oh God, this isn’t quite right, I have to go and see about it, hopefully it’ll be 
nothing’, but perhaps if I weren’t in this high risk I would just leave it ride until it’s too late 
or something perhaps…(p7, immediate, w7) 
 
Participants described how worry stemming from their risk status would lead them to 
act.  
   Because of the family factor, I would be more aware of it [symptoms.] (p7, immediate, w7) 
 I might be over, sort of worrying about it, and [thinking] if I haven’t actually got the 
symptoms, but because I know I’m at risk, I get symptoms, twinges, and I think ‘I wonder’ all 
the time. (p8, over 3 weeks, w8) 
 
Confidence was also an important facilitator, with participants describing that having 
confidence made it easier to voice their concerns to the GP. Confidence was often 
embedded in risk status, with some women describing themselves as being confident 
and assertive due to their increased genetic risk. 
I’m quite confident. I’m not ashamed or afraid to talk to anyone about anything. (p6, 
immediate, w4) 
If I didn’t feel the appointment time was quick enough I’d explain the situation over the 
phone and say why I wanted to see the doctor and spell it out to the receptionist. (p4, 1 
week, w3) 
It does make you a stronger person [experiencing family members with OC] because you get 
more determined I do believe, because you get more determined in your way. Because like 
in the beginning, I was palmed off by my GP as we were with a different practice, not 
through any fault of his but, oh you're being over-exaggerating, you're being too cautious. 
(p7, immediate, w7 
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Women also felt that they had to be very confident in some instances in order to be 
listened to or taken seriously by health professionals. 
There’s no leeway for being meek and mild, you have to do what you have to do. (p2, 
immediate, w6) 
So often with the NHS you have to be assertive, which is a shame. (p4, 1 week, w3) 
 
Information was noted as a source of increasing confidence. Women felt that having 
knowledge and information was important in helping them to prepare for 
consultations with health professionals. 
I find I’m more confident by reading information. (p3, 1 week, w5) 
If you’re armed with that information then the doctors can’t say ‘oh you’ll be all right, love, 
you know, it’s just a bit of ageing and diverticulitis or whatever’. If you actually know that 
information it’s easier to push. (p4, 1 week, w3) 
 
Positive attitudes were frequently discussed, with beliefs that presenting to get 
medical help and acting on any worrying symptoms would be beneficial. Women 
discussed acting on these concerns, and the importance of facing the possible 
consequences as opposed to ignoring them. 
I believe in facing, you know, if you’ve got a problem then you face it and deal with it. (p2, 
immediate, w6) 
But as I said I think the best is to go, and hopefully it isn’t, but if it is, there is a cure. You 
know, looking at the bright side of it, isn’t it? (p7, immediate, w7) 
The ostrich in the sand thing doesn’t get you anywhere does it? (p7, immediate, w7) 
 
On the other hand, some participants described how they would be initially hesitant as 
a result of fear if they thought they were experiencing symptoms. However, in such 
instances participants reported that they would still seek help. 
Nature’s thing is you’d panic obviously, that is the human thing, but I would…I would go to 
the GP. (p7, immediate, w7) 
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5.4.6 System barriers  
System barriers relating to difficulty accessing primary health care and difficulties 
communicating with their GPs were described. Women expressed feelings of difficulty 
accessing GPs, with anticipated problems with getting GP appointments or long 
onward referrals. 
Every day in this region, you can forget it, if anything goes wrong, nothing can be done. (p3, 
1 week, w5) 
They haven’t got time to see anyone, have they? They don’t, they’re spending so much time 
on paperwork. (p5, over 3 weeks, w5)  
You’ve got to wait ages, ‘cause you have, ‘cause the healthcare in [names place] for cancer 
isn’t very good. (p5, over 3 weeks, w5) 
 
Concerns were also expressed over the lack of time given for GP consultations. 
Some GPs are too busy. (p4, 1 week, w3) 
Unfortunately, a lot of GPs they are busy and they’ve only got like a 10 minute time slot. 
(p7, immediate, w7) 
 
GPs’ attitudes were also a consideration, with negative perceptions about how GPs 
would react if they were to present with ovarian cancer concerns. Feelings of not being 
taken seriously were discussed, with one participant reporting that GPs would ‘palm 
you off with different things…(p7, immediate, w7)’. 
Some GPs don’t give a damn and others don’t know the information. (p4, 1 week, w3) 
 
Concerns about how the GP would react in the consultation were often embedded in 
experiences of their GP not being aware of their personal risk status. Women felt that 
when the GP did not know their risk status, it was often harder to discuss their 
concerns. 
I said… I think it’s genetic, and they just turned around and didn’t answer. (p3, 1 week, w5) 
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They didn’t know anything about my family history at all. Okay, my file obviously would be 
that thick coming from when I was born, ‘cause they don’t have time to look at it do they? 
(p5, over 3 weeks, w5) 
 
The GPs’ lack of awareness of risk status was described as both a source of frustration 
and an additional emotional burden. Having to explain their risk status took time and 
led to heightened emotion associated with re-living the past. 
‘cause it’s frustrating to have to explain to people and upsetting, and annoying as well. (p5, 
over 3 weeks, w5) 
You would have to go through it all [family history] and whatever… you’ve got to keep going 
through the same thing all the time. (p1, immediate, w3) 
 
5.4.7 System facilitators  
Conversely, having a GP who was aware of their risk status helped some women to feel 
more confident in presenting and expressing their concerns. 
They’ve [GP]  got my medical notes and I would explain to them, I mean, they’ve taken my 
blood samples so they would know that I’ve been on the studies before, so they would just 
forward it on to the right people. (p6, immediate, w4) 
In such instances, there was a sense of relief in not having to reiterate their family 
history. 
It’s better to see the same one as you don’t have to keep going through the same thing all 
the time. (p1, immediate, w3) 
It seems to give me peace of mind, because you don’t have to continually repeat all the 
time. (p7, immediate, w7) 
 
Continuity of care was also discussed, with feelings that seeing the same GP helps 
develop a relationship. This relationship made participants feel more comfortable in 
expressing any concerns. 
She’s young [GP] and she’s very with it and nice to talk to… I would go to her…for her to see 
you on a regular basis and keep an eye on you. (p2, immediate, w6) 
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 I think it’s quite nice [seeing the same GP], because if you get that rapport, I know in a lot of 
practices you don’t see one doctor, you see quite a few… (p7, immediate, w7) 
 
5.4.8 Ovarian cancer information sources 
When asked about sources of ovarian cancer information, the Internet was quoted as 
the most common method: ‘I’d go and Google it’ (p2, immediate, w6), ‘I’d look on the net 
(p6, immediate, w4)’. Information was sought for a variety of reasons. Some women felt 
that information was important for general knowledge about ovarian cancer and to 
help prepare for the future. Others felt that it was useful as a point of reference before 
seeking medical help for a specific concern.  
I’d go on the Internet first. I use it as, like, as a guide. (p3, 1 week, w5) 
I used to keep everything I read about it [ovarian cancer]… and the names of the best 
specialists. (p5, over 3 weeks, w5) 
If you want to check that before you go to your GP, just ‘cause you think you’re worrying 
about nothing, you know, it’s private. (p8, over 3 weeks, w8) 
 
Some participants discussed how they would avoid information-seeking due to 
concerns about the credibility of web-based information. This was often as a result of 
anticipated worry about what they might find. 
I just wouldn’t want to go down the road of just googling the word and no, no, that would 
just put my head into override I expect. (p6, immediate, w4) 
If you’re going back to the Internet, you could start off with something small and end with 
you’ve got God knows what wrong with you. (p7, immediate, w7) 
 
High profile media cases of cancer were also highlighted as raising public awareness of 
ovarian cancer, including Angelina Jolie’s recent public announcement of being a 
BRCA1/2 carrier. 
There’s been a lot more profile around cancer recently, so you see a lot more posters about 
and a lot more things on the telly. (p8, over 3 weeks, w8) 
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5.4.9 Symptom monitoring behaviour 
Women described the different ways they monitored themselves in order to spot any 
symptoms of ovarian cancer. Keeping fit and being aware of their bodies was 
frequently endorsed. Many discussed how keeping fit and slim helped them notice any 
changes more easily. 
I know I don’t look fit, but I go to the gym three times a week, I’m careful of what I eat, you 
know… we know our bodies so well, we know what we are doing to them. (p6, immediate, 
w4) 
 I’m sort of fairly slim across my belly, so I think I’d notice bloating. I know one of the ones 
was bloating that doesn’t go down, is it? I think I’d probably notice that, but with a lot of 
women that may be bigger, they wouldn’t actually see that. (p8, over 3 weeks, w8) 
 
There was also discussion of how family members had been unable to spot symptoms, 
with this experience being a driving force for their own body monitoring. 
 I think that’s what happened with my grandmother and her two sisters. They were all big 
ladies; they didn’t see what going on inside them and it was all kinds of things, and they 
died of it, you know. So I think it’s because they couldn’t really see the physical changes. (p8, 
over 3 weeks, w8) 
 
In terms of aide memoires, different preferences and techniques were expressed. 
Some participants said that they would make notes to help them keep track of any 
symptoms they experienced.  
I’d probably not make a diary, but make some notes of what my symptoms had been, where 
and when, yeah make a bit of a diary. (p4, 1 week, w3) 
    ‘Cause I think you should diary things, shouldn’t you? (p5, over 3 weeks, w5) 
 
Others said that they would just rely on their recall of symptoms. 
I’d just sort of store it in my head probably, and then just go to the GP with general, you 
know, general sort of symptoms and things rather than specific. (p8, over 3 weeks, w8) 
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5.4.10 Sources of support 
Previous participation in ovarian cancer screening studies was noted as a source of 
reassurance to most participants. Women felt that through participation and frequent 
interaction with healthcare professionals, any potential problems would be identified. 
Some participants went on to discuss how they would not necessarily look out for 
bodily changes between scans or tests, because they believed that screening would 
detect anything of concern. 
I think it's just a comforting fact that you know that if something's going to happen you 
know they're going to do something about it and you can come from there thinking, well, 
everything's fine. So it's that feel good factor isn't it. (p7, immediate, w7) 
I think I’ll always be concerned, and at least if you were part of a screening, at least if you 
do get it you’re picked up early. (p4, 1 week, w3) 
 I think, ‘Yeah, that’s me, I’m sorted, I’m okay,’ and then I think it’s time to have another 
one. And I do and I don’t think about it. (p8, over 3 weeks, w8) 
 
In the absence of routine ovarian screening, some participants had asked their GPs to 
continue sending them for tests, while others were paying privately for screening. 
Well that is what she’s doing for me, she’s sending me, as I’ve said, every six months. I think 
that gives me confidence. (p2, immediate, w6) 
I have scans, ultrasound scans every year. I pay for them now because they used to be part 
of the study that I was taking part in and then that all stopped and the funding stopped and 
everything. So I thought I’d keep that up and we… My husband is in agreement and we pay 
for me to have one, well, it was once a year but I might be having them a bit more than that 
now. But… so that’s my way of sort of keeping my eye on things. (p8, over 3 weeks, w8) 
 
Some women explained how they derived reassurance from regularly visiting the GP.  
I would rather be too cautious than dead, basically. I know that sounds really dramatic but I 
do keep on until, you know, I would rather keep on and keep on and keep on and say, look 
there's nothing, rather than leave it lie and then say ‘Oh look, we've got a problem now’, 
which sometimes it's too late isn't it. (p7, immediate, w7) 
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You think ‘Well actually, I ought to go back to the doctor and get checked again and see if 
there’s any screening or research projects I ought to go on, just to check’. (p4, 1 week, w3) 
Information on ovarian cancer was mentioned as a source of comfort, with women 
turning to literature on ovarian cancer in order to feel reassured that they knew about 
the disease. 
Especially in my situation ‘cause I’m classed as high risk, but yeah. No, I’m very pleased that 
there’s information out there. (p6, immediate, w4) 
I think any information is a good thing isn't it, prevention is better than cure. My way of 
looking at it anyway.(p7, immediate, w7) 
 
5.4.11 Sources of worry 
Ovarian cancer information was also described as a source of worry. Feelings of being 
overwhelmed by facts and figures for the disease were expressed. Information was 
often daunting and there were concerns over the credibility of information that 
women encountered. 
It can be overwhelming sometimes, you get too much information. (p3, 1 week, w5) 
 If you read some of the literature that says post-surgery or post treatment, so... a certain 
percentage of women will still successfully be living and that’s actually not a great number. 
And you think, ‘Oh well, never mind, they can’t do anything about it. Let’s forget it, let’s 
carry on without all that faffing about. (p4, 1 week, w3) 
‘Cause too much information could really put that wheel in your head turning. (p6, 
immediate, w4) 
 
Genetic factors were also a source of worry, as participants were concerned about 
their personal risk status. 
        I find it [being at increased risk] distressing, I’ve lost so many members of my family [to 
OC]. (p5, over 3 weeks, w5) 
I know I’m high risk, and I know it [OC] could happen, it’s in my history, and everything like 
that, it’s just a matter of time really. (p8, over 3 weeks, w8)  
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Concerns were expressed about what family members might experience if they were 
to be diagnosed with ovarian cancer. Again, these concerns often stemmed from 
personal experience with the disease and not wanting to put their family member 
through these experiences.  
I don't want my children to go through that. Obviously they went through it with my mum, 
but I don't want them to go through it with their mum. (p7, immediate, w7) 
 I know I’m high risk and I know it could happen, you know, to me for breast or other in, you 
know… ‘cause sometimes there’s some days and I think I’m definitely going to get it. It’s in 
my history and everything like that, and it’s just a matter of time really. And other days I 
think… I know cancers can jump generations. (p8, over 3 weeks, w8) 
 
5.4.12 Tool format 
Certain aspects of the ovarian cancer awareness tools that were shown to participants 
were seen as acceptable, including their short length and simple content. The 
interactive nature of tools was also complimented, in particular the symptom diary 
(see Appendix 20). 
...weeks later [after symptom experience] you think, ‘Oh, I should have written it down 
now’. (p3, 1 week, w5) 
I think it's quite a short, precise, you know I've read things that have gone on forever and by 
the time you've got to the end of it you think right what did I start reading about.  (p7, 
immediate, w7) 
 
Women thought that too much information should be avoided and that the inclusion 
of pictures was useful. Signposting to additional information was also endorsed. 
Comments were also made about how such tools would be useful to take to GP 
consultations.  
It’s showing a body and obviously, you know, where things are, ‘cause it’s like that it’s easier 
to retain it. I think this is a really good [material]... whoever designed it is really good. (p3, 1 
week, w5) 
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Yeah, it’s really good because then you could go down say ‘Well, look I’ve kept a diary and 
this is what I’m experiencing and what I’m feeling’. Yeah, I think it’s really good. (p5, over 3 
weeks, w5) 
     
The interactive nature of the symptom diary (see Appendix 20) was both praised and 
criticised. Some felt that engaging with the interactive aspects was not feasible, and 
that the four week time frame for symptom monitoring was unacceptably long. 
I thought two to three weeks at the very most, ‘cause honestly after one week if you started 
to tick most of those boxes, I would be worried… it’s more worrying in that version because 
you’d be able to see it all in one place. (p2, immediate, w6) 
 
Others felt the diary may be useful once symptoms had been noticed, but that it was 
not useful in providing information about the symptoms. 
If she [GP] gave me that and said, well, would you fill it out for me and let me know how you 
get on with it, it would be most useful. But I wouldn’t particularly pick that up and do it 
without any symptoms. (p2, immediate, w6) 
 
Tool content concerning ovarian cancer symptoms and what to do if symptoms were 
experienced was commonly described as being vague and uninformative. 
I am 78 and it… I think it’s, you know, it’s… it might be useful to say that these things are 
normal in an older person. (p2, immediate, w6) 
I think the only thing that you could do is between say week two and week three you could 
say, ‘If you’re scoring yes every day, go and see a doctor now’. (p4, 1 week, w3) 
 
Interest was expressed in having basic and clear information which outlines the 
symptoms of ovarian cancer. It was felt that this would be useful as it could act as a 
point of reference and could be referred back to as needed.  
It can be overwhelming sometimes, you get too much information. You just want enough, 
like the symptoms and you know, when to go to the GP. (p3, 1 week, w5) 
I mean it [symptom awareness tool] would be a good refresher. (p4, 1 week, w3) 
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Ovarian cancer statistics and facts provided in the tools were also criticised. 
All the percentages and things like that… I wouldn’t even bother to look at that part. (p1, 
immediate, w3) 
Well, you almost think, ‘Well, that’s that then, isn’t it? I’m going to die.’ (p4, 1 week, w3) 
 
Misconceptions and misunderstandings surrounding cervical screening arose when 
participants read information dispelling the myth that cervical screening can detect 
ovarian cancer. 
The smear cannot detect [ovarian cancer], is that true? (p2, immediate, w6) 
I really thought the smear was some sort of detection, but it says here it’s not. (p7, 
immediate, w7) 
 
Healthcare settings were often suggested as a suitable location for delivering ovarian 
symptom awareness tools, including from the GP, GP waiting rooms, consultation 
rooms and family planning centres. 
If the doctor said to you then ‘Here’s a leaflet, keep a diary’ and whatever else... you could 
do it. But if they don’t offer them to you I think that they would just... you wouldn’t see 
them. (p1, immediate, w3) 
I thought they would be in doctors’ surgeries, hospitals. (p3, 1 week, w5) 
…would be in your GPs, chemist perhaps, you know family planning that type of thing. (p7, 
immediate, w7) 
 
Healthcare settings were considered to lend greater credibility than web-based 
sources. 
I think there's so many scaremongers and bad sites on the Internet – there are a lot of good 
as well, but I don't think you are going to get bogus things in the chemist or a surgery. You 
may do, and if you do it's unfortunate, but I think on the Internet you are more inclined to 
get these bogus sites. (p7, immediate, w7) 
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However, many women then went on to discuss how having information resources in 
these places may not be effective due to embarrassment about picking them up in 
public places. 
I think they would be much better in the doctor’s room, yeah when you go in… , ‘cause then 
no one could see you, and I think the leaflets should be with them, not outside. (p5, over 3 
weeks, w5) 
 
Paper based tools were preferred, in part due to the desire to take something along to 
consultations, and partly due to fear of searching for information on the Internet. 
I think I'd prefer to have the paper one because I'd be inclined to think I'm not one of these 
Internet nerds. (p7, immediate, w7) 
 
5.5 Discussion  
A qualitative study has been presented that built on the quantitative findings of the 
study in Chapter 4 through exploration of the impact of perceived threat on anticipated 
symptomatic presentation in women at increased genetic risk. This study has also 
further explored implications for developing an ovarian cancer symptom awareness 
tool with specific content for this risk population. Personal experience of ovarian 
cancer as a result of familial diagnosis was integral to shaping participants’ health 
beliefs and anticipated presentation.   
 
5.5.1 The influence of risk status on anticipated symptomatic presentation 
Personal risk status was a prominent driving force behind many of the beliefs and 
presentation expectations held by the participants. Women’s perceptions of ovarian 
cancer were coloured by their personal and familial experiences of the disease. These 
experiences were discussed in terms of both facilitators and barriers to ovarian cancer 
knowledge, anticipated presentation, and information seeking.  Symptoms of ovarian 
cancer were commonly mentioned, with experiences of symptoms that were unusual 
acting as a trigger in many cases. Emphasis on new and unusual bodily sensations was 
often paired with keeping fit and slim, suggesting that women are trying to undertake 
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risk management strategies that are within their personal control. This behaviour 
could also be deemed as a compensatory mechanism to attempt to control worrying 
thoughts about ovarian cancer risk (Andersen et al. 2002, Schwartz et al. 1995b).  
 
Participants discussed the importance of presenting with symptoms regardless of 
whether it turns out to be ovarian cancer. Similar findings were reported by Low et al. 
(2013a), where participants felt that even if symptoms were not likely to be cancer it 
was considered beneficial to present as it could lead to the detection of other 
conditions. The anticipated willingness to present could be viewed positively since 
women are anticipating engagement with the healthcare system; however, for women 
at increased genetic risk, this could lead to over-presentation and could reflect 
inappropriate help seeking (Andersen et al. 2002, Fallowfield et al. 2010, Kash et al. 
1992, Lerman et al. 1994). The present qualitative findings reinforce those reported in 
Chapter 4 which suggested that the affective component of perceived threat needs to 
be managed in women at increased genetic risk in order to avoid hyper-vigilance and 
possible over burden on the healthcare service (Evans et al. 2014). 
 
Experience with familial ovarian cancer diagnosis was an important facilitator to 
presentation. Women felt they would act quickly should they suspect anything wrong. 
This often stemmed from experiences where family members had delayed 
presentation, or had not monitored bodily changes. Quotes emphasised women’s 
feelings that nothing would stop them seeking medical help if they thought something 
was wrong. The participants discussed how they would not act in the same way as their 
family members, and would instead be proactive and decisive in the event of noticing 
changes they attributed to possible ovarian cancer. The experiences were also 
mentioned as helping to increase confidence in decisions regarding ovarian cancer, 
because women felt knowledgeable as a result of their experiences. This reflects the 
survey findings in which having personal experience with ovarian cancer was associated 
with greater self-efficacy (Chapter 4). This association was only found for women at 
increased genetic risk and not those from the general population sample, suggesting 
that seeing a family member with ovarian cancer makes some women more 
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determined to avoid the same experience themselves (Absetz et al. 2003, Fallowfield et 
al. 2010).  
 
There are positive and negative implications of the views on symptoms that were 
elicited in the current study. If women are experiencing symptoms indicative of ovarian 
cancer, early presentation is important; however, if presenting for any bodily changes it 
could lead to overburdening of the healthcare system. Hyper-vigilance may also be 
harmful to the psychological wellbeing of the individual (Norman and Brain 2005). This 
reinforces the need for provision of clear and concise information about how to 
recognise and act upon the symptoms of ovarian cancer. A symptom awareness tool 
could include this type of information, and could also include statements which 
encourage women to visit their GP and manage their expectations about what is likely 
to happen in the consultations. The fear of diagnosis expressed by participants 
highlights the prominence of the affective component of threat. It suggests that worry 
is influencing women’s behaviour and beliefs, with their personal experience with 
ovarian cancer influencing their fears. This fear in the presence of potential symptoms 
also highlights the need for psycho-educational support.  
 
Increasing knowledge about symptoms and their nature could mitigate against women 
associating any symptom experience with the inevitability of ovarian cancer. Symptom 
education could therefore help women manage their worry levels and reduce the 
likelihood of over presenting. Specifically, tools could focus on promoting the benefits 
of presentation and dispelling the barriers. This could be achieved by providing women 
with clear and concise information about the symptoms of ovarian cancer, their 
frequency, and what to do if they are experienced. Such tools could also facilitate the 
interaction between patient and doctor, and help women to feel more empowered 
about their decision to seek medical advice. 
 
Confidence was discussed as being a driving force by participants who felt they had to 
be confident in order to interact with health professionals (Smith et al. 2005b). Some 
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women talked about personal experiences where health professionals had been 
dismissive of their concerns about ovarian cancer. Some women also reported that 
they would read up on ovarian cancer information prior to going to see their GP, to 
ensure that they were fully prepared to voice their concerns. A symptom awareness 
tool may therefore be used as an act of preparation for GP consultations (Murray et al. 
2003). Information on what to do before a GP visit may therefore be well received if 
incorporated into such a tool. The tool could suggest that women prepare by writing 
down symptoms experienced, or a list of things they would like to be discussed in the 
consultations. This may help to increase confidence about the visit and facilitate the 
doctor-patient interaction. As women found it an emotional burden to reiterate their 
risk status it may be useful to prime them in an awareness tool for such an event so 
that they can be prepared. This may help women feel more confident in presenting 
and if the tool is paper based, it will enable women to take the tool with them to aid 
discussion in the consultation (Murray et al. 2003, Smith et al. 2005b). The need for 
this type of information supports the need for specific content for women at increased 
genetic risk in an ovarian cancer awareness tool. 
 
5.5.2 Ovarian cancer information needs  
Information about ovarian cancer was perceived both positively and negatively and 
could therefore be viewed as a double edged sword. Some women felt empowered by 
reading information and wanted to be up to date with all information about ovarian 
cancer. This was considered by many as a good act of preparation. Others felt that 
information could be overwhelming and would lead to increased worry. Women felt 
that facts and statistics relating to ovarian cancer was a source of concern when 
looking for information about the disease, with it discouraging them from searching for 
information. This was also mentioned when participants were discussing the content 
of symptom awareness tools. The notion of such information deterring women from 
presenting could reflect helplessness because if women read statistics of survival and 
feel the outcomes are poor they may feel there is no point in doing anything about it. 
These are important considerations for tool development because the tool should aim 
to avoid increasing worry or feelings of helplessness. 
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When probed about symptom monitoring behaviour, women expressed different 
personal preferences as to how they would go about this. When it came to reviewing 
the awareness tools, those who were shown the symptom diary expressed that they 
felt this was not useful due to the time frames being too long. It may therefore prove 
useful to explain to women that they need to monitor their symptoms for a certain 
amount of time in order for GPs to consider a diagnosis of ovarian cancer. If women 
present with symptoms too early this could lead to GPs dismissing their concerns.  
Clinical information needs to be considered in order to determine what time frames 
should be advocated to women. 
 
The Internet was commonly mentioned as an information source, and concerns were 
expressed about the vast amounts and varying quality of information that can be 
accessed in this way. Even those who endorsed the Internet as an information resource 
questioned the credibility of some of the information on the Internet. This suggests 
that some women may not be getting the information that they desire about ovarian 
cancer as a result of being concerned about information quality. It also highlights issues 
surrounding how best to disseminate information to women. Provision of evidence-
based information from credible sources, or signposting to such resources could 
therefore help reassure women that they are accessing accurate and trustworthy 
information.   
 
5.5.3 The need for education 
Women reported that reassurance was gained through participation in ovarian cancer 
research and screening studies and the close contact with health professionals that this 
provides. In such cases it was felt that anything troublesome or problematic would be 
detected through participation in such schemes. Utilising medical tests as a source of 
reassurance and hope is potentially worrying due to the uncertainty surrounding the 
clinical effectiveness of ovarian cancer screening (Menon et al. 2009, Rosenthal and 
Jacobs 2006). This trust in ovarian cancer screening was similarly reported by Lancastle 
et al. (2011), where women felt reassured and less distressed as a result of putting faith 
in the effectiveness of screening. The trust that women are placing on screening tests 
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could suggest that women need to be educated about the current opportunities 
available to them. If women are unclear of the opportunities available to them they 
should be encouraged to go and visit their GP or genetic counsellor to discuss their 
personal situation and options. 
 
5.5.4 Study limitations  
The small sample size in the present study could have led to the possibility that not all 
themes were captured relative to the interview questions. Small samples are a 
common feature of qualitative research, with samples vastly smaller than those used 
in quantitative research. However, it was felt that the recurring nature of themes 
identified in the interviews reflects the quality of data. In addition, the data analysis 
method used here is designed to be performed on small samples sizes (Smith 2004).  
 
Study participants were selected based on anticipated presentation times, worry and 
geographical location. If a different sampling technique had been used, such as self-
efficacy or age a broader range of participants may have been included. However, it 
was felt that the sampling used here was adequate and sufficient. The spread of 
anticipated presentation time was chosen to reflect the different presentation beliefs 
of the sample, with this reflecting the outcome of interest.  
 
5.5.5 Implications and future research  
This study has enabled a further exploration of the role of perceived threat for women 
at increased genetic risk of ovarian cancer, and has provided information regarding 
tailored content of an ovarian cancer symptom awareness tool. Work now needs to be 
done in order to gain consensus on what symptom information should be given to 
women. This information is crucial and could help manage expectations and maintain 
psychological wellbeing. Once this symptom information has been gathered it can be 
added to the current findings to develop a draft tool. Once created the awareness 
tools should be presented to a sample of potential users and providers in order to gain 
user feedback.  
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5.5.6 Summary 
The present study has further explored the concept of perceived threat and how 
perceived susceptibility and worry may influence decisions to seek medical help for 
possible ovarian cancer symptoms in women at increased genetic risk of ovarian 
cancer.  Women's perceptions of ovarian cancer and behavioural intentions relating to 
the disease have largely been shaped by their familial experiences with the disease and 
women may be cautious about searching for information independently. This stems 
from concerns over the quality of the information available and the content of some 
informational resources being overwhelming.  
 
Women at increased genetic risk of ovarian cancer are receptive to ovarian cancer 
awareness tools and expressed a desire for simple and clear information to be 
available. The next steps of the project will involve a systematic search of the literature 
to identify symptoms indicative of ovarian cancer. These symptoms will then be 
presented to a group of clinical experts in order to consolidate symptom information. 
This symptom information can then be included in a symptom awareness tool with 
tailored content for women at increased genetic risk of developing ovarian cancer. 
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6 Identification and validation of empirical literature on ovarian cancer symptoms 
 
6.1 Introduction 
Previous chapters have highlighted that a symptom awareness tool which addresses 
the specific health beliefs of women at increased genetic risk of ovarian cancer is 
needed.  Chapter 4 identified the salient health beliefs that influenced anticipated 
symptomatic presentation for women at increased genetic risk of ovarian cancer and 
women from the general population. The aim of the current chapter is to build on this 
knowledge by identifying the symptom information that should be included in an 
awareness tool.  
 
Symptom information should be embedded within information that attempts to 
maintain the psychological wellbeing of the individual. This is particularly important for 
women at increased genetic risk since evidence suggests that encouraging regular self-
monitoring in this population may lead to anxiety and hyper-vigilant early detection 
behaviour (Brain et al. 1999, Fallowfield et al. 2010, Norman and Brain 2005). A key 
theme emerging from the qualitative interviews with women at increased genetic risk 
(Chapter 5) related to anticipated fear in the presence of potential ovarian cancer 
symptoms. Concern over the quality and credibility of information resources was also 
expressed, particularly in relation to information found on the internet.  Provision of 
credible and scientifically sourced symptom information is therefore especially 
important for these women. Information resources may help women manage their 
worry levels, and could facilitate informed decisions to seek medical help.  This is true 
for all women, but is particularly salient for women at increased genetic risk. 
 
6.1.1 The need for symptom consensus  
Despite clinical guidelines providing information on ovarian cancer symptoms, 
disparity exists in the terminology used to describe these symptoms. The systematic 
search in Chapter 3 demonstrated that a wide variety of symptoms are included in 
existing ovarian cancer awareness tools, with an average of eight symptoms in the 
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identified tools. The disparity between the symptoms identified in guidelines 
(Department of Health 2009, National Institute for Health and Clinical Excellence 2011)  
and symptoms in awareness tools suggests that providers of awareness tools do not 
always take into account clinical guidelines. This could lead to confusion among the 
public over what the symptoms of ovarian cancer are. Consensus on these symptoms 
would therefore be beneficial for medical professionals and women wishing to find out 
about the symptoms of ovarian cancer. This point holds for all women wishing to be 
aware of symptoms, not just those at increased genetic risk of developing ovarian 
cancer, as the symptoms of ovarian cancer are the same regardless of risk status.  
 
Evidence suggests that symptoms are present for both early and late stage ovarian 
cancer (Cass and Karlan 2010, Goff et al. 2007, Rossing et al. 2010). Detection of 
ovarian cancer symptoms is difficult for women and health professionals due to the 
high frequency of symptoms that are not unique to the condition (Austoker 2009, 
Hamilton et al. 2009, Kirwan et al. 2002). The language used to describe ovarian cancer 
symptoms is also problematic due to varying terminology used by patients and health 
professionals. Women have been reported to use the term “bloating” to describe both 
persistent and intermittent changes, creating confusion with the term “distension”, 
which is used by health professionals to differentiate persistent changes (Austoker 
2009, Bankhead et al. 2008, Bankhead et al. 2005, Hamilton et al. 2009). This use of 
different wording highlights the need for clarification of the terminology used to 
describe symptoms.  
 
Practically, it may also prove useful to provide brief descriptive information on 
symptoms which could help women to understand the symptoms terms, identify 
symptoms, and potentially disentangle them from other everyday experiences. In 
addition to identifying the symptoms of ovarian cancer, it is important to consider 
thresholds at which the symptoms may be indicative of ovarian cancer.  Judgments 
need to be made based on the best available clinical evidence in order to provide 
women with information that will help them determine whether and when to act on 
symptoms they are experiencing.  One challenge in ovarian cancer is to encourage 
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women to be more aware of the symptoms and increase their understanding in order 
for them to recognise and appraise the symptoms as possible cancer symptoms. 
Increasing the understanding of symptoms could also facilitate the doctor-patient 
interaction, as it may enable women to more accurately express their symptom 
experience (Bankhead et al. 2008). 
 
6.1.2 Aims of the present study 
The present study focused on the symptom content of the ovarian cancer symptom 
awareness tool (OvSTAT). This was achieved by 1) conducting a systematic search of 
the empirical literature to identify symptoms indicative of ovarian cancer, with a 
critical appraisal of study quality and analysis of symptom effect sizes, 2) gaining 
clinical opinion on the symptoms from a group of experts in the form of a virtual 
reference group, and 3) conducting surveys with GPs and women at increased genetic 
risk of ovarian cancer to gain a fuller understanding of symptom experience 
expectations. The three evidence strands were then synthesised to identify the 
content of symptom information to be provided within the symptom awareness tool. 
This allowed the incorporation of symptom information and guidance that was based 
on best available clinical evidence, expert opinion, and the views of likely users and 
providers. 
 
6.2 Methods 
In order to guide the symptom content of the tool, a variety of methods were used to 
ensure that decisions were guided by best available evidence. The methods and results 
for each of the strands of research are presented separately. 
 
6.3 Study 1a. Systematic search of ovarian cancer symptoms in ovarian cancer 
cases and cancer free controls 
First, a systematic search was carried out in order to identify symptoms that are 
associated with ovarian cancer. Information identified from case control studies that 
compared symptom experience in women diagnosed with ovarian cancer and a cancer 
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free control group was then synthesised. Identified papers provided empirical 
evidence on symptoms indicative of ovarian cancer. The PRISMA guidelines were used 
to aid the reporting of the systematic search (Liberati et al. 2009).   
 
6.3.1 Method  
The database PubMed was searched to identify papers that included symptoms of 
ovarian cancer. The Department of Health (2009) and National Institute for Health and 
Clinical Excellence (2011) guidelines were used to guide the content of the systematic 
search. These guidelines identify a total of 10 possible individual symptoms (bloating, 
pelvic pain, abdominal pain, full, appetite, distension, fatigue, back pain, bowel and 
urinary symptoms). The symptoms from these guidelines were entered separately into 
PubMed with “AND ovarian cancer” in order to identify papers which included the 
symptoms. The search strategy is provided in Appendix 23.  
 
6.3.2 Inclusion criteria 
Case-control studies of symptoms experienced in women diagnosed with ovarian 
cancer and cancer-free women were included.  
6.3.3 Exclusion criteria 
Studies were excluded if they concerned symptoms relating to the treatment of 
ovarian cancer, the tumour pathology of ovarian cancer, if secondary data were used, 
or if the studies were concerned with awareness rather than experience of symptoms 
in cancer cases and cancer-free controls. 
 
6.3.4 Data extraction 
All identified articles were assessed for eligibility, with titles and abstracts reviewed 
prior to full article review (Liberati et al. 2009). All symptoms that were indicative of 
ovarian cancer in the included papers were extracted, not just the symptom which 
allowed the study to be detected in the search. This ensured that all symptoms 
indicative of ovarian cancer were examined. Reasons for exclusion were noted for 
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excluded articles. The references of included articles were also searched in order to 
ensure that all relevant articles were identified. Data extracted included the symptoms 
that were associated with ovarian cancer, study population information, study design, 
symptom frequency, odds ratios and study limitations. Data were extracted using a 
standard protocol (see Appendix 24) which was pilot tested and discussed with the 
supervisory team until satisfactory for this review. 
 
6.3.5 Quality assessment 
The quality of included studies was assessed using the Newcastle-Ottawa quality 
assessment scale for case control studies (Wells et al. 2011) (see Appendix 25). The 
scale assesses study quality in terms of seven items across three categories: selection, 
comparability and exposure (Wells et al. 2011). Points were awarded for the selection 
category if: (1) the cases were adequately defined with independent validation of 
ovarian cancer diagnosis; (2) the cases were representative; (3) the selection of 
controls was such that they were community controls, derived from the same 
population as the cases; (4) controls were well defined, with explicit statements of 
absence of ovarian cancer. Points were awarded for comparability if (5) the study 
groups were comparable on potential confounders such as age, medical facility, co-
morbidity (maximum of two points). Points were awarded for exposure if: (6) data 
collection of the outcomes was achieved by secure record or structured interviews 
where researchers were blinded to case/control status; and (7) the same method of 
data collection was used for both cases and controls. The overall quality assessment 
was the sum of met criteria (range 0-8). Overall quality ratings were graded as low (1-
3), average (4-6) or high (7-8). A total of 23% of the quality assessments were double 
coded, with 100% agreement reached. 
 
6.3.6 Data analysis 
ReviewManager (Version 5.2) was used for estimation of effect sizes for each 
symptom. This was achieved by pooling the data on each symptom that was gathered 
from included papers identified in the systematic search. The number of ovarian 
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cancer cases and cancer-free controls experiencing each symptom in each study was 
extracted in order to estimate odds ratios for each symptom. Odds ratios for each 
symptom were then pooled across studies using the inverse variance method. A 
random effects model was used based on the heterogeneity of the included studies. 
 
6.4 Results  
6.4.1 Studies identified in systematic search 
Thirteen case control studies were identified from the systematic search. The search 
yielded 5,866 records, but 5,853 studies did not meet the inclusion criteria and were 
excluded (see Figure 6.1). The main reason for exclusion was that the study was not 
relevant (n=5,699). Characteristics of the 13 included studies can be seen in Table 6.1. 
Over half of the studies were from the USA (54%), the average sample size for cases 
was 357, and 990 for controls. The median age of participants was >40 in all studies, 
except for one (Behtash et al. 2008). The average number of symptoms examined was 
8 (sd 4, range 2-14). Data on symptoms was extracted from medical records or 
insurance claims (n=6), and studies which used interview or survey methods collected 
symptom data through the use of set symptom lists (n=7).  
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Figure 6.1. Flow diagram of study selection for systematic search to identify symptoms 
indicative of ovarian cancer  
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Table 6.1. Country of origin, sample information, symptoms and method of included studies 
 Country Cases 
(n) 
Controls 
(n) 
Cases median 
age 
Controls 
median age 
Symptoms Method 
Behtash et at 
2008 
Iran 100 100  24 (15-35) 24 (15-35) Abdominal pain, bloating, bowel, fatigue, gastrointestinal, 
nausea/vomiting, urinary, vaginal bleeding 
Medical records 
Devlin et al 2010 USA 82 230 ________ _________ Abdominal pain, bloating, urinary  Health insurance 
claims 
Friedman et al 
2005 
USA 69 69  59 (30-87) 59 (30-87) Abdominal pain, appetite, back pain, bloating, bowel, fatigue, 
nausea/vomiting, pelvic pain, urinary, weight change 
Medical records 
Goff et al 2004 USA 44 1011 55 45 (15-90) Abdominal mass, abdominal pain, appetite, back pain, bloating, 
bowel, distension, fatigue, indigestion, nausea/vomiting, pelvic 
pain, urinary, vaginal bleeding, weight change  
Survey (symptom 
list) 
Hamilton et al 
2009 
UK 212 1060 67 (59-78) 67 (59-78) Abdominal mass, abdominal pain, appetite, bowel, bloating, 
distension, urinary, vaginal bleeding 
Medical records 
Kim et al 2009 Korea 116 135 54(18-77) 51(28-71) Abdominal pain, bloating, full, pelvic pain, urinary  Survey (symptom 
list) 
Lim et al 2012 UK 191 268 65* (50-79) 65* (52-78) Abdominal pain, back pain, bloating, bowel, distension, fatigue, 
full, indigestion, nausea/vomiting, pelvic pain, urinary, vaginal 
bleeding, weight change 
Survey (symptom 
list) 
Lurie et al 2009 UK 432 491 55.6* (19-88)  56.7* (19-88) Abdominal mass, abdominal pain, back pain, bowel distension, 
fatigue, nausea/vomiting, urinary, vaginal bleeding, weight change 
Interviews  
(symptom list) 
Olson et al 2001 USA 168 251 --  ---  Abdominal pain, appetite, bloating, bowel, fatigue, 
nausea/vomiting, urinary 
Interviews 
(symptom list) 
Pitta et al 2013 Brazil 60 150 51*   44* Abdominal mass, abdominal pain, appetite, back pain,  bloating, 
bowel, distension, full, fatigue, indigestion nausea/vomiting, 
pelvic pain, urinary, weight change 
Survey (symptom 
list) 
Smith et al 2005 USA 1985 6024 77 (68-101) 78 (68-101) Abdominal pain, bloating, gastrointestinal, pelvic pain  Health insurance 
claims 
Vine et al 2003 USA 267 317 -------(20-74) ------(20-74) Abdominal pain, bloating, bowel, distension, fatigue, indigestion, 
pelvic pain, urinary, vaginal bleeding, weight change  
Interviews  
(symptom list) 
Wynn et al 2007 USA 920 2760 59 59 Abdominal pain, back pain Health insurance 
claims 
*mean age is presented due to non-reporting of median
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6.4.2 Quality of included studies  
The ratings from the modified Newcastle-Ottawa scale are presented in Table 6.2. Four 
studies were rated overall as low quality, seven as average quality, and two as high 
quality.  
Table 6.2. Quality assessment rating of included studies 
 Selection 
(max 4) 
Comparability 
(max 2)  
Exposure 
(max 2) 
Overall quality 
rating*  
Behtash et al 2008 1 2 1 Average 
Devlin et al 2010 2 0 1 Low 
Friedman et al 2005 3 2 1 Average 
Goff et al 2004 3 1 1 Average 
Hamilton et al 2009 4 2 1 High 
Kim et al 2009 1 0 1 Low 
Lim et al 2012 3 1 1 Average 
Lurie et al 2009 4 2 1 High 
Olson et al 2001 1 1 1 Low 
Pitta et al 2013 2 0 1 Low 
Smith et al 2005 4 1 1 Average 
Vine et al 2003 3 2 1 Average 
Wynn et al 2007 3 2 1 Average 
 *overall quality rating scores were low (1-3), average (4-6) or high (7-8) 
 
6.4.3 Symptoms indicative of ovarian cancer identified in included studies 
In addition to the ten symptom terms that were used in the search strategy, a further 
six symptoms were identified and extracted from included articles (vaginal bleeding, 
gastrointestinal symptoms, abdominal mass, nausea/vomiting, weight change and 
indigestion). The thirteen identified studies therefore included a total of 16 symptoms 
indicative of ovarian cancer. The symptoms were abdominal mass, abdominal pain, 
appetite loss, back pain, bloating, bowel changes, distension, fatigue, feeling full, 
gastrointestinal symptoms, indigestion, nausea/vomiting, pelvic pain, urinary, vaginal 
bleeding and weight change. The symptoms identified in each article can be seen in 
Table 6.1. Three articles (Kim et al. 2009, Lim et al. 2012, Vine et al. 2003) provided 
data for the symptom ‘pelvic and abdominal pain’, whereas all other articles that had 
data for pelvic pain or abdominal pain included such data as separate symptoms. 
Therefore the data extracted from these three articles for ‘pelvic and abdominal pain’ 
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were entered for both pelvic pain and abdominal pain in order to reflect the presence 
of the two symptoms. 
 
6.4.4 Estimation of effect size for each symptom 
Estimated effect sizes are presented in order of size of the odds ratio (OR) in Table 6.3. 
Forest plots for each symptom are provided in Appendix 26.  
 
Table 6.3. Number of studies, sample sizes, odds ratios and 95% confidence intervals for 
symptoms pooled across studies (pooled by inverse variance method) 
Symptom  Number of 
studies 
Cases N Controls N ORs (95% CI) 
Abdominal mass 3 704 1701  81.95 (6.49-1034.58) 
Feeling full 3 367 553 30.92 (12.27-77.93) 
Distension 6 1206 3297 27.88 (12.96-59.98) 
Bloating 11 3294 9615 21.49 (10.47-44.11) 
Appetite loss 5 591 1760 14.37 (7.50-27.54) 
Pelvic pain 7 2732 7974 10.69 (4.87-23.44) 
Abdominal pain 13 4646 12866 8.10 (6.26-10.48) 
Indigestion 4 562 1746 6.41 (1.72-23.91) 
Gastrointestinal  2 2085 6124 4.47 (3.54-5.65) 
Urinary  11 1757 3221 3.88 (2.69-5.60) 
Fatigue 8 1331 2657 3.49 (2.29-5.32) 
Vaginal bleeding 6 1246 3247 3.41 (1.57-7.42) 
Weight change 5 1019 1295 3.20 (0.94-10.92) 
Bowel changes 14 2218 6457 2.99 (1.82-4.91) 
Nausea/vomiting 7 1064 2340 2.14 (0.96-4.79) 
Back pain 6 1716 4749 1.81 (0.66-4.94) 
 
6.5 Study 1b. Virtual reference group 
A virtual reference group of experts in ovarian cancer was convened to provide clinical 
opinion on the symptom information identified from the systematic search.  The 
empirically identified symptoms, along with the pooled effect sizes, were presented to 
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the experts to gain opinion on the relevance of the symptom in relation to ovarian 
cancer detection.  
6.5.1 Participants 
Academics and clinicians in the field of ovarian cancer were identified via discussion with the 
supervisory team. Ten experts were identified and sent an invitation via email. Seven 
experts had clinical backgrounds (including gynaecology oncology, ovarian cancer early 
diagnosis and academic primary care with ovarian cancer speciality) and two had academic 
careers focused on ovarian cancer early diagnosis.  
 
6.5.2 Procedure  
Ethical approval for the study was received from Cardiff University School of Medicine 
Research Ethics Committee (see Appendix 27). The email invitation included an 
embedded link to a short online survey. After reading the study information, the 
participants were invited to complete the online consent form before progressing to 
the survey. At the start of the survey, participants were informed: “Please consider a 
woman at risk for ovarian cancer who needs to decide whether or not to consult a 
doctor about her symptoms. (“At risk” refers to a woman with a positive family history 
of ovarian cancer.)”. 
 
6.5.3 Measures  
Questions included relevance of each symptom to ovarian cancer (responses: 1=never, 
2=seldom, 3=quite often, 4=very often, 5=always), ranking of importance (rank from 1-
16 assigned to symptoms), expected frequency (responses: 1=daily, 2=most days, 
3=some days, 4=on one occasion) and duration of symptoms (responses: 1=up to one 
week, 2= 1-2 weeks, 3=2-3 weeks, 4=3-4 weeks, 5=more than a month) for ovarian 
cancer suspicion to be aroused and what symptoms should be retained for a symptom 
list for women at increased risk of ovarian cancer. Participants were also asked in open 
ended questions if they would label any of the symptoms differently, and whether 
they would group any of the symptoms in to similar clusters.  
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6.5.4 Data analysis 
SPSS v20 was used to conduct descriptive and non-parametric data analyses. Averages 
were calculated for symptom duration, frequency and symptom relevance. The 
Friedman Test was used to rank the symptoms in order of importance. This test 
calculates a rank for each of the symptoms individually, and then considers the values 
of the ranks for each symptom in order to calculate an overall rank for all symptoms.  
 
6.6 Results 
Of the ten experts invited to take part, seven completed the online survey, of whom 
two provided partial data. The seven participants consisted of five experts from clinical 
backgrounds and two experts from academic backgrounds.  
 
6.6.1 Relevance of symptoms to ovarian cancer  
Table 6.4 presents the symptoms in rank order of importance for ovarian cancer. 
Abdominal mass was ranked highest, followed by bloating and distension. The 
remaining 13 symptoms were deemed as “seldom” being indicators of ovarian cancer. 
When asked whether each of the symptoms should be retained for inclusion in an 
ovarian cancer symptom awareness list for women at increased genetic risk, seven 
symptoms were endorsed by all respondents: abdominal mass, bloating, distension, 
feeling full, pelvic pain, abdominal pain and appetite loss. These seven symptoms were 
also the highest ranked symptoms and had the largest odds ratios (see Table 6.4). The 
remaining nine symptoms (bowel changes, urinary, fatigue, gastrointestinal, 
indigestion, vaginal bleeding, weight change, back pain and nausea/vomiting) received 
the lowest ranks, had the smallest odds ratios, and were endorsed by a minority of 
experts. Gastrointestinal symptoms and nausea/vomiting received no endorsement, 
with the remaining seven symptoms endorsed by very few of the experts (Table 6.4). 
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Table 6.4. Rank, relevance and endorsement of ovarian symptoms according to virtual 
reference group 
Symptom Rank 
Relevance of 
symptom (mode) 
Number endorsing 
symptom retention 
(n=5) 
ORs (95% CI)a 
Abdominal mass 1.2 3 5 81.95 (6.49-1034.58) 
Bloating 4.1 3 5 21.49 (10.47-44.11) 
Distension 4.7 3 5 27.88 (12.96-59.98) 
Feeling full 6.1 2 5 30.92 (12.27-77.93) 
Pelvic pain 6.3 2 5 10.69 (4.87-23.44) 
Abdominal pain 7.5 2 5 8.10 (6.26-10.48) 
Appetite loss 8.7 2 5 14.37 (7.50-27.54) 
Bowel changes 8.8 2 1 2.99 (1.82-4.91) 
Urinary  9.1 2 1 3.88 (2.69-5.60) 
Fatigue  9.9 2 1 3.49 (2.29-5.32) 
Gastrointestinal  11.4 2 0 4.47 (3.54-5.65) 
Indigestion 11.4 2 1 6.41 (1.72-23.91) 
Vaginal Bleeding 11.4 2 1 3.41 (1.57-7.42) 
Weight change 11.5 2 2 3.20 (0.94-10.92) 
Back pain 11.9 2 1 1.81 (0.66-4.94) 
Nausea/vomiting 12.0 2 0 2.14 (0.96-4.79) 
 aPooled effect sizes from systematic search 
 
 
6.6.2 Guidance on symptom duration and wording  
The symptom guidance from the virtual reference group is summarised in Table 6.5. 
The experts thought that the majority of symptoms should be experienced on most 
days for 2-3 weeks before a woman at increased genetic risk of ovarian cancer should 
seek medical advice. Abdominal mass, distension and nausea/vomiting were thought 
to warrant medical advice sooner than this, and the symptoms fatigue and weight 
change were thought to warrant medical advice after a longer duration. 
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Table 6.5. Summary of symptom duration and frequency information gathered via the virtual 
reference group 
Symptom  Duration mode Frequency mode 
Abdominal mass Up to 1 week  On one occasion 
Abdominal pain 2-3 weeks  Most days  
Appetite loss 2-3 weeks  Most days 
Back pain 2-3 weeks  Most days*  
Bloating 2-3 weeks  Most days 
Bowel changes 2-3 weeks* Some days 
Distension 1-2 weeks Most days 
Fatigue  More than a month* Most days 
Feeling full 2-3 weeks* Most days 
Gastrointestinal 3-4 weeks Most days 
Indigestion  2-3 weeks* Most days 
Nausea/vomiting  1-2 weeks* Most days  
Pelvic pain 2-3 weeks* Most days 
Urinary  2-3 weeks* Most days 
Vaginal bleeding 2-3 weeks  Most days* 
Weight change More than a month  Most days 
*multiple modes exist. Median score is presented instead. 
 
6.6.3 Feedback on symptom duration and frequency  
Four participants provided feedback about wording of symptoms (Table 6. 6), and five 
participants provided feedback about possible clustering of symptoms (Table 6.7). It 
can be seen in Table 6.6 and Table 6.7 that some experts felt that the symptoms had 
overlap or could be correlated with each other. The difficulty that arises when 
describing symptoms is evident in responses (e.g. “bloating is a really problematic 
term”), as is the ambiguity surrounding some of the symptom terms (e.g., 
“Bloating/feeling full/indigestion are in my view poorly differentiated by patients and 
doctors”). 
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Table 6.6. Opinions on symptom labelling expressed by the virtual reference group  
Symptom labelling responses 
'Bloating' is a really problematic term. I use it to mean 'up and down' and distension to mean 
'up and up' but women use it idiosyncratically (and that's OK). You would also have to consider 
if the vaginal bleeding is post-menopausal bleeding or other variants in pre-menopausal 
women. Weight change has to be weight loss and weight gain separately 
Indigestion is an unhelpful term and would be better labelled as dyspepsia (i.e. "heartburn") to 
avoid confusion with bloating. If targeted at patients, then perhaps re-label it as "heartburn". 
Abdo/pelvic pains/bowels change = something wrong with your tummy, appetite loss / weight 
change = not well in self, feeling full / distension / bloating = ? 
I've used the term "difficulty eating" and I guess that's the same as appetite loss but it could 
include some of the other gastrointestinal, indigestion, and nausea issues for some women.  
Mostly I see it important to distinguish frequent (near daily) experiences of this from those who 
have these symptoms "sometimes". 
 
Table 6.6 presents the experts’ opinions on how they would label symptoms, with 
labels given to some symptoms in such a way that multiple symptom terms are 
encompassed, for example “I've used the term "difficulty eating" and “I guess that's 
the same as appetite loss but it could include some of the other gastrointestinal, 
indigestion, and nausea issues for some women”. Expert opinions on potential 
clustering of symptoms can be seen in Table 6.7. Symptoms related to pain and 
symptoms relating to bloating and distension were suggested to be grouped together 
as they are not easily differentiated (Table 6.7).  
Table 6.7. Opinions on symptom clustering expressed by the virtual reference group 
Symptom clustering responses 
I wouldn't group them together, because they can occur independently 
I'd duck the GI symptoms 
Bloating/feeling full/indigestion are in my view poorly differentiated by patients and doctors - I 
would group these together as bloating/indigestion. GI symptoms overlaps with many others 
e.g. indigestion, nausea and vomiting, bowel changes. You could lump these together under GI 
symptoms, but then the patient needs to be told what actually constitute GI - and I'd leave out 
bowel changes from the list of GI symptoms, given the low OR in the list above 
Mass / distension / bloating 
I group Pelvic and abdominal pain together because many women don't appear to differentiate 
them and they are highly correlated.  Similarly I put bloating and distention together both 
because they tend to be correlated but it also seems to draw women's attention to bloating that 
is not episodic but more consistent day to day which is the sort of more concern in my eyes.  I 
also put difficulty eating and feeling full quickly together but I don't feel as strongly about. 
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6.7 Study 1c. Critical thresholds identified by GPs and women at increased genetic 
risk 
Two sets of survey data were used to gain a fuller understanding of symptom 
experience expectations in a sample of women at increased genetic risk and a sample 
of GPs. The women’s survey provided opinion from potential users on the thresholds 
of symptoms they would expect before seeking medical help for ovarian cancer 
concerns. The GP survey provided professional opinion on thresholds of symptoms 
they would expect to see before considering ovarian cancer. Ethical approval for the 
study was received from Cardiff University School of Medicine Research Ethics 
Committee (see Appendix 7). 
 
6.7.1 GP survey method 
Recruitment  
GPs were identified via a database held within the Cochrane Institute of Primary Care and 
Public Health at Cardiff University which contained contact details for 349 GPs. These GPs 
had previously taken part in research within the department and agreed to have their 
contact details stored on the database for future research purposes.  
Inclusion criteria  
Inclusion criteria were the ability to give informed consent. There was no age or gender 
restriction on participation.  
Procedure 
Invitation emails were sent to all GPs on the database. Fourteen emails (4%) were 
automatically returned due to incorrect or defunct email addresses, bringing the total 
number of possible GP responders to 335. Those who wished to participate completed 
an online consent form and then completed the online survey. 
Measures  
Symptom frequency was assessed with the question: “How often would you expect 
this symptom to be experienced before a woman should seek medical advice?” 
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Response options were: up to 1 week, 1-2 weeks, 2-3 weeks, 3-4 weeks, more than a 
month. Symptom duration was assessed with the question: “How long would you 
expect this symptom to be experienced before a woman should seek medical advice?”. 
Response options were: on one occasion, some days, most days, daily. 
6.7.2 Women at increased genetic risk of ovarian cancer survey method 
As part of the survey reported in Chapter 4, two questions on symptom frequency and 
duration contributed to the present phase of the research.   
Procedure  
A total of 475 women were sent the survey, as described in Chapter 4. Women were 
provided with a stamped addressed envelope to return the paper version of the 
survey, and were also provided with a website address if they wished to complete the 
survey online (Chapter 4). 
Measures  
Symptom frequency and duration was assessed with similar questions to those used in 
the GP survey. Frequency was assessed with the question: “How often would you 
expect the symptom to occur during this time before going to get advice?”. Duration 
was assessed with the question: “How long would you wait after noticing the symptom 
before going to get advice?”. The response options for both of these questions were 
the same as the options described for the GP survey. 
6.7.3 Data analysis  
Survey data were analysed using SPSS v20. Average responses for symptom frequency 
and duration were calculated separately for each sample to determine symptom 
frequency and duration for each symptom. The Mann Whitney U test was used to 
compare the responses between the groups. 
6.8  Results 
6.8.1 Sample characteristics  
As described in Chapter 4, 164 women (35%) did not return the form and 28 (6%) were 
excluded due to having undergone a procedure to remove their ovaries. The final 
sample was 283 (63%). Four participants completed the survey online. The average age 
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of the women was 53 years (sd=10). The majority of women were married or 
cohabiting and were educated beyond age 16 (Chapter 4, p81). The GP survey was 
completed by 108 GPs (33%). The average age of GPs was 48 years (sd= 8), 61 (56%) 
were male and 47 (44%) were female. 
6.8.2 Opinion on symptom frequency and duration  
 The symptom duration and frequencies that women and GPs thought would warrant 
medical advice are presented in Table 6.8. 
Table 6.8. Critical thresholds for symptoms from a sample of women at increased genetic risk 
and a sample of GPs (medians for frequency and duration) 
Symptom  Women GPs Statistic 
Abdominal pain F: Most days (3) 
D 1-2 weeks (2) 
F: Most days (3) 
D: 3-4 weeks (4) 
U=12134, z=-2.12, p=0.34 
U= 4651, z=-10.37,p<0.001 
Appetite F: Most days (3.0) 
D: 1-2 weeks (2) 
F: Most days (3.0) 
D: 3-4 weeks (4) 
U=13090,z=-0.44, p=0.66 
U=7651, z=-6.75,p<0.001 
Back pain F: Most days (3) 
D: 2-3 weeks (3) 
F: Most days (3) 
D: More than a month (5) 
U=12519, z=-1.37,p=0.17 
U=6485, z=-8.26,p<0.001 
Bloating         F: Most days (3) 
D: 1-2 weeks (2) 
F: Most days (3) 
D: 3-4 weeks (4) 
U=13285, z=-0.31,p=0.75 
U=6300,z=-8.48,p<0.001 
Bowel  F: Most days (3) 
D: 2-3 weeks (3) 
F: Most days (3) 
D: 3-4 weeks (4) 
U=13320, z=-0.04, p=0.97 
U=6157, z=-8.48, p<0.001 
Distension F: Most days (3) 
D: 1-2 weeks (2) 
F: Most days (3) 
D: 3-4 weeks (4) 
U=13420,z=-0.42,p=0.68 
U=6528, z=-8.30, p<0.001 
Fatigue F: Most days (3.1) 
D: 2-3 weeks (3) 
F: Most days (3.2) 
D: 3-4 weeks (4) 
U=12489, z=-1.17, p=0.24 
U=8027, z=-6.43, p<0.001 
Full F: Most days (3) 
D: 2-3 weeks (2) 
F: Most days (3) 
D: 3-4 weeks (4) 
U=13395,z=-0.11,p=0.91 
U=7657,z=-6.71,p<0.001 
Pelvic pain F: Most days (3) 
D: 1-2 weeks (2) 
F: Most days (3) 
D: 2-3 weeks (3) 
U=12119, z=-1.98,p=0.054 
U=5324, z=-9.45, p<0.001 
Urinary  F: Most days (3) 
D: 2-3 weeks (3) 
F: Most days (3) 
D: 3-4 weeks (4) 
U=12852, z=-0.61, p=0.54 
U=8446, z=-5.88,p<0.001 
Vaginal bleeding F: Most days (3) 
D: 1-2 weeks (2) 
F: On one occasion (1) 
D: Up to 1 week (1) 
U=4315, z=-9.89,p<0.001 
U=9083,z=-4.98,p=<0.001 
*F= frequency, D= duration 
Overall, women anticipated shorter times for symptomatic presentation compared to 
GPs, with these differences statistically significant for all symptoms (p < 0.001). With 
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the exception of the symptoms vaginal bleeding and back pain, GPs felt that medical 
advice should be sought when symptoms are experienced on most days for 3-4 weeks. 
However, women felt they would seek help sooner, with expected durations of 1-2 
weeks or 2-3 weeks for all symptoms. The only statistically significant difference for 
symptom frequency was seen for vaginal bleeding, where women reported an 
expected frequency of ‘most days’ before presenting, compared to the less frequent 
“on one occasion” reported by GPs (p <0.001). 
 
6.9 Discussion  
The results of the current study have demonstrated that it is possible to identify 
symptoms that are associated with ovarian cancer. The use of different methods led to 
a consistent opinion on symptoms and critical thresholds for ovarian cancer symptoms. 
The systematic search identified symptoms that were indicative of ovarian cancer and 
experts then used their prior experience and the data summarised from the systematic 
search to make decisions on the most important symptoms of ovarian cancer. 
Expectations of symptom experience were also gained from a sample of GPs and 
women at increased genetic risk. The current study has presented a set of symptoms 
that can be used in a symptom awareness tool which has specific content for women 
at increased genetic risk of ovarian cancer. 
 
Of the 16 symptoms presented to the virtual reference group, the majority were 
perceived as having low relevance for ovarian cancer.  Only three symptoms 
(abdominal mass, bloating and distension) were viewed as “quite often” being 
indicators of ovarian cancer. All of the other symptoms were viewed as “seldom” being 
indicators, suggesting that the symptoms may have problems with specificity, i.e. they 
could be attributed to conditions other than ovarian cancer. This reflects the vague 
nature of the symptoms and the difficulty that both women and health professionals 
face when trying to attribute symptoms to possible ovarian cancer (Evans et al. 2007). 
The feedback on symptom labelling and clustering also supports this, suggesting that 
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more than just the symptom term needs to be provided in order for women to 
understand what the symptom term means.   
 
6.9.1 What symptoms should be included in OvSTAT? 
The seven symptoms with the highest rankings in the virtual reference group were also 
the seven symptoms that received endorsement for retention in a symptom list by all 
experts in the virtual reference group. This finding paired with the odds ratios from the 
systematic search suggests that these symptoms should be considered for inclusion in 
the symptom awareness tool. Of these seven symptoms, abdominal mass appeared to 
be a stand-alone symptom. When the guidance on symptom duration and frequency is 
considered, abdominal mass is also highlighted as an individual symptom. The experts 
in the virtual reference group expected this symptom to be experienced on one 
occasion for up to a week before medical advice should be sought, whereas all other 
symptoms had longer durations and higher frequencies. However, the inclusion of this 
symptom still needs to be considered, as the findings may reflect the relevance of the 
symptom for other forms of cancer, with ovarian cancer one such possibility. 
Abdominal mass may therefore not be suitable for inclusion in an ovarian cancer 
symptom awareness tool because it is not an ovarian specific symptom. Support for 
this is seen in the absence of this symptom from the National Institute for Health and 
Clinical Excellence (2011) and Department of Health (2009) guidelines. The likelihood 
of a woman being able to detect the symptoms highlighted in the awareness tool also 
needs to be considered. In many cases, abdominal masses are hard to feel or notice 
externally, and are instead often revealed via scans or surgery (Prat 2014). Noticeable 
abdominal masses also tend to present in later stage disease (Prat 2014), and 
therefore may not be suitable to include in a tool which aims to bring about earlier 
detection.   
 
The remaining six symptoms were considered to be indicative of ovarian cancer and 
therefore should be included in an awareness tool.  Based on the findings from the 
virtual reference group, these six symptoms could be grouped into three symptom 
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pairs. Bloating and distension could be grouped, with this evident in the ovarian cancer 
literature where these terms have been used interchangeably (Kim et al. 2009, Lim et 
al. 2012, Vine et al. 2003). Pelvic pain and abdominal pain could also be combined, 
with this grouping observed in some of the identified studies in the systematic search 
in the current study (Bankhead et al. 2008, Bankhead et al. 2005, Hamilton 2009) and 
in the systematic search of ovarian cancer symptom awareness tools (Chapter3). 
Feeling full and appetite loss could also be grouped, as these symptoms relate to issues 
surrounding difficulty with eating.  These potential groupings are also endorsed in the 
symptom labelling and clustering responses from the virtual reference group.  
 
6.9.2 What symptoms should not be included in OvSTAT? 
The remaining nine symptoms received much less support from all strands of the 
current research. These nine symptoms were ranked lowest and did not receive 
unanimous endorsement for retention in a symptom list. These symptoms also had the 
smallest odds ratios, with the odds ratio for weight change, back pain and 
nausea/vomiting particularly supporting exclusion due to the confidence intervals 
crossing one. The group of nine symptoms appear to be more non-specific in nature 
and the results of the current study suggest that these symptoms should not be 
included in the symptom awareness tool. This could be due to the other symptoms 
being stronger indicators of ovarian cancer, which may also be easier for women to 
identify and understand. 
 
6.9.3 Symptom guidance information  
Symptom time frames 
GPs and experts in the virtual reference group expected symptoms to be experienced 
for a longer duration compared to women at increased genetic risk of ovarian cancer. 
This suggests that women’s expectations in relation to symptoms need to be managed, 
and could reflect women’s anticipated anxiety in the presence of possible ovarian 
cancer symptoms. This was similarly mentioned during qualitative interviews in 
Chapter 5, where women felt that they would not wait to complete a four-week 
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symptom diary, and would instead act sooner because they felt that early presentation 
is important. This view on presentation could be viewed positively, with women 
anticipating prompt action rather than adopting a “wait and see” approach. 
Conversely, this could be problematic in terms of potential impact on the healthcare 
systems. This echoes the notion of hyper-vigilance that was highlighted in Chapter 4, 
where there was an association between higher perceived threat and earlier 
anticipated presentation in women at increased genetic risk, due to the influence of 
the affective component of perceived threat.  
 
The finding that GPs expected symptoms to be experienced for a longer time frame 
compared to women suggests that women at increased genetic risk may need to 
experience symptoms for longer than they currently expect in order for the GP to 
consider ovarian cancer. This is an important piece of guidance that could be provided 
to women in OvSTAT. The difference in expected symptom durations could also explain 
some of the frustration that women feel when they present to the GP with concerns 
about possible ovarian cancer symptoms. It is possible that women are presenting at 
too early a time point in the symptom experience and are therefore frustrated at the 
lack of action taken. Educating women about time frames in which to act could help 
maintain their psychological wellbeing, as well as increase the possibility that GPs will 
consider the symptoms as possible indicators of ovarian cancer. The current findings 
suggest that a symptom time frame of ‘most days’ for ‘three weeks or more’ takes into 
account the expectations of experts and GPs, and could be used in OvSTAT. 
Information on time frames could enable women to understand when is the best time 
to act, as well as when to present again if symptoms persist. 
 
Symptom wording 
The virtual reference group also provided useful ideas about the wording of symptoms 
for OvSTAT. These ideas could be incorporated to help explain what is meant by the 
symptom term. Explanations of symptoms could be useful as women previously 
expressed that they felt they did not always understand the symptom content of 
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symptom awareness tools (Chapter 5). Explanations could also help reduce 
misunderstandings between women and healthcare professionals, as they have 
previously been reported to use different terminology and descriptions for symptoms 
(Bankhead et al. 2008, Bankhead et al. 2005, Hamilton et al. 2009).  
 
6.9.4 Limitations of the systematic search 
The 13 identified studies varied in quality, with this possibly influencing the odds ratios 
for the symptoms. However, when sensitivity analysis was conducted to exclude the 
low quality studies it did not greatly change the estimated effect sizes. For the 16 
identified symptoms, a wide variety of effect sizes were observed, possibly reflecting 
methodological problems such as sample size, study timing and stage of disease. 
Different methodologies were used by included studies, with interviews, medical 
records and questionnaires utilised. These variations in data collection methods could 
have influenced findings reported by the studies, and estimation of effect sizes in the 
current study. Interviews allow for detailed responses, and can allow for more 
expansion on points as opposed to questionnaires (Keeble et al. 2014). However, 
interview analysis can be subjective, with low generalisabilty due to smaller samples. 
Questionnaires allow for data to be gathered from a large number of participants in a 
systematic way; however, findings can be limited by recall bias, as participants may 
retrospectively try to remember symptoms. Medical records avoid recall bias, involve 
large amounts of data and often cover a long time frame. However, medical records 
have data quality issues, due to dependence on the accuracy of the data recording 
process (Bankhead et al. 2005, Keeble et al. 2014). 
 
The heterogeneity of studies identified in the systematic search is problematic. The 
observed heterogeneity could be due in part to the low rates of symptoms 
experienced in the control groups. A random effects model was used, which assumed 
that other sources of variation occurred. It can therefore be said that the estimated 
effect sizes represents a truth about the population effect size, but there may be other 
factors as a result of the heterogeneity in the studies. A fixed effects model would 
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have been preferential, as this would allow for more confidence in the estimated 
effect sizes of symptoms that are indicative of ovarian cancer.  
 
Three studies provided data for ‘pelvic and abdominal pain’ combined, whereas all 
other studies that included information for these symptoms did so separately. It was 
decided in order to include the data from the three studies that pooled these 
symptoms together that the data would be entered for both ‘pelvic pain’ and 
‘abdominal pain’. This may be problematic as it may have not accurately reflected the 
symptom that was experienced. However, it was not possible to disentangle this 
information and it was deemed best to reflect the symptom in both symptom codes.  
 
6.9.5 Limitations of virtual reference group 
The virtual reference group method could be a limitation, as the virtual nature of 
participation could be restrictive. Other methods, such as a Delphi round (Hasson et al. 
2000), may be more beneficial in bringing experts together to talk through questions. 
The Delphi technique is also useful as it allows for decisions to be made on the day. 
However, the various locations of experts and associated costs precluded using this 
method. 
 
One participant felt that they were unable to answer all of the virtual reference group 
questions accurately due to wishing to know specific patient information in order to 
make informed decisions. Use of vignettes may therefore have been better. However, 
as the virtual reference group aimed to gain opinion on symptom information that 
could be provided to all women at increased genetic risk in an awareness tool, it was 
envisaged that vignettes would make responses too specific. It was also thought that 
focusing the participants to the research context by asking them to consider the 
information needs of a woman at increased genetic risk who was deciding whether to 
act on her symptoms was sufficient for stating the research purpose. 
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6.9.6 Limitations of GP and women at increased genetic risk surveys 
The GP sample was potentially not representative as they were recruited from a 
database of GPs who had previously participated in research within the department. 
These GPs may therefore have a particularly interest in participating in research 
studies and the results may therefore not be representative of GPs. The 
generalisability of the results from this GP sample could therefore be questioned. One 
way to overcome this in future research would be to recruit GPs directly from practices 
and not from an existing research database in order to have a representative sample, 
however due to the time consuming nature of this type of recruitment it was outside 
of the scope of this PhD. The GP survey was conducted online, whilst the women at 
increased genetic risk mainly responded via postal surveys. This variation in data 
collection method could again raise questions about sample representativeness. The 
GP data collection was done via email and an online survey as it was envisaged that 
this would lead to the optimal response rate from this population. Specifically, it was 
felt that sending GPs a paper based questionnaires would have required more time 
and would have led to lower response rates.  
 
The GP and women’s survey included questions on expected frequency and duration 
of 11 ovarian cancer symptoms. These symptoms are those used in the ovarian cancer 
awareness measure (O-CAM) (Simon et al. 2012a). The virtual reference group 
however, asked experts about the frequency and duration of 16 symptoms. This was 
due to the symptoms for the virtual reference group being guided by the symptoms 
identified in the symptom systematic search. This resulted in the virtual reference 
group providing opinion on some symptoms that were not presented to the 
GP/Women samples. However, as the aim of the virtual reference group was to gain 
clinical opinion on the empirically identified symptoms, it was necessary to ask them 
about all 16 symptoms. All of the 11 symptoms in the GP/Women surveys were also in 
the virtual reference group questions, so it still allowed for comparisons of opinions to 
be carried out.  
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6.9.7 Future research and implications 
Validation of the symptoms identified in this study is a crucial next step for the 
research area. Evaluation of the predictive ability of symptoms indicative of ovarian 
cancer should be undertaken, both for individual and combined symptoms. The 
symptoms identified as indicative of ovarian cancer in the current study can now be 
used for educating women about what symptoms are indicative of ovarian cancer. 
Future research which aims to validate the symptoms could do so in the content of 
different disease stages in order to further explore symptom experience in early and 
late stage. 
 
The symptom information identified in the current study could be provided to all 
women, not just those at increased genetic risk of ovarian cancer. This is because it is 
the ovarian cancer information that the symptoms are embedded within that varies 
according to risk status (as highlighted by the different patterns of health beliefs in 
Chapter 4), and not the actual symptoms. Whilst the symptom information will be 
useful to women from the general population, it is especially important for women at 
increased genetic risk that accurate symptom information, such as specific time frames 
is provided. The current findings suggest that women at increased genetic risk may be 
more concerned in the presence of symptoms than women from the general 
population and may be presenting too early in the symptom experience for ovarian 
cancer to be considered. The symptoms identified in this study can be incorporated 
into OvSTAT with the confidence that they are based on best available clinical evidence 
and expert opinion.  
 
6.9.8 Summary 
The work presented in the current chapter has sought consensus on symptoms, 
thresholds and guidance for the symptom content of OvSTAT. Three potential 
symptom clusters have been identified that can be included in the awareness tool. The 
next chapter will report the creation of the draft OvSTAT, with decisions for tool 
content made based on the findings of the previous studies. The draft tool will also be 
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presented to a sample of potential users and providers in order to gain feedback on 
the content. This will lead to the development of a final version of OvSTAT that is 
based on clinical and empirical evidence, and which has had user feedback throughout 
the development process.  
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7 Creation of draft OvSTAT and user feedback 
 
7.1 Introduction 
The findings from previous chapters were used to create a draft ovarian cancer 
symptom awareness tool (OvSTAT). Common health beliefs were identified for the two 
risk populations as well as unique health beliefs for women at increased genetic risk. 
This led to the creation of a tool that has core elements that address the shared and 
unique health beliefs of these two populations. 
 
The purpose of the OvSTAT was to provide core information regarding the key 
symptoms of ovarian cancer and the critical threshold for when to act on these 
symptoms and seek medical advice (Chapter 7). The OvSTAT also aims to address 
psychological barriers to anticipated symptomatic presentation identified in Chapters 4 
and 5. Evidence from Chapter 4 suggested that the relationship between symptom 
awareness and anticipated presentation was not direct. Therefore the tool also aimed 
to address indirect paths by increasing self-efficacy and reducing barriers, and in 
women at increased genetic risk, to manage ovarian cancer worry. In the following 
chapter, each section of the draft tool will be linked to key empirical findings and 
theoretical concepts from previous chapters of the PhD. 
 
User testing is an important step in the development of complex interventions (Craig 
et al. 2008b). The usability and understanding of the draft tool was therefore explored 
in order to understand how the tool will be received by potential users and providers. 
Testing usability and acceptability determines whether the tool is easy to understand, 
contains the relevant information and is likely to achieve its purpose. Involving 
potential users and providers in this process allows for feedback to be gained from 
people who are likely to come into contact with the tool, and allows for changes to be 
suggested and implemented, improving the design of the tool prior to evaluation.   
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7.1.1 Aims  
This chapter aims to 1) describe the creation of the first draft of OvSTAT, 2) assess 
usability of OvSTAT and 3) present changes made to create the final version of OvSTAT. 
7.2 Development of the draft OvSTAT 
The previous phases of work which were guided by the MRC complex intervention 
guidelines (Craig et al. 2008b) were drawn upon to create the draft tool, along with 
relevant components of The Discern tool (Charnock et al. 1999). Discern was designed 
to guide the evaluation of written consumer health information on treatment options 
(Charnock et al. 1999). As per section one of the DISCERN evaluation Handbook which 
outline requirements for good quality health information the OvSTAT was designed to 
include: 1) a clear statement of the aims, 2) achieving these aims, 3) relevance of the 
publication, 4) information sources, 5) production date, 6) balance of information, 7) 
additional sources of support, and 8) information and areas of uncertainty (Charnock 
et al. 1999). Evidence for the fulfilment of these requirements is shown in the 
description of the tool content in the following section. 
 
7.3 Embedding key findings in the draft tool 
Based on the findings of previous phases the following topic areas were included in the 
tool. 
7.3.1 Front page 
The OvSTAT logo was developed based on a previous study conducted by Dr Jana Witt 
within Cardiff University School of Medicine: OvDEX (oophorectomy decision explorer). 
OvDex is a tool that helps women find out more about the options available to them to 
reduce their risk of developing ovarian cancer. The tool allows women to tailor 
information to their personal situation to help them make an informed decision about 
whether to opt for oophorectomy (http://www.ovdex.co.uk/index.html). A sentence 
on the front page details the purpose and intended audience of the tool. The target 
audience of women at increased genetic risk of ovarian cancer and women from the 
general population reflects the findings of the previous phases of the present PhD. As 
the PhD progressed, it became clear that the specific information needs for women at 
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increased genetic risk could be embedded within core information that could be 
provided for women regardless of risk status. 
  
Figure 7.1. Design and content of front page of OvSTAT 
 
7.3.2 “What is this leaflet for?” 
This section explicitly outlines the aims of the tools and explains to the user what 
information they can expect from the tool. This section also states the importance of 
ovarian cancer symptom awareness and the benefits of presenting early with 
symptoms. The information within this section helps identify the main benefits of 
ovarian cancer symptomatic presentation (i.e., ease of treatment), which reflects the 
HBM (Rosenstock et al. 1988) and the SEM findings (Chapter 4), where perceiving 
more benefits than barriers was associated with presentation. 
 
Figure 7.2. Design and content of what is this leaflet for? section 
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7.3.3 “Ovarian cancer truths”  
The survey findings (Chapter 4) and qualitative interview phase (Chapter 5) showed 
that some women at increased genetic risk of ovarian cancer had misconceptions 
regarding ovarian cancer, primarily concerning the purpose of smear testing. Some 
women believed that the smear test could detect ovarian cancer. This misconception 
was reflected in the inclusion of ‘myth busting’ sections in some of the tools identified 
during the systematic search of symptom awareness tools (Chapter 3). Information to 
dispel this misconception was therefore included in OvSTAT. Previous research phases 
also highlighted the emphasis and trust that women at increased genetic risk were 
placing on familial ovarian cancer screening, even though the effectiveness of ovarian 
cancer screening is not currently known. Text explaining that ovarian cancer screening 
is not currently offered by the NHS was therefore included to reinforce the importance 
of symptom awareness in the absence of other detection strategies.  
 
  
Figure 7.3. Design and content of Ovarian cancer truths section 
 
7.3.4 “What are the symptoms of ovarian cancer?” 
Symptoms and symptom guidance was based on the findings of Chapter 7. Three 
symptom clusters were identified based on the systematic search and virtual reference 
group data. The guidance for experiencing symptoms ‘on most days for 3 weeks or 
more’ reflects the critical thresholds identified by the synthesis of the symptom data in 
Chapter 7. This specific guidance is important to include as it informs readers about 
appropriate presentation times. Positive feedback regarding the use of a female body 
image in tools was well received in qualitative interviews (Chapter 5), in line with 
previous research which has demonstrated the effective use of visual aids in imparting 
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health information (Edwards et al. 2002, Lipkus 2007). An illustration of a female body 
was therefore included to illustrate where the identified symptoms would be 
experienced. The body was used to emphasise the non-gynaecological nature of the 
symptoms of ovarian cancer. Due to the issues identified in Chapter 7 regarding 
symptom terminology and the interchangeable use of many symptom terms, a brief 
explanation for each of the symptoms was also included.  It was envisaged that these 
explanations would help to increase understanding of the symptom clusters, thereby 
improving awareness and appraisal of potential ovarian cancer symptoms despite 
variability in terminology. The symptom explanations could also help to increase self-
efficacy (confidence in noticing a symptom), as women could feel more confident in 
explaining their symptom experience if they recognised their symptoms in OvSTAT. 
Self-efficacy was shown in Chapter 4 to be directly associated with symptom 
knowledge and was indirectly associated with presentation through perceiving more 
benefits than barriers to presentation in both risk populations. In women at increased 
genetic risk, self-efficacy was also indirectly associated through perceived threat 
(Chapter 4). Increasing self-efficacy could therefore be beneficial for multiple reasons. 
  
Figure 7. 4. Design and content of What are the symptoms of ovarian cancer? section 
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7.3.5 “When should I go and see the doctor?” 
Previous phases highlighted the importance of presenting action-oriented information 
as well as awareness raising information in relation to ovarian cancer symptoms. Many 
women anticipated presenting immediately in the presence of possible ovarian cancer 
symptoms (Chapter 4). Women’s understanding of critical thresholds and expectations 
therefore need to be managed, and women need to be informed that they may need 
to experience symptoms for longer time periods in order for doctors to be able to 
correctly assess the relevance of symptoms as indicative of ovarian cancer. 
Importantly, this section also emphasises that women experience these symptoms 
from time to time, and the experience of them does not necessarily indicate that 
ovarian cancer is present. This is crucial information for managing worry levels, which 
is particularly relevant for women at increased genetic risk, for whom the SEM of HBM 
constructs revealed that higher perceived threat (which included worry) was 
associated with immediate anticipated presentation (Chapter 4). Attempts to manage 
perceived threat are therefore especially important for this population and could help 
avoid over-presentation.  
  
Figure 7.5. Design and content of When should I go and see my doctor? section 
 
7.3.6 “What to expect at the doctors” 
This section of OvSTAT provides information about what women might expect if they 
present with concerns about ovarian cancer symptoms. Again, this section attempts to 
manage expectations, and also aims to put women at ease about the consultation 
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process and reduce barriers to presentation (Chapter 4/5). This section also 
encourages women to take OvSTAT with them to the visit in order to prompt them and 
facilitate the doctor-patient discussion. OvSTAT could therefore be a way of helping 
women feel more confident in their decision to present and could also help manage 
expectations of what will happen when they present.  
  
Figure 7.6. Design and content of What to expect at the doctors section 
 
7.3.7 “If you have a family history of ovarian cancer” 
This section of OvSTAT contains specific content for women at increased genetic risk of 
ovarian cancer and aims to address some of the specific information needs of these 
women as outlined in the previous phases. The first paragraph highlights the 
importance of symptom awareness for women who do not choose RRSO. The next 
paragraph in this section helps prepare women at increased genetic risk for their 
medical appointment. The importance of disclosing family history to the doctor is 
emphasised, and women are encouraged to prepare themselves emotionally to share 
this information. Many women in the interviews in Chapter 5 described this as an 
emotional burden, and were disgruntled at their doctor’s lack of knowledge of their 
family history. In reality, doctors may not be aware of all of their patients’ personal 
circumstances, hence it is important for women to raise their family history if they are 
presenting with ovarian cancer symptom concerns.  
 
The final paragraph provides information about who to talk to. This information 
highlights the importance of talking to the doctor about family history and that there 
are specific services available to those who have been identified as being at increased 
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genetic risk. Encouraging women to utilise the Clinical Genetics Service could help 
manage their perceived threat levels (Chapter 4), as specific support and genetic 
counselling can be provided depending on the needs of the individual. 
  
Figure 7.7. Design and content of If you have a family history of ovarian cancer section 
 
7.3.8 “What to do now” 
This section reminds women to seek medical advice if they experience symptoms on 
most days for three weeks or more. It also encourages women to go back to their 
doctors if the symptoms persist or return. This encourages women to be confident in 
re-attending if their concerns continue, and again links to the self-efficacy and 
benefits/barriers findings for the SEM of HBM constructs (Chapter 4). Women are also 
suggested to keep the leaflet so that they can refer to it again if they need it. Keeping 
the leaflet would allow women to take the leaflet to the consultation with them, which 
may facilitate discussion with the doctor. 
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Figure 7.8. Design and content of What to do now… section 
 
7.3.9 “For further information and support”  
The ovarian cancer charity Target Ovarian Cancer agreed to be included in the tool as a 
source of further information and support for women. Therefore if women have any 
particular questions or concerns, they have a dedicated charity with multiple resources 
available to them. This section also details that the tool was created at Cardiff 
University, which highlights that the tool was created in the UK. The funders for the 
project were also detailed here, along with a version number and date which ensures 
readers can see when the information was created. 
  
Figure 7.9. Design and content of For further information and support section 
 
7.4 Methods  
The present study examined the users’ and providers’ understanding of the OvSTAT 
tool and their opinions on content.  The methodology used was the cognitive 
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interviewing technique, which enables an evaluation of the purpose, layout and 
content of health technologies, with a view to designing a version of OvSTAT that is ‘fit 
for purpose’. Ethical approval for the study was received from Cardiff University School 
of Medicine Research Ethics Committee (see Appendix 27). 
 
7.4.1 Cognitive interviews 
User testing involved a sample of users and providers giving feedback and opinion on 
the draft OvSTAT. Verbal probing is a cognitive interviewing technique that can be 
used for user testing (Collins 2003, Willis 2005). Verbal probing is commonly used for 
testing questionnaires, but can also be applied to other materials (Willis 2005). Verbal 
probing involves the participant looking at the material, followed by the interviewer 
asking target questions which are then followed up by probing for specifics relating to 
the question or answer given (Collins 2003, Willis 2005). Verbal probing allows for 
further information to be gathered and encourages the participants to expand and 
explain their answers. The content of the interviews was informed by a topic guide 
with responses probed in order to fully explore the cognitive processes underlying the 
response (Willis 2005).  
 
The main topics were usefulness/understanding of the tool, content and layout, 
improvements and inclusion of a section for women at increased genetic risk (see 
Appendix 28). Other topics that arose during interview were explored though the use 
of probes and prompts. The main probes covered comprehension, paraphrasing and 
improvements (see Appendix 28). 
 
7.4.2 Recruitment 
The study aimed to recruit 8-10 participants, representing a variety of potential users 
and providers. Ten women at increased genetic risk were identified from the pool of 
women who agreed to take part in future research studies when they completed the 
survey in Chapter 4. These women were selected to reflect a range of age (above 50 
and below 50 to reflect cancer risk increasing in older age), anticipated presentation 
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time and ovarian cancer worry levels of potential users. Two women from the general 
population and two GPs were identified from within the Department of Primary Care 
and Public Health, and a clinical genetics specialist was identified from Cardiff and Vale 
University Health Board. Ovarian cancer charity Target Ovarian Cancer was also 
approached to identify a participant with experience of providing information 
materials for women with ovarian cancer concerns. 
 
7.4.3 Procedure  
Women at increased genetic risk were sent an information sheet, consent form, and a 
postage paid pre-addressed envelope. On receipt of the signed consent form the 
participant was contacted and a time and date for the interview was arranged. Once 
the interview had been arranged, the draft OvSTAT (see Appendix 29) was posted to 
the participant. A representative from Target Ovarian Cancer was identified via email, 
and upon receipt of signed consent the draft OvSTAT was posted. Due to geographical 
distance, telephone interviews were conducted with women at increased genetic risk 
and the charity representative. The two women from the general population, two GPs 
and the genetic specialists were interviewed face to face. Participants were consented 
and then given the draft OvSTAT (see Appendix 29) to read at the start of the interview 
prior to the interview commencing. All interviews were audio recorded and 
transcribed verbatim. 
 
7.4.4 Data analysis  
Thematic analysis (Braun and Clarke 2006, Green and Thorogood 2013) was conducted 
using NVivo 8 (QSR International Pty Ltd 2008). The transcripts were read and re-read 
in order to achieve familiarisation with the data. Initial codes were identified and 
applied to the transcripts. Themes representative of the codes were then identified 
based on the codes (Green and Thorogood 2013). Quotes presented in the following 
section represent examples of the identified themes. Insertions to clarify topic content 
are denoted by square brackets. The removal of irrelevant information within the 
quotes is denoted by “…”. 
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The characteristics of each participant are presented in parentheses after each quote 
in the following order: hp1 = health professional one, hp2= health professional two, 
hp3= health professional three, ir1= increased risk participant one, ir2= increased risk 
participant two, ir3= increased risk participant three, g1= general population 
participant one, g2= general population participant two, cr1= charity representative 
participant.  
 
7.4.5 Amendments to OvSTAT 
Amendments to OvSTAT were considered and changes that would result in 
improvements to the tool were made on the basis of the cognitive interview findings. 
 
7.5 Results 
7.5.1 Sample characteristics  
Five women (50%) at increased genetic risk of ovarian cancer agreed to take part in the 
study. Contact could not be made with one participant to arrange an interview, and 
another participant was unavailable for interview during the study period. A total of 
three telephone interviews were arranged and completed with women at increased 
genetic risk of ovarian cancer. Characteristics of these are shown in Table 7.1. 
 
Table 7.1. Age, education level, anticipated presentation time and ovarian cancer worry for the 
three women at increased genetic risk of ovarian cancer 
Participant Age Education Presentation Worry 
1 52 Secondary As soon as I notice 6 
2 64 Up to 16 +4 weeks 7 
3 70 Secondary Over 1 up to 2 weeks 3 
 
Cognitive interviews were also completed with two women from the general 
population, two GPs (one male, one female), one clinical geneticist (female) and one 
ovarian cancer charity representative (female). The cognitive interviews had an 
average length of 17 minutes (range 11- 30 minutes).  
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7.5.2 Cognitive interview findings 
Themes that arose from the cognitive interviews included positive feedback, negative 
feedback and recommendations for improvement. 
7.6 Positive aspects of OvSTAT 
7.6.1 Tool purpose 
Overall, the tool was well received. The aims of increasing awareness of ovarian cancer 
symptoms, and providing information about what to do if symptoms were experienced 
were identified and understood by participants.  
I think it’s a great idea and I think it’s really good, I think it’s been a long time coming, 
there isn’t a lot out there for people like me who are looking for information, apart from 
websites.’ (ir3) 
 ‘it doesn’t overload you with stuff, it just gives you simple things to look out for and then 
like simple steps like if you see this go see a doctor, and like saying not to panic and 
everything.’ (g2) 
 
The section on ovarian cancer truths was viewed positively, with the dispelling of the 
common misconception of the smear test detecting ovarian cancer singled out as 
being particularly useful by health professionals. 
 ‘I think it’s quite good to clarify…that the smear doesn’t check it, because there’s an 
amazing amount of people who think that the smear does.’ (hp2) 
 
The tool was viewed as containing information that would be expected to be included 
in similar health education leaflets. It was also said that this information was presented 
in a logical way, which aided the flow and readability of the tool. 
‘Well as the questions were springing to my mind, actually they were addressed, so I think 
it was a nice logical order so that prompted me to read on.’ (g1) 
‘it’s nice and logically laid out in it’s almost like a timeline isn’t it? So what’s it for, these 
are the symptoms, what you should do next, and what should you expect at the doctors.  I 
think that flows quite nicely.’ (hp2) 
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The length of the tool and the layout of the information in different sections was also 
praised. 
‘people get bored don’t they of reading, whereas actually I thought it was quite good the 
way it was all laid out, who it’s for, broken down into nice bits.’ (ir2) 
‘I liked the colour of the brochure, I thought the typeface and the wording was easy to 
read, and it was clear.’ (ir3) 
The language used in the tool was reviewed positively and was regarded as making the 
tool accessible for women with different literacy levels. 
 ‘it reads like that sort of you know, level of pitch in terms of  what you do reading 
women’s magazines and whatever, so I think that’s probably appropriate, because women 
certainly pick up on that information and bring it in.’ (hp1) 
 
The basic language and lack of medical terminology was discussed as a specific positive 
attribute to the tool. 
 ‘It doesn’t feel too medicalised… I think it’s good and I think talking in the first person, if 
you are experiencing this, I think it’s pitched just right to be honest.’(g1)  
‘I thought it was very easy to read and informative.  Not going into too much, some 
leaflets I’ve seen go into a bit too much blah, blah sciency type things, I thought this was 
very, not simple in a bad way, simple in a good way.’  (ir2) 
 
The logo on the front page of the tool was also praised ‘And I liked the front cover, I liked 
the OvSTAT symbol.  That shows the ovaries presumably?’ (ir3) 
 
7.6.2 Symptom information  
The symptom information was viewed as clear and well-focused. 
‘It’s quite good that there’s not too many symptoms, because that could become a bit 
overwhelming.’ (hp2) 
‘It’s easier to remember those three changes in eating, bloating stomach or pelvic pain.  
Becoming too detailed in medical jargon I think it can just cloud that.’ (g1)  
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The symptom message was perceived to be enhanced by the use of a female body 
illustration. This was praised for breaking up the space, drawing the reader’s attention 
to the symptoms, and for highlighting that the symptoms are not focused around the 
area of the ovaries. 
 ‘it probably is quite helpful… I think getting away from those sort of diagrams of ovaries 
that show like, this is your ovary here, and this is… probably better because it (ovarian 
cancer) is going to present in a non-specific way, and so you need to be… perhaps 
representing that.’ (hp1) 
 ‘Good picture, I liked the picture, actually showing the bloating and you know pointing out 
where to look.’(ir2) 
 
The placing of the picture also received positive feedback, with it viewed as a core 
feature of the tool. 
‘you sort of pick up the leaflet don’t you and open it, and that bit you look at you sort of 
see that first because you’ve got the diagram, and really out of all of it, that is the most 
important bit isn’t it?’ (ir2) 
 
The specific time frames that were provided with the symptoms were described as 
providing a clear message that could be easily understood. 
‘I think lots of people would probably take note of that (3 week timeframe).’ (ir1)  
‘Yeah, I liked the bubbles splitting things up and I liked the fact that you had the headings 
in bold and the important things like the three weeks in bold.’ (g2) 
 
The frequency of experiencing symptoms on ‘most days’ was viewed positively, and 
was described as providing guidance without being too specific. This was noted as 
important as providing specific symptom frequencies may lead to inappropriate help 
seeking. The section that informs that these symptoms may be experienced without 
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them being ovarian cancer was similarly viewed as being useful for managing potential 
concerns.   
‘you have to be careful not to be too specific because if you’re too specific then they’ll say 
well I only had it three times in three weeks and it says I have to have it at least four 
times.’ (hp3) 
‘ it was nice that you’ve said a lot of people have these symptoms… and often they go 
away, but, if you have them a long time you should go and be seen, and that it doesn’t 
mean… that there is a cancer.. it can be caused by other things.’ (hp1) 
 
The explanation of symptoms underneath the female body illustration was described 
as aiding understanding of the symptoms. These sentences that expand on the 
symptom terms were viewed as a useful inclusion.  
 ‘with all types of symptoms, different people mean different things by them.  That 
happens time and time again in consultations so you just get the wrong end of the stick 
from patients and they get the wrong end of the stick from you.  So it’s good to clarify 
what you mean by them.’ (hp2) 
‘you had more information underneath [the body image]  just giving a bit more…especially 
in things like changes in eating, I would have had a question about that if you hadn’t have 
said at the bottom that means fuller quicker because I would have been like, what sort of 
changes because it could have been anything if you didn’t have the explanation.’ (g2) 
 
7.6.3 Encouraging doctor patient interaction  
The section about what to expect at the doctors was praised ‘‘I think all the stuff about 
what to expect at the doctors you know, makes sense, and is quite clear’ (hp1). The 
suggestion to take the leaflet to the consultations was also deemed useful. 
‘‘I think it is a good point to say about… taking the leaflet or being explicit about the fact 
that that’s why you’ve come about your symptoms, because often people will come with 
these symptoms, and it may not necessarily cross your mind that they think they’ve got 
ovarian cancer.’ (hp1) 
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Many of the participants felt that the tool would be useful at encouraging doctor-
patient discussion and could be used in consultations.  
‘I think it’s quite reassuring to take something along to the doctor’s consultation, just to 
help… my description of any symptoms that I’d been experiencing, just as a back up to my 
concern really.’ (g1) 
 
It was felt that the tool could help make the concerns of the patients more explicit, and 
could also help the health professional to focus on the patient’s primary concern. One 
health professional described how patients raising the concern of ovarian cancer could 
make them consider ovarian cancer quicker than they may have done without the 
specific concern being flagged.  
‘if somebody brought something like this, you’d be thinking, oh, actually, I ought to be 
quite sure in my own mind…  I may have seen the patient and I may have been very 
confident that this was their IBS, but if they say to you, oh doctor, do you think I could 
have ovarian cancer, you start to think, oh well, actually, yeah, perhaps I do need to pay a 
bit more attention to that as a possible symptom and perhaps I ought to think more about 
it…because… as much as you try maybe you don’t always get to the bottom of the reason 
that they’ve come or the symptoms that is really bothering them.’ (hp1) 
 
7.6.4 Content for women at increased genetic risk of ovarian cancer  
The concept of one tool that is applicable to all women, with specific content for 
women at increased genetic risk, was well received.  
 ‘I think it should be included all in the one leaflet.  I didn’t think as someone who hasn’t 
got a family member suffering… it didn’t irritate me at all or put me off the leaflet by being 
there.  But I can also empathise that if you did have a family history, that’s going to be an 
extra layer of concern, and it might be irresponsible for the leaflet not to address it.’ (g1)  
‘The family history section goes well…it’s good that everyone’s included in the same 
leaflets, so it’s not sort of like you’re segregating different people like you need a different 
leaflet… it’s nice that everyone’s all grouped together, it’s more inclusive, so, yeah, I’d 
prefer that if they had a separate one.’(g2) 
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However, whilst deemed relevant for all, it was expressed that the tool could fulfil a 
specific role for women at increased risk, with OvSTAT considered as potentially useful 
to women who have sought medical advice about their genetic risk status. 
‘I think it’s good to have a leaflet.  And I think it’s difficult because it’s always non-specific 
what you’re trying to explain so having a leaflet means that you give them something to 
take away, so I think it’s good.’ (hp3) 
 
The content within the increased genetic risk section was regarded as being 
informative and containing adequate levels of information.  
 ‘I think it’s good to talk about that possibly having your ovaries removed as well, because 
that’s been in the news hasn’t it as well, with Angelina Jolie, so I think that’s quite good as 
well.’ (ir2) 
‘the bit about genetics is sufficient because the idea of this is, when do I need to be 
worried that I might have cancer. That’s what this this leaflet is for.  It’s not when do I 
need to worry if my family history is significant.’ (hp3) 
 
The section promoting the importance of disclosing their risk status to their doctor was 
also positively received. 
‘they’d know information about their own risk level, but I think again, to flag up that 
actually it’s not always going to be obvious when you go to the doctor that you’ve had 
testing for your genetic risk…making it clear…  to flag up that this is the reason that you 
are presenting’. (hp1) 
 
7.7 Negatives aspects of OvSTAT 
When probed about any irrelevant information within the tool, the length of the 
introductory section was discussed by some participants. 
‘if you were going to cut anything out, I think, knowing what this leaflet is for, it’s sort of 
the thing where you always put in isn’t it, but really, if somebody picks up a leaflet, like 
they know it’s an information leaflet, and they’ve picked it up to read about ovarian 
cancer in simple terms, because that’s what it says on the front.’ (hp1) 
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7.7.1 Clarification of content 
The first bullet point in the ovarian cancer truths section created confusion with 
participants. It was interpreted by some to mean that there was no method of 
detecting ovarian cancer, whereas it was intended to mean that there is no routinely 
available detection method. 
‘I guess I just thought it was a little bit confusing.’ (hp1) 
‘To me I read that and thought, so how are they going to know whether I’ve got it or not 
when I go to the doctor.  And people might think, well I won’t bother going.’ (hp2) 
‘is there a blood test?’ (ir3) 
 
This confusion was compounded by the second bullet point making a very similar 
point. 
‘Because… then you have said, there’s no screening programme offered for it.’ (hp1) 
‘They obviously can detect it, it’s just you can’t screen for it, and you kind of say that at the 
bottom, in the next line.’ (hp3) 
 
The final bullet point in the ovarian cancer truths section also drew criticism from a 
health professional who felt it is was important to clarify that the purpose of the smear 
test is to detect pre-cancerous cells. 
‘if I was going to be nit-picky I would say it’s not a test for cervical cancer, it’s a test for 
pre-cancerous cells that could in years to come become cervical cancer.’ (hp1) 
 
Questions also arose concerning the explanation of the symptom bloating. Some 
participants felt that this was not explained in a clear way that would be understood 
by all readers. 
 ‘bloating ,I personally didn’t like that explanation that your tummy feels like it’s gone up 
and stays up. I wonder whether you should more say that it’s, because it’s more a blown 
out, isn’t it?  It’s sort of like a, because it’s like you’re pregnant.’ (ir2) 
‘I’m not sure what gone up means.’ (hp2) 
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The different layout of the family history section compared to other sections was 
discussed. This subtle formatting difference was viewed positively as highlighting the 
different content. Language and font differences in comparison to the other sections 
were positively noted. 
 ‘I like the way it (family history section) wasn’t highlighted so strongly in terms of the 
formatting to the centre sections, because it’s not going to be relevant for everyone.’ (g1)  
‘I think it’s maybe that the headings seem smaller than all your other headings.’ (g2) 
‘you go from ‘you’ and ‘your’ in the kind of the general population bit to ‘some women’, in 
the increased risk.’ (cr1) 
 
7.7.2 Missing information  
When participants were asked about the what to expect at the doctors section, 
questions arose as to what tests may be done if the doctor suspects ovarian cancer. 
‘on the ‘what to expect at the doctors’ bit, I just wonder whether there should be 
something about you know, the doctor might give you a ca 125  test or scan or 
something.’ (cr1) 
 
However, when probed about their reasoning for this, many felt that it may be 
detrimental to include this information. 
 ‘if you tell them… your doctor might then do a scan and a blood test and if the doctor 
doesn’t do a scan and a blood test and so on, then you’re raising expectations of things… 
All you as a patient need is to decide if I need to go to the doctor and then you leave it to 
the doctor to decide.’ (hp3) 
 
7.8 Recommendations  
It was suggested that the font on the front page could be changed to emphasise the 
letters that make up ‘OvSTAT’.  
‘just highlight or switch the font sizes.’ (cr1) 
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Suggestions were made to clarify the first bullet point in ovarian cancer truths. These 
included amending the sentence to clarify the meaning, and also removing the 
sentence entirely. 
‘ I guess maybe if you added routine, like a screening or… it’s not routinely looked for, 
maybe it would be a bit sort of clearer for people.’ (hp1) 
‘I don’t know whether they should just be combined (bullet points 1 and 2.).’ (cr1) 
 
A suggestion for how to clarify the role of the smear test was also made.  
‘…say to people that it’s not, your ovaries are not being looked at, it’s a cervical test, the 
cervical smear test is of your cervix only, and nothing else.’ (hp1) 
 
One participant expressed a desire for more information regarding the prevalence of 
ovarian cancer. However, probing this suggestion led the participant to explain how 
they also felt the tool provided adequate guidance to additional information resources 
where this information could be found. 
 ‘if I was going to add one bullet point to anywhere it would be one sentence on prevalence 
of ovarian cancer in the general female population…  But I know that’s something that I 
could go and find out anyway, quite easily on the internet, so it doesn’t trouble me.’ (g1) 
 
The inclusion of information regarding the inherited link with breast cancer was also 
raised.  
‘there is this kind of possible link between breast cancer and ovarian…and if you’ve got that 
BRCA gene, I know you can’t really mention that because obviously people reading this 
won’t necessarily know what that is.’ (ir2) 
 ‘the only other thing you might want to put in there is if you have a family history of breast 
and/or ovarian cancer.  Just you know, obviously some people will have only breast cancer 
but they may then get ovarian cancer.’ (hp4) 
 
Possible explanations to enhance the explanation of bloating were also discussed. 
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‘I wonder whether you can say things like, you know, things like whether you’ve noticed that 
your trousers are tighter, or your clothes are tighter.’ (hp2) 
‘I think you need to say more… out rather up… or blown out.’ (ir2) 
 
Improvements to the information specifically for women at increased genetic risk were 
also made.  
‘how would a woman know that she’s been identified, would she, you know, if she was 
reading that, would it be sort of better to say… I don’t know, or if you’re perhaps worried 
about your family history or something.’ (cr1) 
‘it might be better(to order the section) if you have a family history, who would you talk 
to?  See your GP and they might refer you to genetics and then what might happen next.’ 
(cr1) 
 
Suggestions were also made for more coherent ordering of the information in the 
increased genetic risk section.  
‘I wonder whether that sentence, ‘they may be able to refer you to your local clinic or 
genetic service’. You know rather than saying ‘genetic counselling’ you might say ‘to 
discuss options’. (cr1) 
 
7.8.1 Amendments made to OvSTAT following cognitive interviews 
Amendments to improve OvSTAT that were suggested by participants were considered 
by the supervisory team. Table 7.2 shows the amendments that were made to OvSTAT 
following the cognitive interviews, with the final version of OvSTAT in Appendix 30. 
The readability of OvSTAT was assessed with the Flesch-Kincaid Grade test (Friedman 
and Hoffman-Goetz 2006), with the reading age of the final tool of Grade 6 (11-12 
years old). 
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Table 7.2. Summary of changes made to OvSTAT following cognitive interviews 
Section  Amendment  
Front page Highlight the letters in ‘ovarian cancer symptom awareness tool’ 
that make up ‘OvSTAT’ 
What is this leaflet for? Reworded ‘identified at increased risk of ovarian cancer’ to ‘women 
with a family history of ovarian cancer’ 
Ovarian cancer truths Removed first bullet point  
Ovarian cancer truths Third bullet point reworded to ‘it is a cervical cancer screening test, 
not ovarian cancer’ 
What are the 
symptoms? 
Reworded bloating explanation to ‘feels like it has gone ‘out’ and 
stays ‘out’’ 
When should I go and 
see my doctor? 
Added ‘on most days’ to be consistent with symptom guidance 
Family history Added ‘the doctor will assess your family history, and if you are 
eligible may refer you’ 
Family history Changed font size of headings to be consistent with the rest of the 
document 
Family history Changed the tense to match the rest of the document, now ‘you’ 
instead of ‘some women’ 
Family history Changed ‘for genetic counselling’ to ‘to discuss your personal risk’ 
Family history Changed order of subheadings, moved ‘at your medical 
appointment’ below ‘who can I talk to’ 
Family history Added ‘family history of ovarian or breast cancer’ 
 
7.9 Discussion  
The feedback gained from cognitive interviews with a sample of potential users and 
providers has led to the development of a final version of OvSTAT. The tool was well 
received by a range of users (women at increased genetic risk and women from the 
general population) and providers (GPs, a clinical geneticists and a representative from 
an ovarian cancer charity). Overall, the content and layout of the tool was viewed 
favourably, with the aim of the tool easily identified and the information within the 
tool perceived to be useful and easy to understand. Criticisms were also reported, with 
most suggestions for improvement relating to consistency or clarification. These 
suggestions were incorporated in the final version of OvSTAT. Future research should 
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now evaluate the acceptability and feasibility of OvSTAT as well as its potential to 
influence the determinants of presentation behaviour. 
7.9.1 Positive feedback on the draft OvSTAT 
Participants liked how the tool provided information relating to ovarian cancer 
symptom awareness in a clear and simple manner. The tool was praised for the flow of 
information, which covered the background, the symptoms, what to do if the 
symptoms are experienced, what to expect in the medical appointment, and 
signposting to additional information. The tool was also regarded as being useful in 
dispelling common misconceptions surrounding ovarian cancer, namely, that the 
smear test does not detect ovarian cancer. The inclusion of the ovarian cancer truths 
section was particularly well received by tool providers. This information can help 
educate women about ovarian cancer and emphasises the importance of symptom 
awareness in the absence of routine ovarian cancer screening. The use of a female 
body illustration was noted as aiding visualisation of the symptom origins, and was 
praised for emphasising that the symptoms are non-gynaecological in origin. The 
image placement also received positive feedback, as participants felt that it was the 
focal point of the tool and helped to impart the symptom message. Understanding was 
further enhanced by corresponding symptom descriptions.  
 
The dual audience of the tool was well received and the inclusion of an embedded 
section specifically for women at increased genetic risk of ovarian cancer was 
endorsed. Participants described the all-inclusive nature of this approach, and felt that 
the separate section for women at increased geneticrisk was not detrimental to 
women who were not at increased risk. This finding suggests that a combined tool 
could be acceptable. An inclusive approach may help to manage the psychological 
well-being of women at increased genetic risk, as a separate tool aimed at this 
population could lead to feelings of segregation. Embedding the specific information 
for women at increased genetic risk within a tool for a wider audience may mean that 
symptom information can be processed in a less threatening way.  
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The potential usefulness of OvSTAT in consultations was discussed. Both providers and 
users noted the potential of the tool for enhancing doctor-patient interaction. This was 
also mentioned in relation to information within the increased risk section of the tool. 
The importance of disclosing family history was echoed by the health professionals. 
Health professionals described how in consultations the patient’s main concern for 
presenting was not always clear and that disclosing this information could allow the 
health professional to understand what matters most to the patient (Murray et al. 
2003, Smith et al. 2005b). This highlights the importance of the attempt to empower 
women to disclose potentially emotive information when presenting with ovarian 
cancer concerns within OvSTAT. It also emphasises the importance of this section in 
psychologically preparing women to share this information.   
 
7.9.2 Suggested changes 
 Amendments mainly centred on minor clarifications of content (see Table 7.2). 
However, other recommendations were not acted upon. The lack of specific 
information about tests at medical appointments was identified by some participants, 
but when thoughts around the inclusion of this information were probed, it was 
expressed that including such information may raise expectations about what will 
happen at the medical appointment. The implications of having this type of 
information in writing was discussed by the health professionals, who thought that 
patients having test information in black and white could cause confusion and possibly 
create friction if the doctor does not think the tests are applicable to the patient. The 
omission of this information therefore helps with managing expectations about 
interaction with healthcare professionals, which is particularly important for women at 
increased genetic risk.  
 
Some participants also felt the introductory section was lengthy, and in the instance of 
needing to condense information, this section could be streamlined. However, it was 
decided to keep the section unchanged as those who suggested changes to this section 
only did so after probing for areas of improvements and none of the participants felt 
180 
 
strongly that the change should be made. The Discern tool also details how good 
quality tools have clear aims that tell the reader what is about, what it covers and who 
it is for (Charnock et al. 1999).  This paired with the perceived usefulness of the current 
content of this section by the other participants, guided the decision to keep this 
section unchanged. The use of DISCERN evaluation Handbook enabled decisions to be 
made in order for a good quality health information leaflet to be created (Charnock et 
al. 1999). 
 
7.9.3 Study limitations  
The verbal probing technique could lead to an artificial interview process in 
comparison to standard interview techniques (Willis 1999). However, the purpose of 
the interview needs to be considered here, with verbal probing concerning the analysis 
of specific content (OvSTAT), whereas traditional semi-structured interviews are 
concerned with collecting of data relating to what participants disclose (Willis 2005). 
Verbal probing was therefore a useful technique for exploring and understanding 
users’ and providers’ thoughts about the tool. Effort was also made to ensure that 
probes were non-leading, in order to minimise potential bias.  
 
The sample consisted of a variety of potential tool users and providers. Whilst a larger 
sample may have enabled more people from each of the subgroups to be represented, 
the current numbers were considered sufficient for carrying out preliminary usability 
and acceptability testing. It should also be acknowledged that the women at increased 
genetic risk of ovarian cancer had already participated in the survey in Chapter 4 of the 
thesis and were derived from the UKFOCSS (Jacobs et al. 1999) and PsyFOCS (Brain et 
al. 2012) studies. As a result of their prior research involvement, these women may not 
be representative of women at increased genetic risk of ovarian cancer and may have 
been potentially biased in favour of the tool. 
 
The use of different interview techniques to collect data needs to be considered. Data 
from the women at increased genetic risk and the charity representative were 
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gathered via telephone, whilst the remaining interviews were conducted face to face. 
Telephone interviews were utilised as they allowed for participants based around the 
UK to be included. This method may have led to loss of information, such as non-verbal 
cues or responses. However, the importance of non-verbal information in interpreting 
data has been questioned, and the absence is not thought to impede data quality 
(Novick 2008). The use of different data collection methods may raise questions over 
the comparability of the findings; however, interview responses were considered to be 
comparable due to the use of a standard topic guide. 
 
Information about other risk factors for ovarian cancer, such as gene mutations, age, 
oral contraceptive use and BMI (Andersen et al. 2002, Lockwood-Rayermann et al. 
2009), were not included in OvSTAT. This was based on the aim of the tool. OvSTAT 
was not designed as a risk assessment tool, but instead aims to provide women with 
information on ovarian cancer symptoms and guidance on when to seek help for such 
symptoms. The previous chapters have highlighted the potential for heightened 
perceived threat to be experienced by women at increased genetic risk in response to 
reading ovarian cancer materials. Including risk information was therefore considered 
to be potentially detrimental, as this type of information may cause worry and 
apprehension, and discourage presentation (Beeken et al. 2011). Importantly, risk 
information should be discussed with the appropriate medical professionals, and 
therefore could be discussed when individuals present with ovarian cancer concerns.  
 
7.9.4 Implications and future research 
An ovarian cancer symptom awareness tool (OvSTAT) was created based on the 
previous phases of research. User testing provided evidence which forms an important 
part in the development of complex interventions (Craig et al. 2008b). Overall, OvSTAT 
was viewed positively, with information on the symptoms of ovarian cancer 
considered to be presented in a clear and understandable way. Areas for change were 
identified, leading to tool amendments that aimed to increase its acceptability and 
usability. Further research is needed to assess the acceptability and usability of 
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OvSTAT. The next steps should also validate the tool as being capable of influencing 
the (i) determinants of presentation behaviour and (ii) presentation behaviour itself. 
The results of the current study suggest that OvSTAT was perceived as useful and 
informative, and could therefore potentially be a mechanism through which ovarian 
cancer symptom awareness is improved and timely presentation promoted. 
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8 General discussion 
8.1 Introduction 
The research presented in this thesis set out to identify the determinants of 
anticipated presentation with ovarian cancer symptoms in women at increased genetic 
risk of ovarian cancer. The studies undertaken to understand these determinants led 
to the development of OvSTAT. In this chapter, the findings of these phases of work 
are summarised and synthesised with existing evidence. Methodological strengths and 
weaknesses, as well as wider evaluation and implementation issues, are discussed. 
 
8.2 The need for OvSTAT 
The present research set out to address the question of whether an ovarian cancer 
symptom awareness tool was needed for women at increased genetic risk of ovarian 
cancer. Through the different phases of work that were completed, an understanding 
of the health beliefs and determinants of anticipated presentation in women at 
increased genetic risk was gained. Importantly, analysis of the health beliefs of a 
sample of women from the general population was also undertaken, and allowed 
similarities and differences between the two risk populations to be identified. Initially 
it was envisaged that a symptom awareness tool specifically for women at increased 
genetic risk would be developed. However, as the project progressed it became clear 
that the specific information needs for women at increased genetic risk could be 
embedded within core information applicable to the general population. This decision 
was aided by the mixed-method approach of the PhD, where phases of research were 
guided by the knowledge base identified in preceding phases. Modelling of theory 
relevant to the intervention led to the decision to create a tool with core components 
for all women, and a flexible component that can provide relevant information 
specifically for women at increased genetic risk. This highlights the continuous process 
of developing complex interventions as described in the MRC complex intervention 
guidelines, whereby the different phases of work  influence and shape iterations of the 
intervention (Craig et al. 2008b). The findings of the PhD have revealed the 
determinants of anticipated presentation and support needs of women at increased 
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genetic risk of ovarian cancer, which led to the development of a tool that attempts to 
meet these needs. Embedding this information within a tool that has ovarian cancer 
symptom information for all women maximises the potential exposure and impact of 
the tool. 
 
The systematic search (Chapter 3) highlighted that even though a number of symptom 
awareness tools were currently in circulation, there was no theoretically driven 
awareness tool for women at increased genetic risk of ovarian cancer. This gap 
suggested that it would be worthwhile pursuing the development of a symptom 
awareness tool for this population. The systematic search was also useful in identifying 
examples of tools that could be used in the interviews (Chapter 5), and for identifying 
components of symptom awareness. A wide variety of formats, content and design of 
tools were revealed that were considered when OvSTAT was being developed (Chapter 
7). Components of symptom awareness were further explored in Chapter 6, where the 
symptoms of ovarian cancer and thresholds for when to act on symptoms were 
identified. 
 
Chapters 4 and 5 examined the health beliefs of women at increased genetic risk, 
identifying the impact that perceived threat has on this population and the 
determinants of early anticipated presentation. These two chapters highlighted the 
need for OvSTAT as an information resource for women at increased genetic risk, as 
well as a potential mechanism for managing worry levels. As discussed, women from 
the general population were included as a comparator in the study in Chapter 4, 
allowing an understanding of health beliefs and determinants of anticipated 
presentation in women from the general population. This study was not only useful in 
identifying the unique determinants of awareness and anticipated presentation in the 
increased genetic risk sample, but also for increasing understanding of the ovarian 
cancer health beliefs in a general population sample using a statistical method that has 
not previously been applied in this context. Findings identified common health beliefs 
for the two risk populations (self-efficacy, knowledge and perceived benefits and 
barriers), as well as unique health beliefs for women at increased genetic risk (the 
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make-up of perceived threat and the association with earlier anticipated presentation). 
These findings reinforce the idea that a tool should be created that has core elements 
which address the health beliefs of both populations, as well as tailored content that 
addresses the specific health beliefs of women at increased genetic risk.  
 
A prototype of the symptom awareness tool was generated and tested. Usability and 
acceptability (Chapter 7) was explored with a sample of potential users and providers 
and revealed that OvSTAT could potentially be useful for educating women about the 
symptoms of ovarian cancer, encouraging presentation and facilitating the doctor-
patient interaction in consultations. The multiple phases of work meant that the 
development process for OvSTAT included GPs, oncologists, women at increased 
genetic risk of ovarian cancer and women from the general population. Involvement 
from a variety of people representing potential users and providers highlights the 
rigorous development process of the tool.  
 
8.3 Methodological strengths and weakness 
8.3.1 Health Belief Model 
The HBM was central to the thesis and provided guidance for many aspects of the 
research from questionnaire development to the tool content. The MRC complex 
intervention guidelines describe how an understanding of the research context and 
applicable theories is an important process in intervention development (Craig et al. 
2008a). The use of the HBM throughout the development process has led to an 
understanding of the determinants of anticipated presentation with ovarian cancer 
symptoms, which led to a strong theoretical understanding of the components that 
make up OvSTAT (Craig et al. 2008a, Smith et al. 2012). This understanding is crucial for 
the future of OvSTAT as it allows potential weaknesses in the tool to be identified and 
improved, in addition to providing guidance on what variables should be measured 
before and after use in order to assess the changes brought about by the tool (Craig et 
al. 2008b, Jones et al. 2013). 
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8.3.2 Is the HBM useful in the current context? 
Using the HBM in the current research has highlighted that it is not sufficient to simply 
provide women with the symptoms of ovarian cancer in order to bring about 
symptomatic presentation. Ovarian cancer symptom awareness is embedded within 
other health beliefs, such as perceived threat, self-efficacy, and perceived benefits and 
barriers to presentation. This supports the notion that while improving awareness 
alone will not lead to behaviour change, prompting behaviour change in the absence 
of awareness is even less likely (Redeker et al. 2009). 
 
The use of the HBM indicated that symptom awareness may not be directly linked to 
presentation for ovarian cancer. The lack of a direct association between ovarian 
cancer symptom awareness and anticipated presentation was also reported by Low et 
al. (2013b), and suggests that different mechanisms underpin these processes which 
may be specific to ovarian cancer. Modelling using the HBM in Chapter 4 
demonstrated that ovarian cancer awareness influenced anticipated presentation 
through mechanisms including perceived threat, self-efficacy and perceived benefits 
and barriers. The current research was the first to compare data on levels of worry and 
perceived susceptibility in a general population and increased genetic risk sample, and 
to examine how worry and perceived susceptibility interact with help-seeking 
intentions. The findings of the SEM based on the HBM also contribute to the literature 
in supporting the inclusion of both cognitive and affective measures of perceived 
threat in future research studies, particularly those which involve at risk populations.  
 
The SEMs in Chapter 4 revealed that the HBM accounted for 3-14% of variance in 
anticipated presentation, suggesting that there are other factors influencing 
anticipated presentation that were not measured and that other theories may have 
better explained the determinants of anticipated presentation. The role of intentions 
and subjective norms may have been overlooked in the current study, whereas 
intentions are integral in other theories such as the Theory of Planned Behaviour 
(Ajzen 1991, Gollwitzer and Sheeran 2006) and are important determinants of 
behaviour (Jones et al. 2013). However, since emotional and cognitive representations 
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of risk were thought to be influential for women at increased genetic risk of ovarian 
cancer, the TPB was not applied in the current context. A further shortcoming of the 
HBM is that it focuses on one decision to seek medical help, when in fact this is often a 
multi-stage process (Wyke et al. 2013). It is also important to consider that not 
everyone will present to primary care in the presence of symptoms, instead favouring 
other options such as looking for advice on the internet, or simply managing the 
symptoms that are being experienced (Corner and Brindle 2010). This scenario 
highlights the potential benefits of considering more than one behavioural outcome. 
However, presenting to primary care with symptoms is the gateway to ovarian cancer 
diagnosis, and therefore was chosen as the outcome of interest in the studies 
presented in the thesis.  
 
Andersen’s model of patient delay (Andersen et al. 1995) could be a useful 
conceptualisation of anticipated ovarian cancer symptomatic presentation; however, 
the multiple stages outlined in this model may be best applied to research which 
follows individuals through all stages of the symptom experience, from first appraisal 
through to treatment. The fixed and linear nature of the Andersen model reduces its 
relevance to multiple symptomatic presentations and other modifying influences on 
anticipated presentation, such as those outlined by the HBM. It was therefore felt that 
the holistic applicability of the HBM was preferential for understanding the 
determinants of anticipated symptomatic presentation in the current research context. 
Although Walter et al. (2011) further developed the Model of Pathways to Treatment 
to incorporate a more fluid explanation of presentation behaviour, neither model 
addresses the role of emotions which were considered to be important in the current 
context.  
 
Other theories that could be applied to anticipated presentation are those which focus 
on the social contexts of the individual, such as the Network Episodic Model 
(Pescosolido and Boyer 1999), or those which focus on the individual’s problem solving 
capabilities, such as the Common Sense Model (Leventhal and Diefenbach 1991). 
However, these theories have been described as focusing more on observation instead 
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of action (Smith et al. 2012), have been less widely applied to intervention 
development, and do not focus on the potential emotional considerations of ovarian 
cancer symptomatic presentation. Overall, it was deemed that the HBM was an 
adequate model to use, especially due to its applicability for women at increased 
genetic risk and its frequent application for health promotion purposes (Jones et al. 
2013). It is unlikely that one theory will fully explain anticipated symptomatic 
presentation, highlighted in the multitude of overlapping health behaviour theories in 
existence.  However, the present research showed that some of the key components 
do include threat representation and theories that take this into account are likely to 
be more successful at predicting help-seeking behaviour. 
 
8.4 Mixed methods 
This section will discuss what was gained by the mixed method approach, and the 
strengths and weaknesses of the various methodological approaches that were used 
throughout this thesis. 
 
8.4.1 Qualitative exploration of quantitative findings 
The use of interviews to elaborate and further explore the quantitative findings was a 
worthwhile process which added to the research findings (Emery et al. 2013). In the 
SEMs in Chapter 4, the influence of personal experience with ovarian cancer was not 
readily understood and was observed to be less of an influence for women at 
increased genetic risk than expected. However, when interviews (Chapter 5) were 
conducted to expand and explore the SEM findings, it was evident that experience 
with ovarian cancer was embedded in many aspects of women’s beliefs about ovarian 
cancer. The interviews allowed a deeper understanding of how risk status and 
experience with the disease influences perceptions about the disease and its 
symptoms.  
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8.4.2 Symptom awareness  
The mixed method approach enabled ovarian cancer symptom awareness to be 
examined from multiple angles, including perspectives gained by evaluating existing 
tools, women from different risk populations and GPs. The identification and 
evaluation of existing tools identified that a wide variety of symptoms were included in 
tools and were often not consistent with the current guidelines on ovarian cancer 
symptoms (Chapter 3). These findings highlighted the importance of focussing on key 
symptoms and providing symptom frequency and duration information in OvSTAT, 
which formed the focus of Chapter 6. The survey data from women at increased 
genetic risk and women from the general population highlighted that symptom 
awareness could be improved in both populations (Chapter 4) and further emphasised 
the importance of educating women on the symptoms of ovarian cancer. 
 
The data on symptom frequency and duration from women at increased genetic risk 
and GPs allowed for analysis to be conducted that identified the average symptom 
duration and frequency in the two populations (Chapter 6). These findings revealed 
that women at increased genetic risk anticipated presenting in a shorter time frame 
compared to GPs’ views on when they should present. This finding complimented and 
further endorsed the findings from Chapter 4 where women were anticipating 
presenting immediately after symptoms were experienced. The combined findings 
suggested that women may over-present and that their expectations need to be 
managed in relation to symptomatic presentation. This hyper-vigilance in women at 
increased genetic risk echoes findings from ovarian screening and BSE literature, 
where high levels of worry and perceived risk were associated with hyper-vigilant 
behaviour (Brain et al. 2011, Hay et al. 2006, Norman and Brain 2005, Schwartz, 
Lerman et al. 1995). 
 
8.4.3 Identification of symptoms and critical thresholds to include in OvSTAT 
Work on developing the core symptom content of OvSTAT was done in Chapter 6, 
which identified the symptom information to be included in the tool. The synthesis of 
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the findings from different methodologies arrived at a consistent opinion on symptoms 
and critical thresholds and ensured that the symptoms included in OvSTAT were based 
on empirical data and expert clinical opinion. This was particularly important in the 
current absence of medical consensus on what is an appropriate presentation interval 
for ovarian cancer symptomatic presentation. The methods utilised in Chapter 6 
therefore enabled symptom frequency and duration information to be included in 
OvSTAT, with this a key piece of information for women who are trying to make 
decisions about seeking medical advice. Temporal information was often missing in the 
tools identified in the systematic search (Chapter 3), or was based on arbitrary time 
frames rather than empirical evidence.  
 
Symptom duration and frequency information was particularly important in light of the 
findings from Chapter 4, where many women were anticipating presenting 
immediately after experiencing symptoms. OvSTAT encourages women to present if 
they experience symptoms on most days for three weeks or more. When the findings 
of this thesis are taken in to account this is considered an appropriate interval because 
it aims to manage presentation expectations and maintain the psychological wellbeing 
of the women who use OvSTAT. The reality is that women may need to experience 
symptoms for longer in order for possible ovarian cancer to be considered by health 
professionals. Including time frame information in ovarian cancer materials could be 
considered best practice in light of the symptoms commonly being experienced 
without them being indicative of ovarian cancer (Austoker 2009, Hamilton 2009). This 
is particularly pertinent for women at increased genetic risk who may have heightened 
levels of worry and are often basing their symptom knowledge on relatives’ symptom 
experiences (Chapter 5).  
 
8.4.4 User and provider involvement 
The target audience and potential tool providers were recruited in many phases of the 
work allowing key stakeholders to be influential in the tool development process. The 
development process of OvSTAT would not have been as strong if such a thorough 
191 
 
approach had not been taken. The cognitive interviews allowed for in depth 
understanding of the usability and favourability of the tool and led to issues with the 
tool to be identified and rectified prior to the final version being developed. 
Importantly, this feedback was gained from different angles due to the different 
potential users and providers who were included. Participants from the general 
population provided insight on how a tool with a specific section for women at 
increased genetic risk was perceived by those who are not at increased risk. 
Conversely, women at increased genetic risk provided feedback on a tool for all 
women with a specific section for women at increased genetic risk.  
 
GPs were important to include in the development as they could potentially be 
distributing OvSTAT, or exposed to OvSTAT in consultations if patients present with it. 
The genetic counsellor led to feedback to be gained about the tool in relation to 
women at increased genetic risk and the use of an ovarian cancer charity 
representative provided insight from someone with experience in providing 
information resources for women with ovarian cancer concerns. The cognitive 
interviews with different healthcare professionals and a charity representative could 
also be considered to contribute to early feasibility work for OvSTAT. The GPs felt that 
the tool would be useful for aiding their understanding of the patients’ main concern 
and the genetic counsellor felt that the tool could play an important role in providing 
women who consult to the genetic services with a resource to take home after 
consultations (Chapter 7). 
 
8.4.5 Sample limitations  
Sample limitations associated with opportunistic methods of recruiting women at 
increased genetic risk are acknowledged. Women at increased genetic risk were 
recruited from a pool of women who had participated in UKFOCSS and its 
psychological partner study, and were therefore a well-studied population who may 
not be representative of the population from which they were drawn. Women who 
have chosen to participate in multiple research studies may also have different health 
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beliefs compared to those who did not participate, or may have different health beliefs 
as a result of study participation. Research suggests that women at increased genetic 
risk who are recruited into studies through screening programmes have higher levels 
of worry (Robinson et al. 1997, Trask et al. 2001), whereas those recruited from the 
general population have been reported to have lower levels of worry (Andersen et al. 
2002, Drescher et al. 2000). 
 
Although the general population sample was population representative, these data 
were derived from the ICBP Welsh population (Brain et al. 2014), and for cohort 
studies it is preferable for samples to be drawn from the same (i.e. UK wide) 
population (Mann 2003). In addition, it was not possible to verify the personal risk 
status of individual ICBP participants. Finally, temporal differences in data collection 
methods for the two samples mean that they may not be entirely comparable.   
 
8.4.6 Different risk populations 
OvSTAT contains information for women from the general population and women at 
increased genetic risk. It may therefore have been advantageous to explore the health 
beliefs and information needs of women from the general population in more detail 
alongside the increased genetic risk population. This is because much of the 
information that can be provided to women at increased genetic risk is relevant to 
women from the general population, and vice versa. This is reflected in OvSTAT 
containing core information for all women and a specific section incorporated for 
women at increased genetic risk. It may therefore have been beneficial to include 
women from the general population in other phases of the research, such as 
qualitative interviews, to further explore their ovarian cancer health beliefs. However, 
as previously discussed, it was originally anticipated that a tool solely for women at 
increased genetic risk would be created, and as the thesis progressed it became 
apparent that a tool with a dual audience should be created. The decision to tailor tool 
content according to risk means that one leaflet can be provided for all women, rather 
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than segregation by, and potential reinforcement of worry associated with, increased 
genetic risk status.  
 
8.4.7 Cross-sectional nature of the current research 
Only prospective research can confirm the validity of study findings with regard to 
association between health beliefs and determinants of symptomatic presentation. 
Whilst cross-sectional research is useful in identifying correlates, as was the case in the 
present study, it poses difficulty for inferring causality. However, the large samples, 
time frames and associated costs of prospective research made this an unachievable 
method within the scope of the PhD. It should also be noted that questions concerning 
recognition of symptoms may elicit different responses compared to questions which 
ask participants to recall symptoms. Recognition could lead to increased symptom 
reporting as a result of guessing, whereas recall may elicit truer responses (Stubbings 
et al. 2009, Waller et al. 2004, Yawn et al. 2004). 
 
8.5 Potential limitations of OvSTAT content 
Although some existing symptom awareness tools include information on potential risk 
factors for ovarian cancer, OvSTAT did not include such information. OvSTAT is not 
designed to identify personal risk; rather, it aims to increase symptom knowledge and 
encourage women to go and see their doctor if they have symptom concerns. It is at 
this point that personal risk factors and other sensitive information can be addressed 
with a health professional. The previous phases of research also highlighted the 
heightened perceived threat and potential worry and apprehension women at 
increased genetic risk feel when reading ovarian cancer materials. It was therefore felt 
that including risk information may have detrimental consequences for women’s 
psychological wellbeing and presentation behaviour. The omission of specific risk 
factors such as specific gene mutations, age, oral contraceptive use and BMI (Andersen 
et al. 2002, Lockwood-Rayermann et al. 2009) highlights that OvSTAT is not in itself a 
solution for all educational needs relating to ovarian cancer; instead, OvSTAT is a first 
194 
 
response tool and should initiate thoughts and discussion about ovarian cancer with 
relevant medical professionals. 
 
The symptom awareness tool was created in the form of a leaflet, reflecting the most 
common format of existing ovarian cancer symptom awareness tools as identified in 
the systematic search (Chapter 3). However, what distinguishes OvSTAT from those 
already in existence is the dual audience and the strong theoretical background to 
content development. The acceptability of a leaflet was explored in interviews 
(Chapter 5), where women were asked, unprompted, about their thoughts on 
awareness tools, and were then shown a variety of awareness materials and asked to 
discuss their opinion of them. The responses from the interviews helped shape ideas 
about tool format, with a leaflet created based on the efficiency with which 
information can be imparted, and the potential ease of implementation. The 
acceptability of the leaflet was further explored in cognitive interviews with a variety 
of potential users and providers and was therefore deemed to be an acceptable format 
(Chapter 7). A short, written intervention could prove useful as leaflets have been 
reported to be effective at improving awareness (Austoker et al. 2009, Grunfeld et al. 
2002). 
 
8.6 The future of OvSTAT 
The current research has demonstrated the need to provide women with information 
about ovarian cancer that educates them about the symptoms, when to present if 
these symptoms are experienced, and the importance of symptom awareness in the 
absence of routine screening. It has also demonstrated that the psychological 
wellbeing of women at increased genetic risk needs to be maintained because worry 
(i.e. the affective component of perceived threat) is particularly prominent in this 
population. As outlined in the MRC complex intervention guidelines (Craig et al. 
2008b), the current research  has generated an evidence base which led to the 
preliminary development of an ovarian cancer symptom awareness tool (OvSTAT). 
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Follow-on research to evaluate the clinical utility and actual implementation of the 
tool now needs to be considered. 
 
8.6.1 Feasibility testing 
Potential user and provider attitudes to OvSTAT could be explored with a 
questionnaire study and would allow further insight into usability of the tool. This 
could involve giving OvSTAT to participants and asking questions about content, 
format and implementation. The interviews with women at increased genetic risk 
(Chapter 5) and the cognitive interviews with healthcare professionals (Chapter 7) 
provided a snapshot of the feasibility of OvSTAT. However, studies investigating 
feasibility should also assess whether the tool improves the desired outcomes on an 
individual level, i.e. reduced worry, increased symptom awareness and confidence in 
symptom detection/disclosure, and whether these impact the primary outcome of 
presentation. Importantly, this would also provide an opportunity to address the 
theoretical issue of an appropriate presentation interval. Based on the findings in 
Chapter 6, OvSTAT encourages women to present if they experience symptoms for 
three weeks or more. Field testing could allow for this interval to be tested, exploring 
whether it is appropriate in a clinical setting. Whilst the proposed interval of three 
weeks was based on empirical and clinical findings (Chapter 6), the acceptability of this 
time frame to doctors and patients in clinical settings needs to be explored and 
understood in order for the tool to be successfully implemented. Field testing could 
therefore be conducted with potential users and providers and would be a useful 
precursor to potential larger scale controlled studies, allowing information to be 
gathered on the feasibility of study procedures, measurement, recruitment and 
retention.  
 
8.6.2 Observation 
Consultations in which OvSTAT is used could also be observed in order to assess 
organisational implementation issues, such as how it is used in practice and whether it 
helps patients talk about their ovarian cancer concerns with a health professional. 
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These processes could lead to improvements being made to OvSTAT and are important 
steps in checking that the intervention can be used as intended before progressing to a 
larger trial (Craig et al. 2008a, Hardeman et al. 2005). Alongside ideas for 
implementation, it is important to consider ways of measuring the impact of OvSTAT. 
This is important as once tools are implemented it is often hard to assess their 
potential impact. Impact could also be measured through observing the use of the tool 
in consultations and assessing the influence it had on the clinician and patient.  
8.6.3 Controlled evaluation 
Ultimately, a randomised control trial (RCT) of OvSTAT compared to standard care 
could be carried out in women at increased genetic risk and women from the general 
population. A cluster RCT should be considered in this context, as individual outcomes 
may be dependent on other processes such as GP and practice influences (Craig et al. 
2008a).  An RCT would enable exploration of the determinants of presentation 
behaviour (as outlined in this thesis) to be measured and explored. It would also allow 
for an evaluation of the mode of action which will facilitate symptomatic presentation 
(as outlined in the different sections of OvSTAT), such as increasing knowledge about 
benefits of early presentation, teaching critical thresholds, increasing self-efficacy and 
dispelling myths. A possible RCT could therefore involve participants completing 
psychometric measures at baseline and post intervention to assess the impact of 
OvSTAT on health beliefs. Direct behavioural measures of GP visits could also be 
collected. This would enable assessment of whether the tool influences the 
determinants of presentation behaviour and presentation behaviour itself. However, 
cost effectiveness should be considered, as RCTs involve large numbers of participants 
in order to see effect sizes, and have associated time and financial considerations.  
 
8.6.4 Experimental study of the emotional impact of OvSTAT 
An assessment of the attentional and emotional impact of the tool could be carried out 
using the modified stroop task (mStroop). The mStroop has been used to evaluate 
processing biases in other contexts, using Mogg and Bradley (1998) cognitive 
motivational model of anxiety. According to this model, individuals demonstrate 
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selective processing bias towards stimuli that are congruent with their current worries. 
Recruiting women at increased genetic risk of developing ovarian cancer and women 
from the general population would allow comparisons to be made between the 
different risk populations. Analysis would assess the emotional or intuitive responses 
that women experience in response to the tool, allowing information-processing 
responses to the tool to be measured, and as a function of risk status. In particular, this 
experimental study could also allow for further exploration of the affective and 
cognitive representations of risk perceptions that were highlighted in Chapter 4. 
Understanding of the different representations could be expanded and further 
explored in terms of the Dual Process Theory (Epstein 1994), which suggests that 
people have two responses to information processing. System One refers to fast 
responses, and could relate to affective representations of risk perception, whereas 
System Two is more deliberative and could explain the cognitive representation of risk 
perception (Epstein 1994). In the context of cancer, people could initially respond to a 
symptom with an emotional response, with System One initially evoking a fear 
response, but System Two will then over-ride this response as a result of reflecting on 
the situation, leading to considerations to act on the symptom and to dispel negative 
beliefs about cancer (Robb et al. 2014). The mStroop task could allow for deeper 
exploration of the affective and cognitive responses to ovarian cancer information as a 
function of risk status, which would allow for the idea of dual processing in this context 
to be explored. 
 
An evaluation of the psychological impact of OvSTAT could prove particularly useful in 
light of the current interest surrounding stratified medicine, which involves targeting 
resources and screening programmes at those who are most at risk or predisposed to 
the condition (Dent et al. 2013). If such an approach was implemented, advances in 
testing for gene mutations would mean that increased numbers of women could have 
risk assessments regardless of their known family history (Meisel et al. 2013). In this 
context, it will be even more important to have information readily available to help 
women manage their increased risk status. 
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8.6.5 Implementation considerations and challenges 
For women at increased genetic risk of ovarian cancer, support groups and charities 
should be considered as dissemination opportunities. Other healthcare professionals 
could also disseminate OvSTAT, with health education leaflets commonly found in GP 
waiting rooms. This could be a useful way of providing the leaflet to women from the 
general population. Interviews in Chapter 5 revealed suggestions from participants as 
to potential places to access awareness tools. GP surgeries were a common 
suggestion, with the GP waiting room, or the consultation itself viewed as potential 
access points. However, this approach depends on individual GP and organisational 
“buy-in” to the intervention. Evans et al. (2014) investigated the attitudes towards 
raising public awareness of gynaecological cancers in 621 GPs. Positively, most of the 
GPs (77%) viewed raising awareness of gynaecological cancers as important, however, 
when asked whether they would distribute a leaflet about this in their practices, only 
half said they would. Increased demand on resources and the emotional impact on the 
patient were salient barriers to implementation (Evans et al. (2014). GPs felt that 
mailing out the leaflet to patients would be costly, with other methods, such as having 
the leaflet in the practice, posters and hosting it on the practice website viewed as 
more favourable options(Evans et al. 2014). These finding suggests that in order for 
leaflets to be endorsed and distributed within a primary care setting the distribution 
preferences, costs and benefits of implementation need to be considered and 
presented to practices (Evans et al. 2014). This further supports the previously 
discussed preliminary studies of OvSTAT and also suggests that in such studies an 
evaluation of the cost of implementation should also be assessed.  
 
8.7 Conclusion  
In the absence of routine ovarian screening, the psychological wellbeing of women at 
increased genetic risk for ovarian cancer needs to be maintained, since evidence 
presented in this thesis indicates that the affective component may predominate over 
the cognitive component of perceived threat in these women. The creation of OvSTAT 
could be a mechanism through which ovarian cancer symptom awareness and 
presentation is improved, as well as a mechanism through which women manage their 
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levels of worry and self-manage their risk status. Further research is needed to 
evaluate the acceptability of OvSTAT and its impact on ovarian cancer awareness, 
worry and presentation behaviour.    
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Appendix 1. Search terms for grey literature search 
Internet search terms 
 
1. Terms:             Ovarian cancer symptoms 
                       Symptoms of ovarian cancer 
                       Signs of ovarian cancer 
                       Ovarian cancer 
                       Ovarian cancer symptom awareness 
                       Ovarian cancer signs 
                       Ovarian cancer detection 
                       Early signs of ovarian cancer 
                       Ovarian cancer symptom checker 
                       Ovarian cancer symptom information  
                       How to detect ovarian cancer 
                       Ovarian cancer self diagnosis 
                       Ovarian cancer self diagnosis tool 
                       Ovarian cancer risk 
                       Ovarian cancer warning signs 
 
2. New terms from Department of Primary Care and Public Health: What is 
ovarian cancer 
                                       Do I have ovarian cancer? 
                                       Common symptoms of ovarian cancer 
                                       Gynaecological cancer symptoms 
                                       Common ovarian cancer symptoms 
                                        
 
3. New from Target Ovarian Cancer: Ovarian cysts and their signs and symptoms 
                                           Pelvic pain and increased abdominal size 
           Pelvic pain and bloating 
                                                        Pelvic pain and difficulty eating 
           Pelvic pain and increased urinary frequency 
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Appendix 2. Database search strategy 
Search 
number 
Search Terms: PychInfo, Embase, Medline Results 
1 (ovar* OR gynae* OR gyne*).mp. 693903 
2 (cancer* OR malig* OR neoplasm*).mp. 4505303 
3 (symptom* OR sign OR indicat* OR detect* OR diagno* 
OR calculat*).mp. 
13533657 
4 1 and 2 and 3 102965 
5 (aware* OR knowledge* OR attitude* OR recogni* OR lay 
concept* OR health belief* OR expectation OR 
information* OR education* OR reconi* OR 
promot*).mp. 
6979549 
6 4 and 5 18558 
7 (tool OR material* OR aid* OR information OR leaflet OR 
booklet OR intervention OR health education OR 
promot*).mp. 
6189782 
8 6 and 7 10958 
9 Limit 16 to English Language 9883 
10 Limit 9 to humans 8604 
11 Limit 10 to female 6264 
12 RNA or  RNA messenger or  sequence analysis or signal 
transduction or transforming growth factor beta or  DNA 
fragmentation or apoptosis or exp adenoviridae/ or exp 
genes or antigens or membrane protein or 
Immunohistochemistry OR proteomic* or genomic 
 
4753757 
13 11 not 12 4411 
14 Deduplicate 13 3102 
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Appendix 3. Data extraction form 
 
Content  
Evidence (yes, no and evidence in relevant source column) 
1. Characteristics of the source:  Tool Website Author  
Who was the tool developed by    
Country of origin of website    
Brief description of website (charity, 
health provider, heavily advertised, 
navigation ease etc) 
   
Affiliation with any other organisations    
Funding source for tool    
Advertisements on the website    
Are responses/data that people input into 
the tool collected by the source 
   
Position of website in search engine results     
2. Characteristics of the tool    
Name of tool    
Tool format (diary, video, slideshow etc)    
Does it provide instructions on how to use 
tool: if so are these presented on the tool 
itself or the website 
   
Does the tool concern increasing 
awareness 
   
Does the tool concern encouraging 
presentation 
   
Is there a specific target audience for the 
tool (all women, those at risk, GP’s etc) 
   
Information of how tool was created    
References to academic papers for 
information provided (if these are not 
provided on the tool itself are they are on 
the website?) 
   
If so, are these papers relevant to the 
target audience and the tool 
    
Contact information provided on tool    
Is a theory stated for any aspect of the tool 
content 
   
Is there a version number and date on the 
tool 
   
Is there a next update/review date on the 
tool 
   
Does the tool open in a new window or is 
it embedded in the current window 
   
How do you use it eg  just online, print out    
How long does it take to complete    
222 
 
Does it have an information standard mark 
or quality mark for the information 
provided 
   
Are terms of use for the tool explained on 
the tool: if not are these provided on the 
website? 
   
3. Provision of information:     
Does the tool try to change knowledge, 
attitudes or norms? 
   
Does the website mention any campaigns 
to advertise their materials?  
   
Does the tool provide ovarian cancer 
facts/information: incidence, mortality etc 
   
Are positive or negative frames used on 
the tool: eg death and survival rates 
   
Does it dispel common 
misconceptions/myths about ovarian 
cancer (eg smear test does not detect 
ovarian cancer) 
   
Are personal accounts of symptom 
experience included in the tool? 
   
4. Communication:     
What does the tool tell you (ie feedback)    
Is the tool interactive (does it require input 
or do you simply read it) 
   
Does the tool provide feedback based on 
personal health information 
   
Is the reading age of information provided    
5. Format of tool    
Yes/no responses    
Scales     
Age groups    
Free text    
 Numerical information:    
- Percentages    
- Frequencies    
- Probabilities     
Are consistent formats used    
Graphs    
Pictures     
Visual diagrams    
Videos     
How many pages of the tool are there    
Do you move step by step through pages 
of the tool 
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Can you return to previous pages of the 
tool 
   
Is it easy to return the tool to the tool if 
you link to other web pages 
   
6. Symptoms:    
 List ovarian cancer symptoms mentioned 
in tool 
   
Any other symptoms mentioned in the tool    
Does the tool provide symptom threshold 
information 
   
Does the tool provide information on 
symptom frequency 
   
Does the tool provide information of 
symptom duration 
   
Positive predictive value of symptoms 
included in tool? 
   
Does the tool ask people to recall 
symptoms 
   
Does the tool ask people to recognise 
symptoms 
   
Does the tool ask about people’s 
confidence in symptom knowledge 
   
Is any reasoning for symptom recognition 
given 
   
7. Risk information    
Are increased risk groups described in the 
tool 
   
Are risk factors stated in the tool    
Does the tool suggest places to gain extra 
information on ovarian cancer: if not does 
the website provide this information? 
   
Does the tool allow input for family history 
of cancer 
   
Are individuals asked to input perceived 
personal risk status into the tool 
   
Is a personal risk status generated by the 
tool 
   
8. Behaviour change and medical 
guidance:  
   
Does the tool prompt or encourage self 
monitoring of symptoms 
   
If so does the tool suggest information on 
how to carry out said behaviours ie. How 
often, where etc 
   
Does the tool provide materials to help 
change behaviour 
   
Guidance to visit GP provided in tool?    
Information on when to re-visit GP    
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provided in tool? 
Does the tool ask about presentation 
behaviour (eg how long after noticing a 
symptom would it take for you to seek 
help) 
   
Does the tool ask people to engage in a 
behavioural contract ie “if… then” goal 
setting 
   
Can you print the tool out    
Can you order a physical copy    
Does the tool encourage disclosure to 
others 
   
9. Does the tool address:    
Fear or distress    
Self efficacy    
Barriers to presenting with symptoms    
Benefits of symptom awareness    
10. Other     
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Appendix 4. Country of origin, format and source information of identified tools 
Name of tool Origin Format Source  Website type 
1. Australia Awareness 
Brochure 
Australia Leaflet www.ovariancancer.net.au Charity  
2. Early detection 
Australia 
Australia Factsheet www.canceraustralia.nbocc.
org.au 
Government 
3. Dr Oz Australia Diary www.doctoroz.com TV show 
4. Australia symptom 
diary 
Australia Diary www.ovariancancer.net.au Charity 
5. OC Australia factsheet 
Australia Flyer www.canceraustralia.nbocc.
org.au 
Government 
6. TV advert Australia Video www.nbocc.org.au Government 
7. No one knows your 
body like you do 
Australia Flyer www.canceraustralia.nbocc.
org.au 
Government 
8. It’s time to shout out Canada Factsheet www.itstimetoshout.com Charity 
9. OC Canada Knowledge 
Centre 
Canada Quiz www.ovarianknowledge.ca Charity 
10. Think ovarian! Canada Factsheet www.ovarianknowledge.ca Charity 
11. New Zealand 
gynaecology leaflet 
NZ Leaflet www.nzgcf.org.nz Charity 
12. Ashkenazi Inheritance UK Leaflet www.ovarian.org.uk Charity 
13. BEAT Symptom 
Checker 
UK Symptom 
checker 
www.ovacome.org.uk Charity 
14. BEAT Symptom Tracker UK Diary www.beatonline.info Charity 
15. Detecting OC CRUK UK Leaflet www.cancerresearchuk.org Charity 
16. OC diary Innermost 
Secrets 
UK Diary www.innermostsecrets.com Charity 
17. Ovarian Cancer Action 
diary 
UK Diary www.ovarian.org.uk Charity 
18. QriskOvary 
UK Risk 
calculator 
www.qcancer.org  
19. Remember the 
symptoms 
UK Leaflet www.ovarian.org.uk Charity 
20. Swollen tummy? 
UK Leaflet www.targetovariancancer.o
rg.uk 
Charity 
21. Target quiz 
UK Quiz www.targetovariancancer.o
rg.uk 
Charity 
22. What women need to 
know 
UK Leaflet www.eveappeal.org.uk Charity 
23. 15 symptoms women 
ignore 
USA Slideshow www.medicinenet.com Health 
24. Break the silence 
conversation starter 
USA Leaflet www.ovarian.org Charity 
25. CDC gynaecology diary USA Diary www.cdc.gov Government 
26. NOCC bookmark USA Bookmark www.ovarian.org Charity 
27. NOCC Quiz USA Quiz www.ovarian.org Charity 
28. Ova-1 calendar 
USA Diary www.ova-1.com Drug 
company 
29. Ova-1 Quiz 
USA Quiz www.ova-1.com Drug 
company 
30. OC symptoms USA Bookmark www.ovca.net Charity 
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31. OC warning signs 
USA Symptom 
diagram 
www.cancerdancer.org Charity 
32. Ovarian Cancer 
National Alliance  
(OCNA) app 
USA Diary app www.ovariancancer.org Charity 
33. OCNA symptom diary USA Diary  www.ovariancancer.org Charity 
34. OCNA factsheet USA Factsheet  www.ovariancancer.org Charity 
35. OAK symptom card 
USA Symptom 
card 
www.oaky.org Charity 
36. Ovations for the future 
USA Leaflet www.ovationsforthecure.or
g 
Charity 
37. WCN understand your 
risk 
USA Leaflet www.wcn.org Charity 
38. WCN women’s guide USA Leaflet www.wcn.org Charity 
39. Mahon paper USA Leaflet n/a n/a 
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Appendix 5. Symptoms included in identified tools 
Name of material Symptoms 
1. Australia awareness 
Brochure 
1. Increased abdominal size or persistent bloating 
2. Unexplained abdominal or pelvic pain 
3. Difficulty eating or feeling full quickly  
4. Needing to urinate often or urgently  
5. a change in bowel habits 
6. Unexplained weight gain or loss 
7. Vaginal bleeding 
8. Back pain 
9. Indigestion or nausea 
10.Excessive fatigue 
2. Early detection Australia 1. Abdominal bloating or a feeling of fullness 
2. Loss of appetite 
3. Unexplained weight gain 
4. Constipation 
5. Heartburn 
6. Back, abdominal or pelvic pain 
7. Frequent urination 
8. Fatigue 
9. Indigestion 
10. Pain during intercourse 
3. Dr Oz 1. Bloating or increased abdominal size 
2. Pelvic or abdominal pain 
3. Difficulty eating or feeling full quickly 
4. Feeling a frequent or urgent need to urinate 
4. Australia symptom diary 1. Pelvic/abdominal pain 
2. Increased abdominal size/bloating 
3. Urinary frequency/urgency 
4. Difficulty eating/feeling full 
5. Changes in your bowel habits 
6. Unexplained weight gain or loss 
7. Bleeding in between periods or after menopause 
8. Back pain 
9. Indigestion or nausea 
10. Excessive fatigue 
5. Ovarian cancer: Australia 
factsheet 
1. Abdominal bloating  
2. feeling full 
3. appetite loss 
4. unexplained weight gain  
5. constipation 
6. heartburn  
7. back pain  
8. frequent urination  
9. Abdominal/pelvic pain  
10. fatigue 
6. TV advert 1. Abdominal bloating   
2. Abdominal or back pain  
3. Appetite loss or feeling full  
4. Changes in toilet habit   
5. Unexplained weight gain or loss   
6. Indigestion or heart burn  
7. Fatigue 
7. No one knows your body 
like you do 
1. Abdominal bloating 
2. Abdominal or back pain 
3. Appetite loss or feeling full quickly 
4. Changes in toilet habits 
5. Unexplained weight loss or gain 
6. Indigestion or heartburn 
7. Fatigue  
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8. Its time to shout out  1. Fatigue 
2.  Persistent pressure or pain in abdomen or pelvis 
3. Weight gain  
4. Frequent or urgent urination  
5. Back pain  
6. Gas  
7.  Changes in bowel movements  
8.  Difficulty eating or feeling full quickly 
9. Bloating or swelling of the abdomen 
10. Vaginal bleeding 
11. Painful intercourse 
9. Ovarian Cancer Canada 
Knowledge Centre 
 
 
 
1. Swelling or bloating in the abdomen 
2. Pelvic discomfort or heaviness 
3. Back or abdominal pain 
4. Gas, nausea and indigestion 
5. Changes in your bowel habit 
6. Needing to empty your bladder frequently 
7. Menstrual irregularities 
8. Fatigue 
9. Weight loss or weight gain not otherwise explained: 
10. Think Ovarian!  1. Swelling or bloating of the abdomen 
2. Pelvic discomfort or heaviness 
3. Back or abdominal pain 
4. Fatigue 
5. Gas, nausea, indigestion 
6. Change in bowel habits 
7. Emptying your bladder frequently 
8. Menstrual irregularities 
9. Weight loss or weight gain 
11. NZ Gynaecological 
lealflet 
 
 
 
 
 
1. Increased abdominal size 
2. persistent bloating  
3. Pelvic and/or abdominal pain  
4. Difficulty eating and feeling full quick  
5. urinary problems,  
6. changes in bowel habits,  
7. extreme fatigue  
8. back pain  
9. Abnormal vaginal bleeding or discharge, especially after menopause 
10. Pain during sexual intercourse   
11. Itchy skin around the opening in the vagina  
12. Ashkenazi Inheritance: 1. Persistent pelvic and abdominal pain 
2. Difficulty eating/feeling full quickly 
3. Increased abdominal size/persistent bloating – not bloating that comes and 
goes 
13. BEAT Symptom Checker 1. Have you noticed an increase in abdominal size or persistent bloating 
recently? 
2. Have you had difficulties eating or have you been feeling full too quickly 
recently? Eg heartburn, nausea or loss of appetite 
3. Have you had persistent pelvic or abdominal pain recently? 
4. Have you experienced urinary problems, changes in bowel habit, extreme 
fatigue or back pain recently? 
14. BEAT Symptom Tracker 1. Abdominal bloating (Belly feels noticeably fuller and tighter or as if it‘s 
pressured or full of gas) 
2. Bigger than usual abdomen (Size of belly feels bigger than usual) 
3. Tight or hard abdomen (Belly feels harder than usual)/Can feel lumps in 
abdomen (Any unusual lumps or bumps in your belly not noticed before 
4. Feeling full more quickly than usual (Eating small amounts of food fills you 
up more quickly than usual)  
5. Reduced appetite (Off food or noticeably lower appetite than usual)  
6. Heartburn (A burning sensation at the bottom of the chest that radiates 
toward the throat or mouth)  
7. Nausea or vomiting (Feeling sick or being sick)  
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8. Burping more than usual (Trapped wind in your stomach)  
9. Not getting food down or regurgitating food (Difficult to get food down to 
the extent that liquid or food can feel like it‘s coming back up) 
10. Abdominal pain or discomfort (Feeling uncomfortable, cramping or other 
pain in your belly)  
11. Indigestion (A feeling of belly discomfort brought on by eating food)  
12. Pain on passing urine or opening bowels (Pain before, during or after 
passing urine or opening bowels)  
13. Groin, vaginal or rectal pain (Pain in the pelvis, vagina or groin, or 
rectum)  
14. Pain during/after sexual intercourse (Pain during or after sex)  
15. Other pains such as back, chest, leg, shoulder (Pains in the back or the 
side of the body. Pains in the chest and shoulder. Pains in the buttocks, 
hips, legs) 
16. Constipation or diarrhoea (Straining or difficulty opening bowels. Or 
loose bowel motions (or even loss of bowel control)  
17. Excessive passing of wind (Noticeably increased flatulence.) 
18. Rectal bleeding (Blood coming from the bottom.)  
19.  Vaginal discharge or bleeding (Discharge of fluid (including blood) from 
the vagina which is out of the ordinary)  
20. Passing urine frequently (or leaking) (Noticeably increased number of 
visits to toilet to pass urine, or occasional leaking accidents.) 
21. Difficulty passing urine (Reduced urine flow (difficulty start or dribbling 
flow).  
22. Cough (Cough or tickly throat either with or without sputum) 
23. shortness of breath (noticeably out of breath or panting after little or no 
exertion)  
24.  Tiredness or Lack of energy (Tired out more than usual or by minimal 
exertion)  
25. Weight loss or gain without trying (Noticeable loss of weight without any 
change in your diet) 
15. Detecting ovarian 
cancer: CRUK 
1. Pelvic or tummy pain 
2. Increased tummy size 
3. Bloating that does not go away 
4. Difficulty eating or feeling full quickly: 
5. changes in bowel habit, 
6. passing urine more often than usual,  
7. bleeding after the menopause,  
8. extreme tiredness 
9. back pain. 
16. Ovarian Cancer diary: 
Innermost secrets 
1. Pelvic or abdominal pain 
2. Increased stomach size 
3. bloating - not bloating that comes and goes 
4. Difficulty eating/ feeling full quickly  
5. Urinary symptoms/ 
6. Changes in bowel habit/  
7. Excessive tiredness/ 
8. Backache  
9. Persistent stomach pain 
10.increased abdominal size and persistent bloating 
11. similar to IBS 
17. Ovarian Cancer Action 
diary 
1. Pelvic/abdominal pain  
2. Increased stomach size/bloating - not bloating that comes and goes 
3. Difficulty eating/feeling full quickly  
4. Urinary symptoms  
5. Change in bowel habit  
6. Excessive tiredness  
7. Backache 
18. Qrisk Ovary Are you currently experiencing:  
1. Rectal bleeding?  
2. Postmenopausal bleeding? 
3. Abdominal pain?  
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4. Abdominal distension? 
5. Loss of appetite? 
6. Unintentional weight loss? 
19. Remember the 
Symptoms 
1. Persistent pelvic/stomach pain  
2. Increased stomach size 
3. Persistent bloating  
4. Difficulty eating/Feeling full quickly  
5. Needing to urinate suddenly or more often  
6. Changes in bowel habit e.g. diarrhoea or constipation 
7. Excessive tiredness  
8. Back pain 
20. Swollen tummy?  1. Persistent pelvic or abdominal pain (that’s your tummy and below) 
2. Increased abdominal size/persistent bloating – not bloating that comes and 
goes 
3. Difficulty eating or feeling full quickly 
4. Urinary symptoms (needing to wee more urgently or more often than 
usual) 
5. Changes in bowel habit 
6. Extreme fatigue (feeling very tired) 
7. Unexplained weight loss 
21. Target quiz 1. Feeling full or having difficulty eating, on most days  
2. Persistent tummy pain  
3. Being bloated or having a swollen tummy on most days  
4. Urinary symptoms (needing to wee more urgently or often than usual) 
22. What women need to 
know…  
1. Persistent pelvic and abdominal pain 
2.  Increased abdominal size/persistent bloating – not bloating that comes 
and goes 
3. Difficulty eating and feeling full quickly 
23. 15 Symptoms women 
ignore 
1. Bloating  
2. Abdominal pain or pelvic pain  
3.  Feeling full quickly - even without eating much  
4.  Urinary problems, such as having an urgent need to go to the bathroom 
24. Break the silence 
conversation starter 
1. Bloating 
2.  Pelvic or abdominal pain 
3.  Trouble eating or feeling full quickly 
4.  Feeling the need to urinate urgently or often 
5. Fatigue or a persistent lack of energy 
6. Upset stomach,  
7. heartburn (persistent indigestion), 
8. gas, or nausea 
9.  Back pain 
10. Pain during intercourse 
11. Constipation, unexplained changes in bowel habits, or diarrhea 
12. Menstrual changes 
13.  Unexplained weight loss or gain  
14. sleep changes 
15. bowel habits  
16. headaches” 
25. CDC diary 1. Abnormal vaginal discharge 
2. Pelvic pain or pressure 
3. Abdominal or back pain 
4. Bloating 
5. Changes in bathroom habits 
6. Abnormal vaginal bleeding 
26. NOCC Bookmark 1. Bloating 
2. Trouble eating or feeling full quickly 
3. Pelvic or abdominal pain 
4.  Feeling the need to urinate urgently or often  
5. Fatigue 
6. Upset stomach or heartburn 
7. Back pain 
8. Pain during sex 
9. Constipation 
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10. Menstrual changes 
27. NOCC Quiz 1. Pelvic or abdominal pain or discomfort 
2. vague but persistent gastrointestinal upsets such as gas, nausea, and 
indigestion 
3. frequency and/or urgency of urination in the absence of an infection 
4.  unexplained weight gain or weight loss 
5.  pelvic and/or abdominal swelling, 
6. bloating and/or feeling of fullness;  
7. Ongoing unusual fatigue 
8. Unexplained changes in bowel habits. 
28. Ova-1 calendar 1. Abdominal pain 
2. Bloating 
3. Difficulty eating/feeling full quickly 
4. Urinary urgency or frequency 
5. fatigue  
6. upset stomach  
7. back pain  
8. pain during intercourse 
9. constipation  
10. menstrual changes 
29. Ova-1 quiz 1. Or you may have irregular menstrual periods.  
2. It can also cause constipation.  
3. Abdominal swelling that makes clothes fit tighter can occur.  
4. This swelling is often accompanied by weight loss. 
30. Ovarian cancer 
symptoms 
1. Bloating 
2. Pelvic or abdominal pain 
3. Difficulty eating or feeling full quickly 
4. Urinary symptoms (urgency or frequency) 
Other symptoms: 
5. Fatigue 
6. Indigestion 
7. Back pain 
8. Pain with intercourse 
9. Constipation  
31. Ovarian cancer warning 
signs 
1. Abdominal pressure 
2. fullness 
3. swelling or bloating 
4. Persistent indigestion, gas or nausea  
5. Changes in bowel habit, such as constipation 
6. Loss of appetite or quickly feeling full 
7. Increased abdominal girth or clothes fitting tighter around your waist 
8. A persistent lack of energy /Fatigue  
9. Lower back pain  
10. Pelvic discomfort or pain   
11. Bloating and gas 
12. Slender poop 
32. OCNA app 1. Bloating 
2. Pelvic or abdominal pain 
3. Difficulty eating or feeling full quickly 
4. Urinary symptoms (frequency or urgency) 
33. OCNA symptom diary 1. Bloating  
2. Pelvic/abdominal pain 
3. Difficulty eating or feeling full quickly 
4. Urinary symptoms 
34. OCNA factsheet 1. Bloating  
2.  Pelvic and abdominal pain  
3. Difficulty eating or feeling full quickly  
4. Urinary symptoms (urgency or frequency)   
5. Fatigue / 
6. Indigestion 
7.  Back pain  
8. Pain with intercourse 
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9.  Constipation  
10. Menstrual irregularities  
35. OAK Symptom Card 1. Bloating 
2. Pelvic or abdominal pain 
3. Difficulty eating or feeling full quickly 
4. Urinary symptoms (urgency or frequency)  
5. fatigue 
6. indigestion 
7.  back pain,  
8. pain with intercourse 
9. constipation  
10. menstrual irregularities 
36. Ovations for the future 
 
1. Bloating  
2. Pelvic or abdominal pain  
3.  Trouble eating or feeling full quickly  
4. Urinary symptoms, such as urgent or frequent feeling of needing to go 
37. WCN understanding your 
risk 
1. Bloating 
2. Pelvic or abdominal pain 
3.  Difficulty eating or feeling full quick 
4. Urinary symptoms (urgency or frequency ) 
5. Fatigue 
6.  Indigestion 
7.  Back pain 
8. Pain with intercourse 
9.  Constipation 
10. Menstrual irregularities  
38. WCN womens guide 1. Bloating 
2. Pelvic or abdominal pain 
3. Difficulty eating or feeling full quickly 
4. Urinary symptoms (urgency or frequency)  
5. Fatigue  
6. Indigestion  
7. Back pain  
8. Pain with intercourse  
9. Constipation  
10.Menstrual irregularities  
39. Mahon (1996) paper 1. Vague, unexplained abdominal pain or swelling 
2. A sense of abdominal fullness 
3. Loss of appetite 
4. Nausea and vomiting 
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Appendix 6. Health Belief Model construct coverage in identified tools 
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Appendix 7. Ethical approval 1 
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Appendix 8. Questionnaire for women at increased genetic risk 
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Appendix 9. Questionnaire from the ICBP that was used to gather data for women 
from the general population 
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Appendix 10. Principal components analysis of Health Belief Model items for increased 
genetic risk group. 
Item  Factor IPBa IIPBe IIIFear IV PS 
 
I would be too embarrassed  0.48 0.06 0.22 -0.002 
I would be worried about wasting the doctor’s time 0.61 -0.12 0.23 0.18 
I would have too many other things to worry about 0.69 -0.09 0.27 0.11 
I wouldn’t feel confident talking about my symptom with the 
doctor 
0.54 0.03 0.15 0.24 
It would be difficult for me to get an appointment  0.70 -0.03 -0.10 -0.26 
I would be too busy to make time to go to the doctor 0.77 -0.14 -0.07 -0.07 
 
If ovarian cancer is diagnosed early, it can be treated more 
successfully 
0.10 0.88 -0.05 0.02 
If found early, ovarian cancer can often be cured  -0.11 0.81 -0.02 -0.14 
Going to the doctor as quickly as possible after noticing a 
symptom of ovarian cancer could increase chances of surviving 
-0.06 0.84 -0.09 0.04 
 
I would be too scared  0.15 -0.09 0.91 0.02 
I would be worried about what the doctor might find 0.19 -0.07 0.87 0.06 
 
Compared to most other women your age, how likely do you 
think it is that you will get ovarian cancer at some time in your 
life? 
0.05 -0.06 -0.003 0.93 
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Appendix 11. Principal components analysis of Health Belief Model items for general 
population group 
 
Item  Factor IPE IIPRB IIIPBe IVPS 
I would be too scared  0.84 0.11 -0.02 0.05 
I would be worried about what the doctor might find -0.85 0.05 -0.07 0.01 
I would be too embarrassed  0.56 0.35 0.01 0.01 
I wouldn’t feel confident talking about my symptom with the 
doctor 
0.46 0.38 -0.04 -0.25 
It would be difficult for me to get an appointment
1 
0.40 0.34 0.06 -0.14 
     
I would have too many other things to worry about 0.06 0.75 -0.06 -0.01 
I would be too busy to make time to go to the doctor 0.04 0.74 0.04 0.06 
I would be worried about wasting the doctor’s time 0.22 0.57 -0.06 0.07 
     
If ovarian cancer is diagnosed early, it can be treated more 
successfully 
-0.01 0.02 0.83 0.05 
Going to the doctor as quickly as possible after noticing a 
symptom of ovarian cancer could increase chances of 
surviving 
0.03 -0.01 0.80 -0.05 
If found early, ovarian cancer can often be cured  -0.10 0.07 0.74 -0.04 
Compared to most other women your age, how likely do you 
think it is that you will get ovarian cancer at some time in 
your life? 
0.01 0.04 -0.04 0.96 
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Appendix 12. Correlation matrix for variables in whole SEM 
 
 1 2 3 4 5 6 7 8 9 Mean (sd) 
Experience 1.00         0.37(0.42) 
Self-efficacy .01 1.00        2.31(0.93) 
Knowledge .02 .24** 1.00       6.69(2.70) 
Age .25 .08* -.05 1.00      62.06(9.5) 
Benefits  
Minus barriers 
-.07** .14*** .15*** .27*** 1.00     1.20(2.14) 
Threat  0.37*** -.10*** .01 -.42*** -.16** 1.00     
Worry .21** -.06** -.02 -.23*** -.07** .45*** 1.00   5.30(1.44) 
Perceived 
susceptibility 
.40 -.11** -.01 -.45*** -.14** .85*** .38*** 1.00  2.78(0.95) 
Anticipated 
presentation  
.01 -.05** -.04 -.06** -.24*** -.01 .01 .03 1.00 0.53(0.50) 
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Appendix 13. Correlation matrix for variables in increased genetic risk SEM 
 
 1 2 3 4 5 6 7 8 9 Mean (sd) 
Experience 1.00         0.91(0.29) 
Self-efficacy .17** 1.00        2.20(0.70) 
Knowledge .06 .31*** 1.00       6.07(2.60) 
Age .11 .06 -.07 1.00      52.87(10.40) 
Benefits  
Minus barriers 
.06 .21** .15* .23*** 1.00     -0.70(3.60) 
Threat .04 -.10 .07 -.19** -.05 1.00     
Worry .02 -.13* .06 -.18** -.29*** .98*** 1.00   6.15(1.94) 
Perceived 
susceptibility 
.01 -.05 .04 -.09 -.11* .35*** .35**
* 
1.00  4.21(0.71) 
Anticipated 
presentation  
-.02 -.05 -.06 -.04 -.34*** -.16*** -.09 -.02 1.00 0.59(0.49) 
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Appendix 14. Correlation matrix for variables in general population SEM 
 
 1 2 3 4 5 6 7 8 9 Mean (sd) 
Experience 1.00         .23(.42) 
Self-efficacy .04 1.00        2.34(.93) 
Knowledge .07* .22*** 1.00       6.85(2.73) 
Age .03 .004 -.05** 1.00      64.53(9.48) 
Benefits  
Minus barriers 
.01 .17*** .10** .04 1.00     1.74(2.14) 
Threat .13 -.19 .19 -.25* -.02 1.00     
Worry .09* -.04 .04 -.08 -.01 .36 1.00   5.3(1.42) 
Perceived 
susceptibility 
.04* -.09** .10** -.16** -.01 .64* .25*** 1.00  2.34(.93) 
Anticipated 
presentation  
-.02 -.04** -.03 -.01* -.18*** -.01 -.002 -.005 1.00 0.51(.52) 
 
 
261 
 
Appendix 15. Increased genetic risk group SEM multigroup invariance analysis across 
relationship status 
 
 x
2
 Df Δx
2
 Δdf CFI ΔCFI 
Configural model 34.13 24   .93  
Model 1 44.80 32 10.67 8 .91 .02 
Model 2 44.81 33 10.68 9 .91 .02 
Model 3 57.52 37 23.39* 13 .85 .08 
Model 4 64.42 47 30.29 23 .87 .06 
Model 5 65.14 49 31.01 25 .88 .05 
Note. Δx
2 
=difference in x
2 
between models; Δdf= difference in degrees of freedom between models; ΔCFI = 
difference in CFI between models. Numbers in bold indicate goodness of fit. Model 1= constrained structural 
weights. Model 2= constrained structural weights and intercepts. Model 3 = constrained structural weights, 
intercepts and means. Model 4= constrained structural weights, intercepts, means and covariance’s. Model 5 = 
constrained structural weights, intercepts, means, covariance’s and residuals.  *p<.05. 
Δx2 were not significant for models 1,2, 4 and 5, indicating invariance, with model 3 
indicating nonvariance. ΔCFI indicates nonvariance for all models. 
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Appendix 16. Increased genetic risk group SEM multigroup invariance analysis across 
education 
 
 x
2
 Df Δx
2
 Δdf CFI ΔCFI 
Configural model 33.49 24   .92  
Model 1 39.54 32 6.05 8 .94 -.02 
Model 2 43.39 33 9.90 9 .92 .00 
Model 3 58.55 37 25.06* 13 .82 .10 
Model 4 76.97 47 43.48* 23 .75 .17 
Model 5 77.61 49 44.12* 25 .77 .15 
Note. Δx
2 
=difference in x
2 
between models; Δdf= difference in degrees of freedom between models; ΔCFI = 
difference in CFI between models. Numbers in bold indicate goodness of fit. Model 1= constrained structural 
weights. Model 2= constrained structural weights and intercepts. Model 3 = constrained structural weights, 
intercepts and means. Model 4= constrained structural weights, intercepts, means and covariances. Model 5 = 
constrained structural weights, intercepts, means, covariances and residuals.  *p<.05. 
Δx2 were not significant for models 1 and 2, indicating invariance. ΔCFI indicates 
invariance for model 2 
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Appendix 17. Interview topic guide 
Main points to be gained from interview: 
< anchor symptom awareness, confidence and help seeking in past experience, where 
relevant. If not, then the questions are hypothetical.> 
PREVIOUS SYMPTOM EXPEREINCE: 
Exploration of what symptoms previously experienced and what action was taken, or 
hypothetical if have not experienced any 
BARRIERS:  
Thoughts about the barriers that were identified in the questionnaires 
WAYS TO OVERCOME BARRIERS AND FACILITATORS: 
Would higher awareness levels and improved confidence make individual more likely 
to present? 
ACCEPTABILITY OF MATERIAL: 
Thoughts on a symptom awareness materials: pros and cons, content. 
Prologue 
1. Introduce yourself, explain where you’re from, ensure they’re comfortable etc. 
2. Check understanding of reason for meeting and role of researcher, give an 
opportunity for questions:  
“Before we start, I wonder if you have any questions about this study or about why 
I’ve come to talk with you today? 
I am a researcher and I’m not medically trained, so I’ve not got the expertise to 
answer questions of a clinical nature. ” 
3. Set the focus of the interview. Base this around the following:  
“You previously completed a questionnaire about ovarian cancer symptom 
awareness and beliefs. We want to further understand what beliefs woman at 
increased risk of ovarian cancer have. We would like to know how confident you feel 
in knowing the symptoms and what you would do if you thought you were 
experiencing them. We are also interested in finding out if you have any experiences 
which you think may affect your awareness or behaviour. We are interested in these 
things as we want to establish whether there is a need for a symptom awareness 
material to be created.” 
 
4. After establishing what is understood about the study, and answering any questions, 
explain that the interview will be recorded:  
“I would like to record what you say as that saves me having to scribble when you’re 
talking and means that I can concentrate on what you’re saying. The recording will 
only be heard by people who are working on this project. The interview will be 
264 
 
transcribed and your identity and the identity of any person you talk about today 
will be anonymised in any published work. Is that okay with you?”                                               
 
5. Obtain consent for the interview and for the recording (provide information sheet 
again). If not already done, set up and switch on the recording equipment while the 
volunteer signs the consent form. 
 
6. Explain how the interview will work:  
 
“I’ve planned some ideas about the sorts of things I’d like us to talk about today, and 
if it’s okay with you we’ll try and base our conversation around those points. Having 
said that, if you want to tell me about anything that I don’t ask about, please just tell 
me. Also, if you find a question difficult to answer, please say and we can move on or 
I could try to ask it in a different way. Of course, if you’d prefer not to answer any 
question, that is absolutely fine. There aren’t any right or wrong answers to anything 
I ask you, we’re just interested in your own opinions and experiences. Does that all 
sound alright to you?” 
 
 
 
PREVIOUS SYMPTOM EXPERIENCE/ 
SYMPTOM APPRAISAL 
 
Q1: have you ever experienced symptoms that you thought may be OC? 
IF YES Make note of symptoms mentioned for later questions 
 What made you think that the symptoms were possibly related to OC? 
 Did you do anything to find out more information about the symptoms you 
were experiencing? 
 How were they detected – by yourself or through ovarian screening? 
 Did you tell anyone close to you? (cf. we know that having a confidante 
encourages women to seek help for breast symptoms) 
 Go to Q2 
 
IF NO:  
 Do you think OC has symptoms?  
     Make note of symptoms mentioned for later questions 
 If you were experiencing these symptoms, how confident do you feel that you 
would notice them? 
 Is there anything you think you would do to help you monitor the symptoms? 
 Would you feel confident going to your doctor to talk about these symptoms 
if you did experience them in future? 
 What would make you confident in going? 
Rationale: Explore whether or not they 
have experienced OC symptoms, and 
actual or anticipated confidence in 
symptom detection and help-seeking. 
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 What would make you decide not to go? (if they mention particular 
symptoms that would make them more/less confident in going, could 
also explore type of symptom/time frame here.) 
 GO TO Q3 
 
Q2 Did you go to see the doctor with symptoms you thought were possibly related to 
OC? 
 
-if went to the doctor 
Q2a: at what point did you decide to go to the doctor? 
 how long after noticing it did you go? 
 Did you feel confident going to your doctor? 
 Did one of the symptoms you experienced make you go more so than others? 
 Did something change in the symptom to make you go? 
 Did the length of time you experienced the symptom have any influence of 
decision to go? 
 
-if did not go to the doctor   
Q2b: Did you think about going to your GP? 
 What made you decide against going to the GP? 
 What would make you go to the GP? 
-type of symptom? 
-the amount of time you experienced the symptom for? 
 
Q3: have any of your relatives or close friends experienced OC symptoms? 
IF YES 
 What symptoms were they? 
 How were these symptoms experienced? 
 Has the symptom experience of this person influenced your thoughts about OC 
symptoms? 
          -probes: has it made you look out for this symptom more? 
IF NO: move to next section 
 
BARRIERS 
 
If we could now talk about things that might put you off going to the doctor to seek 
advice if you were experiencing symptoms you thought might be OC ….. 
 
Q4: can you think of anything that might put you off going to the doctor in such a 
situation?  
Rationale: To elaborate on barriers that were 
identified as important determinants of 
awareness, worry and presentation from the 
questionnaire. 
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 IF YES, can you tell me more about this? 
-prompts: what would be the main reason to stop you from going? 
                Are there any other reasons? 
 IF NO, can you tell me why? 
-prompts: is this because you feel nothing would put you off? 
                Is this because you would not go to the doctor at all? 
 
Q5: Would you feel comfortable talking to your GP about possible OC symptoms you 
were experiencing? 
 IF YES: can you explain why? 
                would you do any preparation prior to visit? 
                Would you take anything to the GP with you to help you talk? 
 IF NO; can you explain your reasons?  
                Would you go somewhere else?  
                Would anything help you go to the GP? 
 
 
Q6: have any of your friends or family previously been to the GP to seek help for 
symptoms they were experiencing? 
 IF YES: did they feel confident about going to see the GP? 
                  Did they find the visit to the GP useful? 
                  Do you think their experienced has influenced what you would do if you 
experienced symptoms you thought might be OC? 
 IF NO: is this because they did not go to the GP? Or do you not know of anyone 
who has previously experienced symptoms they thought were OC? 
 
 
 
 
WAYS TO REDUCE BARRIERS   
 
Q7: do you think that women at increased risk of OC should have better awareness 
of OC symptoms? 
IF YES: 
 Can you explain why you think improved symptom awareness is needed? 
IF NO: 
 Can you explain why you don’t think better symptom awareness is needed? 
 
Q8: do you sometimes worry about whether or not you know the symptoms of OC? 
IF YES: 
 Why do you think that is? 
 Do you do anything to help you find out about symptoms? Ie internet? 
 Do you think having clear information on what the symptoms of OC are 
would help you worry less? 
IF NO: 
 Is that because you are confident in your OC symptom knowledge? 
 Or is because you tend to worry 
Rationale:  Would increasing 
symptom awareness and 
confidence reduce barriers? 
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Q9: Do you think that information on what the symptoms of OC are would help you 
in deciding to go the GP if you were experiencing them? 
IF YES: 
 Can you explain why you think this would be? 
 Do you think that additional information about what to do when symptoms are 
experienced is needed to help with this decision? 
-prompts: do you think it would be more useful to have this info? 
                Do you think this info would make no difference? 
                Do you think something else would more important?  
-If yes, can you tell me about what you think? 
IF NO: 
 Can you explain why you think this might be? 
 Can you think of other types of information that would help you decide to go to 
the GP if you were experiencing symptoms of OC? 
 Do you think information about what to do when symptoms are experienced 
would be helpful? 
-prompts: do you think it would be more useful to have this info? 
                Do you think this info would make no difference? 
 
 
 
ACCEPTABILITY OF AWARENESS 
MATERIAL 
 
If we could now talk about a symptom awareness material. As mentioned, we are 
considering creating a symptom awareness material specific for women at increased 
risk. 
 
Q10: Do you think a symptom awareness material should be created? 
 Can you think of any advantages of having a symptom awareness material? 
 Can you think of any disadvantages? 
 Can you think of anything you think should be included in such a material? 
 Do you think there is anything that should not be included? 
 
Q11: I have brought along an example of a symptom awareness material, can you tell 
me what you think of it? <give them time to look at material> 
 Can you tell me what you like most about it? 
 Can you tell me what you like least about it? 
-prompts: What do you think about the length of it? 
                 What do you think of the pictures/illustrations? 
                 What do you think about the colours? 
Rationale:  Whether they 
think there is a need for a 
symptom awareness tool. 
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                 Do you think it is informative? 
                 Would you prefer to read this information on the website? 
                 Is there anything particular you would like to see in it? 
 
 
ROUND UP 
1. CLARIFICATION OF QUESTIONNAIRE RESPONSES: 
As appropriate, clarify:  
Anything not completed / ambiguous  
Pursue any additional threads of interest that were highlighted during the interview 
 
 Explain the findings of the interviews will go together to with those of the 
questionnaire to help with the creation of a symptom awareness material 
 Ask if have any questions 
 
2. FUTURE CONTACT 
 
i. Ensure that they know how to contact us for further help/information/to 
add further information 
 If any clinical questions, will direct them to their GP and have helpline 
numbers/charity details to hand. 
ii. Check if it is okay to contact them later after listening to the conversation 
if there is anything you want to clarify 
 
3. THANKS and GOODBYE 
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Appendix 18. Target ovarian cancer leaflet 
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Appendix 19. It’s time to shout out factsheet 
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Appendix 20. Ovarian Cancer Action symptom diary 
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Appendix 21. Be clear on cancer leaflet 
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Appendix 22. Ethical approval 2 
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Appendix 23. Search strategy for systematic search 
 
The below symptoms from the Department of Health Key Messages (2009) and NICE 
guidelines (2012) were entered into PubMed.  
 
1. Bloating  AND ovarian cancer 
2. Pelvic pain AND ovarian cancer 
3. Abdominal pain AND ovarian cancer 
4. Distension AND ovarian cancer 
5. Full AND ovarian cancer 
6. Appetite AND ovarian cancer 
7. Fatigue AND ovarian cancer 
8. Back pain AND ovarian cancer 
9. Bowel AND ovarian cancer 
10. Urinary AND ovarian cancer 
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Appendix 24.  Extraction sheet for studies identified in the systematic search 
 
Author information Symptom  Sample Design  Results  Limitations  
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Appendix 25. Newcastle -  Ottawa quality assessment scale  
Note: A study can be awarded a maximum of one star for each numbered item within the Selection and 
Exposure categories. A maximum of two stars can be given for Comparability.  
 
Selection 
1) Is the case definition adequate? 
a) Yes, with independent validation  
b) Yes, eg record linkage or based on self reports 
c) No description 
2) Representativeness of the cases 
a) Consecutive or obviously representative series of cases   
b) Potential for selection biases or not stated 
3) Selection of Controls 
a) Community controls  
b) Hospital controls 
c) No description 
4) Definition of Controls 
a) No history of disease (endpoint)  
b) No description of source 
Comparability 
1) Comparability of cases and controls on the basis of the design or analysis 
a) Study controls for _______________  (Select the most important factor.)   
b) Study controls for any additional factor   ________________ 
Factors controlled for could include any design factors eg age, medical facility, co-morbidity. If one 
factor adjusted for select a), if two or more are adjusted for select a) and b) 
 
Exposure 
1) Ascertainment of exposure 
a) Secure record (eg surgical records)  
b) Structured interview where blind to case/control status  
c) Interview not blinded to case/control status 
d) Written self-report or medical record only 
e) No description 
2) Same method of ascertainment for cases and controls 
a) Yes  
b) No 
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Appendix 26. Estimation of effect sizes for 16 symptoms identified in systematic 
search. Symptoms are presented in alphabetical order. 
 
Symptom 1: Abdominal mass 
 
Symptom 2: Abdominal pain 
 
Symptom 3: Appetite loss 
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Symptom 4: Back pain 
 
Symptom 5: Bloating  
 
Symptom 6: Bowel changes 
 
*four studies provide two data entries for bowel symptoms: asterisks denote data for ‘constipation’ and 
the other entry for the study refers to data for ‘diarrhoea’   
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Symptom 7: Distension 
 
Symptom 8: Fatigue 
 
Symptom 9: Feeling full 
 
Symptom 10: Gastrointestinal  
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Symptom 11: Indigestion  
 
Symptom 12: Nausea/ vomiting 
 
 
Symptom 13: Pelvic Pain 
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Symptom 14: Urinary 
 
*One study provide two data entries for urinary symptoms: asterisks denote data for ‘urinary urgency’ 
and the other entry for the study refers to data for ‘urinary frequency’   
Symptom 15: Vaginal bleeding 
 
Symptom 16: Weight change  
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Appendix 27. Ethical approval 3. 
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Appendix 28. Cognitive interview topic guide 
Interviewer note: need to stress to the respondent that: 
 We are not primarily collecting survey data on them, but rather testing the leaflet 
before it is finalised.  
 All comments on the leaflet are welcome – including criticisms.  
 Scripted probes are included for each section.  One of the key assumptions of the 
cognitive interviewing approach, however, is that issues may well come up in 
answering the questions that cannot be anticipated in advance of the interview.  
It is therefore important that you as an interviewer are sensitive to such issues 
and probe spontaneously around areas not covered by the scripted probes if 
these come up. 
 
Pre-amble: 
Before we begin, I need to give you some information so that you understand why the 
research is being done and what it would involve.  
We are carrying out research to understand people’s views of an ovarian cancer information 
leaflet. 
At this stage, we are testing the leaflet before it is finalised, so we are interested in your 
views, both positive and negative. 
Taking part is voluntary.  It is up to you to decide whether or not to take part.  If you decide 
to take part you are still free to stop at any time and without giving a reason.  If you prefer, 
you can also skip individual questions on the survey.  
All the information that is collected will be anonymous and kept strictly confidential.   
I will start by asking you some questions about the leaflet. This will help identify good 
things in the leaflet as well as things that may need more changing. However, please 
feel free to stop me at any stage during to mention anything that you think might be 
relevant. If you feel that you would rather not answer a question then that is fine…….. 
 
1. Usefulness/understanding 
What do you think about the leaflet? 
- What do you think the purpose of the leaflet is? 
- Do you understand why this leaflet might be offered to people? 
- Did any questions spring to mind when you were reading the leaflet? 
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-  What do you think about the information in the leaflet? 
- Do you think it is informative? 
   -is there too much/too little information?  
 
2. Content and layout  
- Is the leaflet easy to read? 
- Was the content/wording clear? Was it too simplistic or complex? 
- Were there any words that were unfamiliar to you? 
- Were there any parts you did not understand? 
- Was the text an easy size to read? 
- What do you think about the colours? 
- What do you think about the length of the leaflet? 
- What do you think about the order of information?  
- What do you think about the different sections? 
- What do you think of the pictures/illustrations? 
- Do you think there should me more pictures/illustrations?  
- Would you prefer to read this information on a website? 
 
3. Improvements  
- Can you tell me what you like most about the leaflet? 
- Can you tell me what you like least about it?  
- Do you think the leaflet would be useful for women wanting to find out 
about the symptoms of ovarian cancer? 
- Are there areas that need improving? (language, font, format, graphics) 
- Are there any things that should be removed to improve it? 
- Is there anything particular you would like to see in it that is not currently 
included? 
Section for GPs/Genetics: (ask about the section for women at increased risk if it is not 
brought up in discussion through the above questions) 
   - What do you think about the section for women at increased risk of cancer? 
Other probes that could be used: 
 Did any questions come to mind when you were reading it? 
 Why do you think that might be important? 
 Why do you think that should be changed? 
 Is there anything else you would like to mention about the leaflet? 
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Appendix 29. Draft OvSTAT (side one) 
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Final OvSTAT (Side two) 
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Appendix 30. Final OvSTAT (side one) 
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Final OvSTAT (side two) 
 
